US20140275910A1 - Multi-Function Analyte Test Device and Methods Therefor - Google Patents
Multi-Function Analyte Test Device and Methods Therefor Download PDFInfo
- Publication number
- US20140275910A1 US20140275910A1 US14/292,557 US201414292557A US2014275910A1 US 20140275910 A1 US20140275910 A1 US 20140275910A1 US 201414292557 A US201414292557 A US 201414292557A US 2014275910 A1 US2014275910 A1 US 2014275910A1
- Authority
- US
- United States
- Prior art keywords
- medication
- information
- user
- therapy profile
- health monitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/24—Querying
- G06F16/245—Query processing
-
- G06F17/30424—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Definitions
- a hand-held electronic meter such as a blood glucose meter such as the Freestyle® blood glucose monitoring system available from Abbott Diabetes Care Inc., of Alameda, Calif. which receives blood samples via enzyme-based test strips.
- the patient lances a finger or alternate body site to obtain a blood sample, applies the drawn blood sample to the test strip, and inserts the test strip into a test strip opening or port in the meter housing for analysis and determination of the corresponding blood glucose value which is displayed or otherwise provided to the patient to show the level of glucose at the time of testing.
- glucose meters are generally configured with limited functionalities related to glucose testing. Additionally, patients who rely on the usage of glucose meters or other health related devices to monitor and treat health conditions, such as diabetes, also rely on a supply of consumable products employed by said glucose meters or other health related devices.
- test strips and insulin For patients who are frequent users of the health related devices, such as diabetics that test glucose levels and possibly administer insulin several times daily, having a sufficient supply of the test strips and insulin is critical. More often than not, it is the case that patients run out of the test strips or insulin, which necessitates a trip to the drugstore or healthcare professional office, which in some cases, may not be practical or convenient. Furthermore, it is also inconvenient to consistently maintain a log or keep track of the number of test strips and amount of insulin that remains until replenishment strips and insulin are purchased.
- a medication dosage calculation function into a health monitor device, such as a blood glucose meter, configured to perform data analysis and management based on, for example, the glucose level detected using the health monitor device.
- methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, retrieving stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determining a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, where the determined current dose level includes a predetermined type of medication classification are provided.
- FIG. 1 is a health monitor device with a medication dose calculation function in accordance with one embodiment of the present disclosure
- FIG. 2 is a block diagram of the health monitor device with a medication dose calculation function of FIG. 1 in one embodiment of the present disclosure
- FIG. 3 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with one embodiment of the present disclosure
- FIG. 4 is a flowchart illustrating the medication dose calculation procedure of FIG. 3 in accordance with one embodiment of the present disclosure
- FIG. 5 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with another embodiment of the present disclosure
- FIG. 6A shows a health monitor device with medication dose calculation function in accordance with another embodiment of the present disclosure
- FIG. 6B is a block diagram of a configuration of the health monitor device shown in FIG. 6A in one embodiment
- FIG. 6C is an illustration of a display of the health monitor device shown in FIG. 6A in one embodiment
- FIG. 7 shows a touch-screen health monitor device in accordance with one embodiment of the present disclosure
- FIG. 8 is a flow chart illustrating a medication dosage calculation procedure for use in one or more embodiments of the present disclosure
- FIG. 9 is a flow chart illustrating an analyte concentration determination and medication dosage calculation in one embodiment of the present disclosure.
- FIG. 10 is a flow chart illustrating a procedure for determining a recommended update to a long-acting insulin dosage regimen in one embodiment
- FIG. 11 is a flow chart illustrating a procedure for calculating a dosage recommendation for a long-acting insulin and a fast-acting insulin in one embodiment
- FIG. 12 is a flow chart illustrating a means for calculating a dosage recommendation for one or more selectable medication types
- FIG. 13 is a flow chart illustrating a means for calculating insulin dosage information for more than one type of insulin in another embodiment
- FIG. 14 illustrates a block diagram of a replenishment management system in accordance with one embodiment of the present disclosure
- FIG. 15 is a flowchart illustrating user account registration setup and account subscription process in accordance with one embodiment of the present disclosure
- FIG. 16 is a flowchart illustrating an overall replenishment procedure for the user account in accordance with one embodiment of the present disclosure
- FIG. 17 is a flowchart illustrating the replenishment procedure shown in FIG. 16 in further detail in accordance with one embodiment of the present disclosure
- FIG. 18 is a flowchart illustrating the replenishment procedure shown in FIG. 16 in further detail in accordance with another embodiment of the present disclosure
- FIG. 19 is a flowchart illustrating a user account update and maintenance procedure in accordance with one embodiment of the present disclosure.
- FIG. 20 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure
- FIG. 21 is a flowchart illustrating contextual based therapy management in accordance with one embodiment of the present disclosure.
- FIG. 22 is a flowchart illustrating contextual based therapy management in accordance with another embodiment of the present disclosure.
- health monitor devices such as blood glucose meter devices
- therapy management including for example, medication dosage calculation functions, such as a single-dose calculation function for administration of rapid acting insulin and/or long acting insulin, and/or related data analysis capabilities incorporated in the health monitor devices.
- method, device or system are provided to determine therapy management profile, recommended medication dose information based on, for example, fast or rapid acting and/or long acting insulin, to treat physiological conditions associated with diabetes or other appropriate conditions.
- patients with Type-1 or Type-2 diabetic conditions may improve their diabetes management, and further, the patients, users or healthcare providers may be provided with tools to improve the treatment of such conditions.
- FIG. 1 shows a health monitor device with a medication dose calculation function in accordance with one embodiment of the present disclosure.
- Health monitor device with a medication dose calculation function 100 includes a housing 110 with a display unit 120 provided thereon. Also shown in FIG. 1 is a plurality of input buttons 130 , each configured to allow the user of the health monitor device with a medication dose calculation function 100 to input or enter data or relevant information associated with the operation of the health monitor device with a medication dose calculation function 100 .
- the user of the health monitor device with a medication dose calculation function may operate the one or more input buttons 130 to enter a calibration code associated with a test strip 160 , or other fluid sample reception means, for use in conjunction with the health monitor device with a medication dose calculation function 100 .
- the health monitor device with a medication dose calculation function 100 may include a blood glucose meter with bolus calculation function configured to calculate a single dose bolus dosage of a medication such as insulin such as long acting, fast acting or rapid acting insulin.
- the test strip 160 for use in conjunction with the health monitor device with a medication dose calculation function 100 may be a blood glucose test strip configured to receive a blood sample thereon, in order to determine a blood glucose level of the received blood sample.
- the user may operate the one or more input buttons 130 to adjust time and/or date information, as well as other features or settings associated with the operation of the health monitor device with a medication dose calculation function 100 .
- the strip port for receiving the test strip 160 may be integrated with the housing of the health monitor device 100 , or alternatively, may be provided in a separate housing or as a separate component that may be physically or electrically coupled to the health monitoring device 100 .
- a component including the strip port may be provided in a separate snap-on type housing which physically snaps onto the housing of the health monitor device 100 . Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Method” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination”, the disclosure of each of which is incorporated herein by reference for all purposes.
- input unit 140 which, in one embodiment, may be configured as a jog dial, or the like, and provided on the housing 110 of the health monitor device with a medication dose calculation function 100 .
- the user or the patient may operate the input unit 140 to perform calculations and determinations associated with one or more medication dose estimation functions, such as a bolus dose estimation function, of the health monitor device with a medication dose calculation function 100 .
- a strip port 150 which is configured to receive the test strip 160 (with fluid sample provided thereon) substantially in the direction as shown by the directional arrow 170 .
- a microprocessor or a controller unit 210 ( FIG. 2 ) of the health monitor device with a medication dose calculation function 100 may be configured to determine the associated analyte level in the fluid sample, and display the determined analyte level on the display unit 120 .
- the health monitor device with a medication dose calculation function 100 may be configured to automatically enter into a medication dosage calculation mode to, for example, estimate a medication dosage amount based on information stored in the health monitor device with a medication dose calculation function 100 (such as the patient's insulin sensitivity, for example), and/or prompt the patient to provide additional information, such as the amount of carbohydrate to be ingested by the patient for determination of, for example, a carbohydrate bolus dosage determination.
- the patient may operate the input unit 140 in conjunction with the user interface menu provided on the display unit 120 to provide the appropriate information.
- the health monitor device with a medication dose calculation function 100 may be configured to prompt the patient to select whether to retrieve a predetermined or preprogrammed medication dosage amount such as, for example, a correction bolus or a carbohydrate bolus, following the display of the determined analyte level from the test strip 160 .
- a predetermined or preprogrammed medication dosage amount such as, for example, a correction bolus or a carbohydrate bolus, following the display of the determined analyte level from the test strip 160 .
- the health monitor device with a medication dose calculation function 100 may be configured to automatically prompt the user or patient to select whether a medication dosage determination is desired following an analyte test using the test strip 160 .
- Example embodiments of the present disclosure are directed mainly toward measuring the levels of glucose, such as a blood glucose level, however it is to be understood that the present embodiments may also be configured to measure the levels of other analytes, drugs, or physiological conditions.
- analyte levels that may be determined include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones (e.g., ketone bodies), lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin.
- Assays suitable for determining the concentration of DNA and/or RNA are disclosed in U.S. Pat. No. 6,281,006 and U.S. Pat. No. 6,638,716, the disclosures of each of which are incorporated by reference herein.
- concentration of drugs such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
- FIG. 2 is a block diagram of the health monitor device with a medication dose calculation function of FIG. 1 in one embodiment of the present disclosure.
- the health monitor device with a medication dose calculation function 100 ( FIG. 1 ) includes a controller unit 210 operatively coupled to a communication interface 220 and configured for bidirectional communication.
- the controller unit 210 is further operatively coupled to a test strip interface 230 , an input section 240 (which, for example, may include the input unit 140 and the plurality of input buttons 130 as shown in FIG. 1 ), an output unit 250 , and a data storage unit 260 .
- the test strip interface 230 is configured for signal communication with the inserted test strip 160 ( FIG. 1 ) for determination of the fluid sample on the test strip 160 .
- the test strip interface 230 may include an illumination segment which may be configured to illuminate the strip port 150 ( FIG. 1 ) using a light emitting diode (LED), for example, during the test strip 160 insertion process to assist the user in properly and accurately inserting the test strip 160 into the strip port 150 .
- LED light emitting diode
- the test strip interface 230 may be additionally configured with a physical latch or securement mechanism internally provided within the housing 110 of the health monitor device with a medication dose calculation function 100 ( FIG. 1 ) such that when the test strip 160 is inserted into the strip port 150 , the test strip 160 is retained in the received position within the strip port 150 until the sample analysis is completed.
- a physical latch or securement mechanism may include a uni-directionally biased anchor mechanism, or a pressure application mechanism to retain the test strip 160 in place by applying pressure on one or more surfaces of the test strip 160 within the strip port 150 .
- the output unit 250 may be configured to output display data or information including the determined analyte level on the display unit 120 ( FIG. 1 ) of the health monitor device with a medication dose calculation function 100 .
- the output unit 250 and the input section 240 may be integrated, for example, in the case where the display unit 120 is configured as a touch sensitive display where the patient may enter information or commands via the display area using, for example, a finger or stylus or any other suitable input device, and where, the touch sensitive display is configured as the user interface in an icon or motion driven environment, for example.
- the communication interface 220 in one embodiment of the present disclosure includes a wireless communication section configured for bi-directional radio frequency (RF) communication with other devices to transmit and/or receive data to and from the health monitor device with a medication dose calculation function 100 .
- the communication interface 220 may also be configured to include physical ports or interfaces such as a USB port, an RS-232 port, or any other suitable electrical connection port to allow data communication between the health monitor device with a medication dose calculation function 100 and other external devices such as a computer terminal (for example, at a physician's office or in a hospital environment), an external medical device, such as an infusion device or including an insulin delivery device, or other devices that are configured for similar complementary data communication.
- a computer terminal for example, at a physician's office or in a hospital environment
- an external medical device such as an infusion device or including an insulin delivery device, or other devices that are configured for similar complementary data communication.
- the wireless communication section of the communication interface 220 may be configured for infrared communication, Bluetooth® communication, or any other suitable wireless communication mechanism to enable the health monitor device with a medication dose calculation function 100 for communication with other devices such as infusion devices, analyte monitoring devices, computer terminals, communication enabled mobile telephones, personal digital assistants, or any other communication devices which the patient or user of the health monitor device with a medication dose calculation function 100 may use in conjunction therewith, in managing the treatment of a health condition, such as diabetes.
- devices such as infusion devices, analyte monitoring devices, computer terminals, communication enabled mobile telephones, personal digital assistants, or any other communication devices which the patient or user of the health monitor device with a medication dose calculation function 100 may use in conjunction therewith, in managing the treatment of a health condition, such as diabetes.
- FIG. 3 is a flowchart illustrating the analyte level determination and medical dose calculation procedure in accordance with one embodiment of the present disclosure.
- a test strip 160 is detected by the controller unit 210 (or the test strip interface 230 ) ( 310 ) of the health monitor device with a medication dose calculation function 100 ( FIG. 1 ).
- the fluid sample such as a blood sample
- the inserted test strip 160 is analyzed ( 320 ) to determine the corresponding analyte level, such as a glucose level, and the determined analyte level is output ( 330 ) on the display unit 120 ( FIG. 1 ) for example, in units of mg/dL.
- a prompt command is generated and output to the patient to select if the medication dosage calculation is desired ( 340 ). More specifically, in one embodiment of the present disclosure, the controller unit 210 ( FIG. 2 ) is configured to generate a command and display in the display unit 120 to query the user as to whether a medication dosage calculation determination is desired by the patient. Thereafter, a determination of whether or not the patient has selected to have the medication dosage calculation performed by the controller unit 210 is made ( 350 ). In one embodiment, the patient may operate one or more of the input buttons 130 or the input unit 140 to select whether or not to have the medication dosage calculation performed.
- the determined analyte value is displayed and/or stored ( 360 ), e.g., in memory of the health monitor device, and the routine terminates.
- the controller unit 210 FIG. 2
- the controller unit 210 may be configured to store the determined analyte value in the data storage unit 260 with associated time and/or date information of when the analyte value determination is performed.
- the measured analyte value may be stored substantially concurrently with the display of the analyte value.
- the health monitor device with a medication dose calculation function 100 is configured to enter the medication dosage determination mode ( 370 ), described in further detail below in conjunction with FIG. 4 , where the desired type of medication dosage is determined and provided to the patient.
- the health monitor device with a medication dose calculation function 100 may be configured to store the glucose data even in the event the user selects to perform the medication dose calculation.
- FIG. 4 is a flowchart illustrating the medication dose calculation procedure of FIG. 3 in accordance with one embodiment of the present disclosure.
- the controller unit 210 FIG. 2
- the controller unit 210 is configured to prompt the patient (for example, by displaying the options to the patient on the display unit 120 ( FIG. 1 )) to select the type of desired medication dosage calculation 410 .
- the controller unit 210 may be configured to output a list of available medication dosage calculation options including, for example, bolus calculation options such as a carbohydrate bolus, a correction bolus, a dual or extended bolus, a square wave bolus, or any other suitable medication calculation function which may be programmed into the health monitor device with a medication dose calculation function 100 (and for example, stored in the data storage unit 260 ).
- bolus calculation options such as a carbohydrate bolus, a correction bolus, a dual or extended bolus, a square wave bolus, or any other suitable medication calculation function which may be programmed into the health monitor device with a medication dose calculation function 100 (and for example, stored in the data storage unit 260 ).
- the selected medication dosage calculation routine is retrieved ( 420 ) from the data storage unit 260 , and thereafter executed ( 430 ).
- the execution of the selected medication dosage calculation ( 430 ) may include one or more input prompts to the patient to enter additional information as may be required to perform the selected medication dosage calculation.
- a food database may be stored in the data storage unit 260 or elsewhere for easy access (e.g., personal computers (PCs), personal digital assistants (PDAs), mobile telephones, or the like and to which the health monitor device may be coupled (e.g., wirelessly or by physical connection) to easily retrieve such information) to conveniently determine the corresponding carbohydrate amount associated with the type of food which the patient will be ingesting.
- the patient may provide the actual estimated carbohydrate count if such information is readily available by the patient.
- the patient is prompted to provide, in addition to a dose amount, a time duration information for the extended portion of the bolus dosage to be infused or otherwise delivered to the patient.
- the patient may further be prompted to provide insulin sensitivity information, and any other information as may be necessary to determine the selected bolus dosage amount in conjunction with other relevant information such as insulin on board information, and the time of the most recently administered bolus (so as to provide a warning to the patient if a bolus dosage has been administered within a predetermined time period, and a subsequent administration of the additional bolus dosage may potentially be harmful).
- the calculated medication dosage amount is stored ( 440 ) in the data storage unit 260 , and the calculated medication dosage amount is output displayed to the patient ( 450 ) on the display unit 120 of the health monitor device with a medication dose calculation function 100 , or audibly if the health monitor device is so configured.
- storing and output displaying the calculated medication dosage amount may be substantially concurrently performed, rather than sequentially.
- FIG. 5 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with another embodiment of the present disclosure.
- a test strip 160 is inserted into the strip port 150 of the health monitor device with a medication dose calculation function 100 and detected ( 510 ), the fluid sample on the test strip 160 is analyzed to determine the corresponding analyte level ( 520 ), and thereafter, output displayed ( 530 ).
- a medication dosage calculation routine is retrieved ( 540 ).
- the controller unit 210 ( FIG. 2 ) is configured to enter into the medication dosage determination mode, and to execute pre-programmed or predetermined medication calculation routine ( 550 ), and thereafter, output display the calculated medication dosage amount ( 560 ).
- the health monitor device with a medication dose calculation function 100 may be programmed or configured to automatically enter into the medication determination mode upon completion of the fluid sample analysis for analyte level determination.
- the health monitor device with a medication dose calculation function 100 may be configured to execute different types of medication dosage calculation based on the patient specified parameters.
- the health monitor device with a medication dose calculation function 100 may be configured to perform a carbohydrate bolus determination when the test strip sample analysis is performed within a predetermined time period of a meal event.
- the health monitor device with a medication dose calculation function 100 may be programmed by the patient to automatically select the carbohydrate bolus determination if the test strip fluid sample analysis is performed within one hour prior to a meal time (which may be programmed into the health monitor device with a medication dose calculation function 100 ).
- FIG. 6A shows a health monitor device with medication dose calculation function in accordance with another embodiment of the present disclosure.
- a health monitor device 600 in accordance with one or more embodiments may be used for determining a concentration of an analyte in blood or interstitial fluid.
- the health monitor device 600 may be an analyte test meter, such as a glucose test meter that may be used for determining an analyte concentration, such as a blood glucose concentration, of a sample for determination of a blood glucose level of a patient, such as a patient with Type-1 or Type-2 diabetes.
- the health monitor device 600 may be a small portable device designed to be palm-sized and/or adapted to fit into, for example, a pocket or purse of a patient.
- the portable health monitor device 600 may have the appearance of a personal electronic device, such as a mobile phone or personal digital assistant (PDA), so that the user may not be identified as a person using a medical device. Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Method” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination”, the disclosure of each of which is incorporated herein by reference for all purposes.
- the health monitor device 600 may be a larger unit for home use and designed to sit on a shelf or nightstand. In yet another embodiment, the health monitor device 600 may be designed for use in a hospital or doctor's office.
- the larger health monitor device units 600 may have the same functionality as the portable health monitor device 600 as described in further detail below.
- a health monitor device 600 includes a housing 610 and a display unit 620 provided thereon.
- the display unit 620 may be a dot-matrix display.
- other display types such as liquid-crystal displays (LCD), plasma displays, light-emitting diode (LED) displays, or seven-segment displays, among others, may alternatively be used.
- the display unit 620 may display, in numerical or graphical form, for example, information related to, among others, a patient's current analyte concentration.
- Also incorporated within the housing 610 of the health monitor device 600 may be a processor 660 ( FIG. 6B ) and a memory device 670 ( FIG.
- the memory device 670 may store raw and/or analyzed data as well as store instructions which, when executed by the processor 660 ( FIG. 6B ), may provide, among others, instructions to the display unit 620 , and may be used for analysis functions, such as analyte concentration analysis and medication dosage calculations.
- the memory device 670 may include a readable and/or writable memory device such as, for example, but not limited to a read only memory (ROM), random access memory (RAM), flash memory device, or static random access memory (SRAM).
- ROM read only memory
- RAM random access memory
- SRAM static random access memory
- an optional transmitter/receiver unit 680 may be incorporated into the housing 610 of the health monitor device 600 .
- the transmitter/receiver unit 680 may be used to transmit and/or receive analyzed or raw data or instructions to/from, for example, optional peripheral devices, such as a data analysis unit or a medication administration unit in a data network.
- the transmitter/receiver unit 680 ( FIG. 6B ) is a transceiver capable of both transmitting and receiving data.
- the transmitter/receiver unit 680 ( FIG. 6B ) may be configured for wired or wireless transmission, including, but not limited to, radio frequency (RF) communication, RFID (radio frequency identification) communication, WiFiTM or Bluetooth® communication protocols, and cellular communication, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM).
- RF radio frequency
- RFID radio frequency identification
- WiFiTM radio frequency identification
- Bluetooth® Bluetooth®
- cellular communication such as code division multiple access (CDMA) or Global System for Mobile communications (GSM).
- CDMA code division multiple access
- GSM Global System for Mobile communications
- the health monitor device 600 may include a rechargeable power supply 690 ( FIG. 6B ), such as a rechargeable battery.
- the health monitor device 600 may also include a plurality of input buttons 630 .
- Each of the plurality of input buttons 630 may be designated for a specific task, or alternatively, each of the plurality of input buttons 630 may be ‘soft buttons’.
- each of the plurality of buttons may be used for a variety of functions. The variety of functions may be determined based on the current mode of the health monitor device 600 , and may be distinguishable to a user by the use of button instructions shown on the display unit 620 .
- Other input methods may also be incorporated including, but not limited to, a touch-pad, jog-wheel, or capacitive sensing slider inputs.
- Yet another input method may be a touch-sensitive display unit, as described further below and shown in FIG. 7 .
- the health monitor device 600 may also include a strip port 640 which may be configured for receiving a test strip 650 .
- the test strip 650 is configured to receive a fluid sample, such as a blood sample, from a patient.
- the test strip 650 may then be inserted into the strip port 640 , whereby the health monitor device 600 may analyze the sample and determine the concentration of an analyte, such as glucose, in the sample.
- the analyte concentration of the sample may then be displayed on the display unit 620 as the analyte level of the patient.
- the health monitor device 600 may use a conversion function to convert a measured analyte concentration of a sample to a blood analyte concentration of a host.
- the analyte concentration of the analyzed sample may be stored in the memory 670 ( FIG. 6B ) of the health monitor device 600 .
- the stored analyte concentration data may additionally be tagged with date and/or time data related to the date and/or time the fluid sample was taken and analyzed.
- the analyte concentration data may be transmitted via the transmitter/receiver unit 680 ( FIG. 6B ) to one or more peripheral devices for storage and/or further analysis.
- strip port to receive the test strip may be provided as a separate component that is configured to physically or electrically couple to the health monitoring device 600 . Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Methods” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination” the disclosures of each of which are incorporated herein by reference for all purposes.
- the health monitor device 600 may include instructions for calculating a medication dosage.
- the medication dosage may be, for example, a dosage of insulin in response to a blood glucose concentration data determined from the fluid sample on the test strip 650 received at the strip port 640 .
- the medication dosage calculation may be based, at least in part, on a current patient analyte concentration data averaged with stored values of previous analyte concentration data.
- the instructions for calculating a medication dosage may include instructions for calculating a dosage for a variety of types of medication, such as a variety of types of insulin.
- Insulin types may include, but are not limited to, long-acting insulin types such as LANTUS® (insulin glargine), available from Sanofi-Aventis, and LEVEMIR®, available from NovoNordisk, intermediate-acting insulin types such as Neutral Protamine Hagedorn (NPH), and LENTE insulin, fast-acting insulin types including recombinant human insulin such as HUMULIN®, available from Eli Lilly and Company, and NOVALIN®, available from NovoNordisk, bovine insulin, and porcine insulin, rapid-acting insulin types such as HUMALOG® (Lysine-Proline insulin), available from Eli Lilly and Company, APIDRA® (glulisine insulin), available from Sanofi-Aventis, and NOVOLOG® (aspart insulin), available from NovoNordisk, and very
- the instructions for calculating a medication dosage may be instructions for calculating a recommended update to an existing medication dosage regimen.
- Data related to a current medication dosage regimen may be stored in the memory 670 of the health monitor device 600 , including current prescribed medication types and dosages and an algorithm for calculating recommended medication dosage changes.
- Calculated medication dosage recommendations may be displayed to the patient on the display unit 620 of the health monitor device 600 for patient intervention, or further may be transmitted directly to a medication administration device, such as an insulin pump, for a medication dosage regimen update.
- the health monitor device 600 may include programming for alarm functions. Alarms may be used to inform patients when current analyte concentrations are outside threshold levels, when medication dosage regimens need to be updated, or when an error is detected. Alarms may be in the form of a visual, auditory, or vibratory alarm.
- the health monitor device 600 may include an integrated medication delivery system (not shown). Additional information is provided in US Patent Publication No. US2006/0224141 published on Oct. 5, 2006, titled “Method and System for Providing Integrated Medication Infusion and Analyte Monitoring System”, the disclosure of which is incorporated by reference for all purposes.
- the integrated medication delivery system may be in the form of a drug delivery injection pen such as a pen-type injection device incorporated within the housing 610 of the health monitor device 600 . Additional information is provided in U.S. Pat. Nos. 5,536,249 and 5,925,021, disclosure of each of which are incorporated herein by reference for all purposes.
- the integrated medication delivery system may be used for injecting a dose of medication, such as insulin, into a patient based on a prescribed medication dosage, and may be automatically updated with dosage information received from the medication dosage calculator described above.
- the medication dosage of the medication delivery system may include manual entry of dosage changes made through, for example, the input buttons 630 of the health monitor device 600 .
- Medication dosage information associated with the medication delivery system may be displayed on the display unit 620 of the health monitor device 600 .
- FIG. 6C is an illustration of a display of the health monitor device shown in FIG. 6A in one embodiment.
- the display unit 620 of the health monitor device 600 may display a variety of data values to a patient.
- the display unit 620 may display a current analyte concentration, such as the current blood glucose concentration of a patient, a recommended update to the patient's medication dosage regimen, such as insulin dosage updates, and the date and/or time of the current or most recent analyte test.
- the display unit 620 may show the current function of said ‘soft buttons’ for the particular current operational mode of the health monitor device 600 .
- Other information that may be displayed on the display unit 620 may include, but is not limited to, current medication dosage regimen data, recommended medication type, and historical patient analyte concentration data.
- Information on the display unit 620 may be displayed in a variety of manners or format including, for example, numerical data, graphical data, symbols, pictures, and/or animations.
- the user may be able to choose the display style, for example, by pushing one of the input buttons 630 .
- the display unit 620 may be a black and white display unit, or may alternatively be a color display unit, whereby, information may be displayed in a variety of colors. Colors may be used as indicators to a patient of changes in the current displayed information, or may be used for aesthetic purposes to allow for easier navigation of the data and/or menus.
- the brightness, contrast, tint, and/or color settings of the display unit 620 may be adjustable.
- the health monitor device 600 may incorporate a continuous analyte monitoring device, where a transcutaneously implanted sensor may continually or substantially continually measure an analyte concentration of a bodily fluid.
- a transcutaneously implanted sensor may continually or substantially continually measure an analyte concentration of a bodily fluid.
- sensors and continuous analyte monitoring devices include systems and devices described in U.S. Pat. Nos. 6,175,752, 6,560,471, 5,262,305, 5,356,786, U.S. patent application Ser. No. 12/698,124 and U.S. provisional application No. 61/149,639 titled “Compact On-Body Physiological Monitoring Device and Methods Thereof”, the disclosures of each of which are incorporated herein by reference for all purposes.
- the health monitor device 600 may be configured to operate or function as a data receiver or controller to receive analyte related data from a transcutaneously positioned in vivo analyte sensor such as an implantable glucose sensor.
- the analyte monitoring system may include a sensor, for example an in vivo analyte sensor configured for continuous or substantially continuous measurement of an analyte level of a body fluid, a data processing unit (e.g., sensor electronics) connectable to the sensor, and the health monitor device 600 configured to communicate with the data processing unit via a communication link.
- the sensor and the data processing unit may be configured as a single integrated assembly.
- the integrated sensor and sensor electronics assembly may be configured as a compact, low profile on-body patch device assembled in a single integrated housing and positioned on a skin surface of the user or the patient with a portion of the analyte sensor maintained in fluid contact with a bodily fluid such as an interstitial fluid during the sensor life time period (for example, sensor life time period including about 5 days or more, or about 7 days or more, or about 14 days or more, or in certain embodiments, about 30 days or more).
- the on-body patch device may be configured for, for example, RFID or RF communication with the health monitor device 600 to wirelessly provide monitored or detected analyte related data to the health monitor device 600 based on a predetermined transmission schedule or when requested from the health monitor device 600 .
- Predetermined transmission schedule may be programmed or configured to coincide with the analyte sample detection by the analyte sensor (for example, but not limited to including once every minute, once every 5 minutes, once every 15 minutes).
- the health monitor device 600 may be programmed or programmable to acquire the sampled analyte data (real time information and/or stored historical data) in response to one or more requests transmitted from the health monitor device 600 to the on-body patch device.
- embodiments include the on-body patch device including the data processing unit coupleable to the analyte sensor so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor positioned transcutaneously.
- the data processing unit in certain embodiments may include a portion of the sensor (proximal section of the sensor in electrical communication with the data processing unit) which is encapsulated within or on the printed circuit board of the data processing unit with, for example, potting material or other protective material.
- the data processing unit performs data processing functions, where such functions may include but are not limited to, filtering and encoding of analyte related signals, for transmission to the health monitor device 600 .
- the sensor or the data processing unit or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user.
- transmitter/receiver section 680 of the health monitor device 600 includes an RF receiver and an antenna that is configured to communicate with the data processing unit, and the processor 660 of the health monitor device 600 is configured for processing the received data from the data processing unit such as data decoding, error detection and correction, data clock generation, and/or data bit recovery.
- the health monitor device 600 in certain embodiments is configured to synchronize with the data processing unit to uniquely identify the data processing unit, based on, for example, an identification information of the data processing unit, and thereafter, to periodically receive signals transmitted from the data processing unit associated with the monitored analyte levels detected by the sensor.
- the analyte monitoring system may include an on-body patch device with a thin profile that may be comfortably worn on the arm or other locations on the body (under clothing worn by the user or the patient, for example), the on-body patch device including an analyte sensor and circuitry and components for operating the sensor and processing and storing signals received from the sensor as well as for communication with the health monitor device 600 .
- the on-body patch device may include electronics to sample the voltage signal received from the analyte sensor in fluid contact with the body fluid, and to process the sampled voltage signals into the corresponding glucose values and/or store the sampled voltage signal as raw data.
- the on-body patch device in one aspect may further include an antenna such as a loop antenna to receive RF power from an external device such as the health monitor device 600 described above, electronics to convert the RF power received via the antenna into DC (direct current) power for the on-body patch device circuitry, communication module or electronics to detect commands received from the health monitor device 600 , and communication component such as an RF transmitter to transmit data to the health monitor device 600 , a low capacity battery for providing power to sensor sampling circuitry (for example, the analog front end circuitry of the on-body patch device in signal communication with the analyte sensor), one or more non-volatile memory or storage device to store data including raw signals from the sensor or processed data based on the raw sensor signals.
- an antenna such as a loop antenna to receive RF power from an external device such as the health monitor device 600 described above
- electronics to convert the RF power received via the antenna into DC (direct current) power for the on-body patch device circuitry
- communication module or electronics to detect commands received from the health monitor device 600
- communication component
- the health monitor device 600 may also be configured to operate as a data logger, interacting or communicating with the on-body patch device by, for example, periodically transmitting requests for analyte level information from the on-body patch device, and storing the received analyte level information from the on-body patch device in one or more memory components 670 .
- the various processes described above including the processes operating in the software application execution environment in the analyte monitoring system including the on-body patch device and/or the health monitor device 600 performing one or more routines described above may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships.
- the software required to carry out the inventive process which may be stored in a memory or storage device of the storage unit of the various components of the analyte monitoring system described above in conjunction to the Figures including the on-body patch device or the health monitor device 600 may be developed by a person of ordinary skill in the art and may include one or more computer program products.
- an apparatus for bi-directional communication with an analyte monitoring system may comprise a storage device having stored therein one or more routines, a processing unit operatively coupled to the storage device and configured to retrieve the stored one or more routines for execution, a data transmission component operatively coupled to the processing unit and configured to transmit data based at least in part on the one or more routines executed by the processing unit, and a data reception component operatively coupled to the processing unit and configured to receive analyte related data from a remote location and to store the received analyte related data in the storage device for retransmission, wherein the data transmission component is programmed to transmit a query to a remote location, and further wherein the data reception component receives the analyte related data from the remote location in response to the transmitted query when one or more electronics in the remote location transitions from an inactive state to an active state upon detection of the query from the data transmission component.
- Embodiments also include the on-body patch device including sensor electronics coupled to an analyte sensor is positioned on a skin surface of a patient or a user.
- an introducer mechanism may be provided for the transcutaneous placement of the analyte sensor such that when the on-body patch device is positioned on the skin surface, a portion of the sensor is inserted through the skin surface and in fluid contact with a body fluid of the patient or the user under the skin layer.
- the RF power supply in the health monitor device 600 may be configured to provide the necessary power to operate the electronics in the on-body patch device, and accordingly, the on-body patch device may be configured to, upon detection of the RF power from the health monitor device 600 , perform preprogrammed routines including, for example, transmitting one or more signals to the health monitor device 600 indicative of the sampled analyte level measured by the analyte sensor.
- communication and/or RF power transfer between the health monitor device 600 and the on-body patch device may be automatically initiated when the health monitor device 600 is placed in close proximity to the on-body patch device.
- the health monitor device 600 may be configured such that user intervention, such as a confirmation request and subsequent confirmation by the user using, for example, the display 620 and/or input components 630 of the health monitor device 600 , may be required prior to the initiation of communication and/or RF power transfer between the health monitor device 600 and the on-body patch device.
- the health monitor device 600 may be user configurable between multiple modes, such that the user may choose whether the communication between the health monitor device 600 and on-body patch device is performed automatically or requires a user confirmation.
- the electronics in the on-body patch device in one embodiment may be configured to rely on the RF power received from the health monitor device 600 to perform analyte data processing and/or transmission of the processed analyte information to the health monitor device 600 . That is, the on-body patch device may be discreetly worn on the body of the user or the patient, and under clothing, for example, and when desired, by positioning the health monitor device 600 within a predetermined distance from the on-body patch device, real time glucose level information may be received by the health monitor device 600 . This routine may be repeated as desired by the patient (or on-demand or upon request, for example) to acquire monitored real time glucose levels at any time during the time period that the on-body patch device is worn by the user or the patient.
- the health monitor device 600 may include an integrated analyte test meter and lancing device for lancing a bodily fluid sample, such as a blood sample, and measuring an analyte concentration, such as a blood glucose concentration.
- an integrated analyte test meter and lancing device for lancing a bodily fluid sample, such as a blood sample, and measuring an analyte concentration, such as a blood glucose concentration.
- FIG. 7 shows a touch-screen health monitor device in accordance with one embodiment of the present disclosure.
- a touch-screen health monitor device 700 may include the same functions and basic design as a health monitor device 600 without a touch-screen.
- a touch-screen health monitor device 700 would include a larger display unit 720 compared to the display unit 620 of a health monitor device 600 without a touch-screen in order to accommodate the extra area required for any touch-screen buttons 730 that may be used.
- a touch-screen health monitor device 700 includes a housing 710 , thereon which lies the touch-screen display unit 720 .
- the touch-screen health monitor device 700 may also include a strip port 740 for receiving a test strip 750 , which may include a fluid sample for analysis, such as a blood sample for a blood glucose concentration analysis.
- FIG. 8 is a flow chart illustrating a medication dosage calculation procedure for use in one or more embodiments of the present disclosure.
- a device such as a health monitor device 600 ( FIG. 6A ) receives an analyte concentration ( 810 ) for the current analyte level of a patient.
- the analyte level is compared to a predetermined threshold analyte level ( 820 ). For example, if the analyte is glucose and the analyte level is a blood glucose level of a patient, the threshold blood glucose level may be between 80 mg/dL and 120 mg/dL, or a tailored threshold determined by a healthcare professional.
- a list of available medication types may be displayed ( 830 ) on the display unit 620 of a health monitor device 600 .
- the analyte concentration level is a blood glucose concentration level for a patient suffering from, for example, diabetes
- the list of available medication types may be a list of available insulin types. From the list of available medication types, a medication type is selected ( 840 ) and a recommended dosage for the selected medication type based upon the current analyte concentration level is calculated ( 850 ) and displayed ( 860 ).
- FIG. 9 is a flow chart illustrating an analyte concentration determination and medication dosage calculation in one embodiment of the present disclosure.
- a fluid sample is detected ( 910 ), for example, by applying the fluid sample to a test strip 650 and inserting the test strip 650 into a strip port 640 of the health monitor device 600 .
- a current analyte concentration is calculated ( 920 ) based on analysis of the fluid sample.
- the health monitor device 600 may include a display unit 620 , such as a dot-matrix display, and the current analyte concentration is displayed ( 930 ) on the display unit 620 .
- the health monitor device 600 may include instructions or routines to perform a long-acting medication dosage calculation function.
- a long-acting medication may be a medication wherein a single dose may last for up to 12 hours, 24 hours, or longer.
- the instructions for a long-acting medication dosage calculation function may be in the form of software stored on the memory device 670 ( FIG. 6B ) and executed by the processor 660 ( FIG. 6B ) of the health monitor device 600 .
- the long-acting medication dosage calculation function may be an algorithm based on the current concentration of an analyte of a patient, wherein the long-acting medication dosage calculation function compares the current analyte concentration value to a predetermined threshold ( 940 ), which may be based on clinically determined threshold levels for a particular analyte, or may be tailored for individual patients by a doctor or other treating professional. If the current analyte concentration is above the predetermined threshold, the long-acting medication dosage calculation function may use the current analyte concentration value to calculate a recommended dosage of a long-acting medication ( 950 ). Once calculated, the recommended medication dosage may be displayed ( 960 ) on the display unit 620 of the health monitor device 600 .
- the health monitor device 600 may be configured to measure the blood glucose concentration of a patient and include instructions for a long-acting insulin dosage calculation function. Periodic injection or administration of long-acting insulin may be used to maintain a baseline blood glucose concentration in a patient with Type-1 or Type-2 diabetes.
- the long-acting medication dosage calculation function may include an algorithm or routine based on the current blood glucose concentration of a diabetic patient, to compare the current measured blood glucose concentration value to a predetermined threshold or an individually tailored threshold as determined by a doctor or other treating professional to determine the appropriate dosage level for maintaining the baseline glucose level.
- the long-acting insulin dosage calculation function may be based upon LANTUS® insulin, available from Sanofi-Aventis, also known as insulin glargine.
- LANTUS® is a long-acting insulin that has up to a 24 hour duration of action. Further information of LANTUS® insulin is available at www.lantus.com.
- Other types of long-acting insulin include LEVEMIR® insulin available from NovoNordisk (www.levemir-us.com).
- FIG. 10 is a flow chart illustrating a procedure for determining a recommended update to a long-acting insulin dosage regimen in one embodiment.
- Some patients with diabetes including patients with type-1 diabetes and patients with type-2 diabetes, may require or be recommended to take insulin as a method for maintaining a safe blood glucose level.
- a medical professional may determine that a dosage regimen of long-acting insulin, such as LANTUS® insulin, may be beneficial to a patient for maintaining a safe baseline blood glucose level.
- Long-acting insulin may be taken as, for example, a daily bolus dosage, and may have up to a 24 hour duration of action.
- Long-acting insulin may be used as an alternative for patients who may not wish to use an insulin pump, which provides a patient with a steady basal glucose level throughout the day.
- a patient may require only the long-acting insulin dose to maintain a safe baseline blood glucose level, and may not require periodic doses of a fast or rapid acting insulin to correct for spikes in blood glucose levels resulting from, for example, carbohydrate intake.
- long-acting insulin may be taken as an injection by, for example, a syringe or injection pen, as an oral stimulant from, for example, an inhaler, or as a transdermal patch delivery system.
- a glucose measuring device such as the health monitor device 600 described above in conjunction with FIG. 6A , may prompt for a fasting blood sample ( 1010 ) to measure a fasting blood glucose level.
- a fasting blood sample may be a blood sample of a patient taken after a predetermined period of time without food, such as 8 hours without food typically obtained in the morning after a period of sleep.
- the fasting blood sample may be received on a test strip 650 , which may be inserted into a strip port 640 of the health monitor device 600 for analysis.
- the health monitor device 600 may request and await confirmation that the provided blood sample is a fasting sample ( 1020 ).
- the confirmation that the provided blood sample is a fasting sample may be provided by the patient to the health monitor device 600 through, for example, the input buttons 630 of the health monitor device 600 .
- the health monitor device 600 may determine whether the provided blood sample is a fasting sample by determining if the current time is in the morning following what would typically be a predetermined period of sleep, or comparing the current time to stored past data and basing whether the sample is a fasting sample or not based upon trends of what time during the day that previous provided fasting samples were obtained.
- the health monitor device 600 may calculate and display the current blood glucose level of the provided sample with a warning that the displayed value is not a fasting blood glucose level ( 1030 ). In one aspect, if the provided blood sample is not a fasting sample, no recommended long-acting insulin dosage regimen update is calculated or displayed.
- a fasting blood glucose level may be determined by analyzing the blood glucose level of the received blood sample ( 1040 ). Once the fasting blood glucose level is determined, the value may be stored ( 1050 ) in a memory 670 of the health monitor device 600 , or alternatively, the value may be transmitted for storage in a memory of a secondary device or computer. In one embodiment, the stored fasting blood glucose level data may be time and/or date stamped. Once the fasting blood glucose level data is stored in the memory 670 , the data may be compared to a predetermined threshold value. In another embodiment, the current fasting blood glucose level may be averaged with stored fasting blood glucose level data from preceding days ( 1060 ), for example, the preceding, one, two, or four days, for comparison to the predetermined threshold value ( 1070 ).
- a dosage recommendation algorithm may be implemented based on the fasting blood glucose level.
- the dosage recommendation algorithm may be stored in the memory 670 in the health monitor device 600 and executed by the processor 660 in the health monitor device 600 , to calculate and display on a display unit 620 a recommended long-acting insulin dosage ( 1080 ).
- the dosage recommendation algorithm may be stored in a peripheral device containing a memory, and data may be transmitted to one or more peripheral devices over a data network for analysis and the results transmitted back to the health monitor device 600 for display.
- the severity of the symptoms of diabetes for patients may vary from individual to individual.
- Insulin used to maintain a stable baseline blood glucose level may be administered through, among others, the use of an insulin pump in the form of a basal insulin infusion (small dosages of insulin injected into the body at periodic intervals throughout the day), or may be administered through the use of single daily injections of long-acting insulin, such as LANTUS® insulin.
- long-acting insulin may be administered at various other intervals, such as twice a day, or every other day.
- Fast-acting and rapid-acting insulin for example, are more often used as single dose bolus injections for immediate correction to periodic blood glucose level fluctuations, which may be used in conjunction with the long-acting insulin used to maintain the baseline blood glucose level.
- Accurate calculation and administration of insulin to a diabetic patient is used as a measure for maintaining safe blood glucose levels in order to avoid incidents of hyperglycemia.
- FIG. 11 is a flow chart illustrating a procedure for calculating a dosage recommendation for a long-acting insulin and a fast-acting insulin in one embodiment.
- long-acting insulin dosage regimens are calculated and adjusted based upon a patient's fasting blood glucose level, or the blood glucose level of a patient after a predetermined length of time, such as 8 hours, without food (or after 8 hours of sleep).
- the fasting glucose level may be considered to be the baseline glucose level of a patient, and is further used for determining a long-acting insulin dosage calculation, which is typically used for controlling the baseline glucose level of a patient.
- fast-acting insulin bolus dosages are typically calculated based upon a current or future blood glucose level regardless of activities such as eating and exercise, as fast-acting insulin bolus dosages are typically used to correct a current on-the-spot blood glucose level fluctuation.
- a glucose measuring device such as the health monitor device 600 described above in conjunction with FIG. 6A , may prompt for a fluid sample ( 1110 ) to measure a blood glucose level.
- the fluid sample may be received ( 1120 ) at a strip port 640 of the health monitor device 600 in the form of a blood sample applied to a test strip 650 .
- the received sample may then be analyzed in order to measure a blood glucose concentration level ( 1130 ).
- the measured blood glucose concentration level may then be compared to a predetermined threshold level ( 1140 ) for determination of whether an insulin dosage may be required in order to adjust the blood glucose concentration level to a safe or optimal level.
- the health monitor device 600 may calculate a recommended dosage of long-acting insulin ( 1150 ) as well as a recommended dosage of a fast-acting insulin ( 1160 ).
- the dosages may be calculated based upon one or more software algorithms stored within a memory unit 670 and executed by the processor 660 of the health monitor device 600 . Once calculated, the recommended dosages of long-acting and fast-acting may be displayed on a display unit 620 of the health monitor device 600 ( 1170 ).
- the health monitor device 600 may only recommend a long-acting insulin dosage when the received blood sample is a fasting blood sample. In another embodiment, the health monitor device 600 may determine whether to recommend a long-acting insulin dosage or a fast-acting insulin dosage or both, based upon the current time of day, whereby the time of day consideration may be determined by analyzing trends of previous data stored in the memory 670 of the health monitor device 600 .
- a health monitor device 600 ( FIG. 6A ) with a medication dosage calculator may include a medication type selector function.
- the medication type selector function may allow a patient to request a recommended dosage for a variety of medication types.
- FIG. 12 is a flow chart illustrating a means for calculating a dosage recommendation for one or more selectable medication types.
- a health monitor device 600 may prompt for a fluid sample ( 1210 ) and subsequently analyze the fluid sample to ascertain an analyte concentration ( 1220 ).
- the health monitor device 600 may be a blood glucose measuring device, and may receive a fluid sample in the form of a blood sample applied to a test strip 650 and inserted into a strip port 640 of the health monitor device 600 .
- the blood sample may be analyzed to discern a blood glucose concentration, which may be used as an indicator for the blood glucose level of a patient from which the sample was obtained.
- a medication type selection is received ( 1230 ).
- the medication type selection may be established via a number of different methods, including providing a list of available medication types for which the health monitor device 600 is programmed to calculate dosage information.
- the health monitor device 600 is a glucose measuring device intended for the measurement of a patient's blood glucose level
- the corresponding medication for dosage calculation may be insulin.
- the glucose measuring device may include programming or algorithms for calculating insulin dosage information for a variety of insulin types, including long-acting insulin, intermediate acting insulin, fast-acting insulin, rapid-acting insulin, and very-rapid acting insulin. Further, programming or algorithms may be exclusive to specific insulin compositions, even amongst the general categories of insulin types.
- the medication type may be selected automatically by the health monitor device 600 based on, for example, a pre-programmed treatment regimen.
- the program or algorithm associated with the selected medication type may be applied to the ascertained analyte concentration in order to calculate a recommended medication dosage ( 1240 ).
- the recommended medication dosage and the ascertained analyte concentration may then be displayed on a display unit 620 of the health monitor device 600 ( 1250 ).
- the selected medication type may also be displayed on the display unit 620 to allow for confirmation that the recommended medication dosage is meant for the correct medication type.
- a list of available medication types for display and for selection may be limited to a predetermined list of available medications as indicated by the user, or alternatively by a doctor or other treating professional.
- a list or subset of available medication types for selection may be limited to a predetermined list of available (or pre-stored) or permitted medication stored in the health monitor device 600 .
- the list of available or permitted medication may be stored in the memory 670 of the health monitor device 600 .
- the health monitor device 600 may include programming or software instructions which, when a particular medication is selected, other medication known or determined to be incompatible with the selected medication (for example, due to potential adverse reactions when mixed with the selected medication), may automatically be removed from the list of available medication types before providing the list to the user of the health monitor device 600 .
- the memory 670 of the health monitor device 600 may store information related to a patient's medical history, for example, information related to medications the patient has been previously determined to cause allergic or undesirable reactions. Accordingly, the memory 670 may store, for example, a dynamic list of available medications that are appropriate for the medication dose determination in response to or based on a selection of a type of the medication selected for dosage calculation, or alternatively, based on one or more other characteristics based on the physiological condition of the user or the medication composition.
- a patient may make use of more than one medication to control a disease or health condition.
- diabetic patients including patients with Type-1 and severe Type-2 diabetes, may benefit from using more than one type of insulin to help control their blood glucose level.
- long-acting insulin to maintain a stable baseline blood glucose level
- fast-acting insulin injections to compensate for periodic blood glucose level fluctuations resulting from, for example, carbohydrate intake.
- techniques for calculating adjustments to daily insulin dosages to maintain a safe baseline blood glucose level, as well as on-the-spot dosage recommendations to correct for periodic blood glucose level fluctuations are provided.
- FIG. 13 is a flow chart illustrating a means for calculating insulin dosage information for more than one type of insulin.
- the more than one type of insulin may include a combination of a long-acting insulin and a rapid-acting insulin.
- dosages of the long-acting insulin may be calculated based upon a fasting blood glucose level of a patient.
- a health monitor device 600 FIG. 6A
- the fasting blood sample may be a blood sample taken from a patient after a predetermined length of time, such as at least 8 hours, without food and applied to a test strip 650 to be inserted into a strip port 640 of the health monitor device 600 for analysis.
- the health monitor device 600 may prompt for the fasting blood sample at the same time every morning. Once the fasting blood sample is received by the health monitor device 600 , the sample may then be analyzed in order to ascertain a blood glucose concentration ( 1320 ) of the patient from which the sample was obtained. Once ascertained, the blood glucose concentration may be stored ( 1330 ) in a memory 670 of the health monitor device 600 . In one aspect, the stored blood glucose concentration may be date and/or time stamped.
- An algorithm for calculating a long-acting insulin dosage recommendation may then be applied to the ascertained blood glucose concentration in order to calculate a recommended long-acting insulin dosage ( 1340 ) to be displayed on a display unit 620 of the health monitor device 600 ( 1350 ).
- the algorithm or routine for determining a long-acting insulin dosage recommendation may be a dosage update algorithm based upon initial settings as determined by, for example, a healthcare professional or an insulin manufacturer specification.
- an initial daily prescribed dosage of long-acting insulin such as LANTUS® insulin (which has up to a 24 hour active time)
- LANTUS® insulin which has up to a 24 hour active time
- 10 IU International Unit
- One International Unit (IU) of insulin is the biological equivalent of 45.5 micrograms ( ⁇ g) pure crystalline insulin.
- 10 IU/day of LANTUS® insulin may be the starting dosage of a long-acting insulin regimen.
- the fasting blood glucose concentration may be measured on a daily basis, and each measurement stored in a memory.
- the fasting blood glucose concentration average may be compared to a predetermined target fasting blood glucose concentration threshold.
- a recommended update to the daily dosage of long acting insulin may be calculated weekly, based upon the average glucose concentration of the preceding two or more days, and follow the below dosage schedule:
- the algorithm for calculating a long-acting insulin dosage recommendation may be a daily dosage update.
- the algorithm may compare a fasting blood glucose concentration to a predetermined threshold level, for example, a target threshold level as determined by a healthcare professional. If the fasting blood glucose concentration is greater than the target threshold level, the algorithm may recommend an increase of 1 IU/day of long-acting insulin. This may continue each day until the fasting blood glucose concentration is at or below the target threshold level.
- the target threshold level of fasting blood glucose concentration may be set by the user or may be a customized target threshold as determined by a healthcare professional.
- the algorithm for calculating a long-acting insulin dosage recommendation may be based on both an upper and lower threshold value.
- a healthcare professional may recommend a safe fasting blood glucose concentration between a predefined range.
- the algorithm may update the long-acting insulin dosage on a daily basis.
- the algorithm may recommend an increase to the current long-acting insulin dosage by 1 IU/day, while if the fasting blood glucose concentration is less than the lower threshold, the algorithm may recommend a decrease to the current long-acting insulin dosage by 1 IU/day.
- the fasting blood glucose concentration is between the upper and lower threshold, the algorithm may recommend no change to the current long-acting insulin dosage regimen.
- the algorithm for calculating a long-acting insulin dosage recommendation may be based upon past and present fasting blood glucose concentration values.
- the algorithm may not recommend an update to a current glucose dosage unless the fasting blood glucose concentration is above or below a certain upper and lower threshold.
- the algorithm may not recommend an update to a current glucose dosage unless the fasting blood glucose concentration is outside a certain threshold for a certain number of consecutive days, such as, for example, for two or more straight days.
- a software program for calculating the insulin dosage update may be programmed to not recommend an update to an insulin dosage regimen for safety measures in the case that the current fasting blood glucose concentration is in error or is not an acceptable value.
- the algorithm may be programmed to not recommend an update to an insulin dosage regimen if the insulin dosage regimen was recently updated, for example, if the insulin dosage regimen was updated within the preceding two days.
- an alarm system may activate.
- the alarm system may be in the form of an auditory, visual, and/or vibratory alarm, or may be an alarm notification transmitted over a data network to, for example, a healthcare professional.
- Other values that may activate the alarm system may include, an upper or lower threshold current blood glucose value, a threshold number of consecutive days wherein the fasting blood glucose value increased or decreased, a missed expected sample time, or if an error is detected.
- the health monitor device 600 may also include programming to calculate a fast-acting insulin dosage.
- a fast-acting insulin injection may be used to help stabilize blood glucose concentration fluctuations throughout the day due to, for example, carbohydrate intake.
- the health monitor device 600 may prompt for a non-fasting bodily fluid sample ( 1360 ), which may be in the form of a blood sample applied to a test strip 650 and received at the strip port 640 of the health monitor device 600 .
- Non-fasting blood samples may be taken periodically throughout the day at regular intervals or at irregular intervals depending upon a patient's physical state, such as when a patient determines that his/her blood glucose level is lower or higher than one or more predetermined threshold or desired level.
- events may also define when a patient takes a non-fasting blood sample, such as before or after meals, exercise, or after taking other medications.
- the blood sample may then be analyzed and a blood glucose concentration is determined ( 1370 ).
- An algorithm for calculating a fast-acting insulin dosage recommendation may then be applied to the ascertained blood glucose concentration in order to calculate a recommended fast-acting insulin dosage ( 1380 ) to be displayed on a display unit 620 of the health monitor device 600 ( 1390 ).
- the algorithm may be designed for calculating a dosage recommendation for an intermediate, rapid, or very-rapid acting insulin type or a combination thereof.
- a health monitor device 600 including programming for calculating a medication dosage or therapy profile recommendation may further include an integrated medication delivery system.
- the integrated medication delivery system may automatically deliver the medication dosage as recommended by the health monitor device 600 .
- the health monitor device 600 may be preprogrammed with information related to the medication of the medication delivery system thus eliminating any possible errors resulting from a patient's accidental entry of a wrong medication in a medication selector function of the health monitor device 600 .
- the medication delivery system may be detachable from the health monitor device 600 .
- a health monitor device 600 including programming for calculating medication dosages for two or more medication types may further include an integrated medication delivery system.
- the medication delivery system may include two or more reservoirs, each designated for storing one of the two or more medication types, and each with an individual delivery mechanism.
- the two or more reservoirs may share a single delivery mechanism.
- the medication delivery system may automatically deliver each medication in doses as recommended by the health monitor device 600 .
- the health monitor device 600 may include a corresponding docking station or one or more other peripheral devices.
- the docking station may include, among others, a transmitter whereby when the health monitor device 600 is docked to the docking station, the health monitor device 600 and docking station may communicate over a data network with, for example, a healthcare provider, for the transfer of data or receipt of instructions or new dosage regimens.
- the docking station transmitter may be configured for transmission protocols including, but not limited to, cellular telephone transmission, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM), internet communication, facsimile communications, and/or telephone communication.
- CDMA code division multiple access
- GSM Global System for Mobile communications
- the docking station may also be configured to provide power for recharging a rechargeable battery of the health monitor device 600 .
- the docking station may be configured for communication with a personal computer for additional storage, programming, and/or communication.
- the health monitor device 600 may include software for monitoring and ordering replacements for consumable products associated with the health monitor device 600 .
- Consumable products may include, among others, analyte test strips, lancing devices, types of medication, such as types of long-acting and fast-acting insulin, medication deliver devices, such as syringes or injection pens, integrated lancet and testing striplet devices, sensors for an implantable sensor glucose monitoring system, or batteries.
- FIG. 14 illustrates a block diagram of a replenishment management system in accordance with one embodiment of the present disclosure.
- the replenishment management system 1400 includes a server terminal 1410 operatively coupled to one or more user terminals 1420 via a data network 1430 .
- each of the user terminals 1420 are also configured to be operatively connected to a respective one or more testing or monitoring devices 1440 .
- a financial account terminal 1460 operatively coupled to the data network 1430 for communication with the server terminal 1410 and a corresponding one of the user terminals 1420 .
- the testing or monitoring device 1440 may include a health monitor device as described above in conjunction with FIG. 6A , which may be configured to automatically and wirelessly transmit the measured analyte data to the server terminal 1410 at a predetermined frequency over the wireless connection 1451 .
- the server terminal 1410 may be configured to detect and receive the measured analyte data from the health monitor device and to store the received data in a corresponding user account associated with the health monitor device.
- the health monitor device is configured to transmit medication dosage information, such as insulin dosage information, to the server terminal 1410 .
- the medication dosage information may be information related to periodic dosages of long-acting and/or fast-acting insulin.
- each of the user terminals 1420 , the financial account terminal 1460 , and the server terminal 1410 are operatively coupled to the data network 1430 via a corresponding data communication link 1450 .
- the data communication link 1450 may include a wired or wireless communication path which may be configured for secure, encrypted bi-directional data exchange over the data network 1430 .
- the data communication link 1450 in one embodiment may include Wi-Fi data communication, infrared data communication (for example Infrared Data Association (IrDA) communication), Bluetooth® data communication, ZigBee® data communication, USB or FireWire cable based data communication, Ethernet cable based data communication, and dial up modem data communication.
- IrDA Infrared Data Association
- the user terminals 1420 may include, among others, one of a personal computer (including a desktop or a laptop computer) or a handheld communication device such as an iPhone, Blackberry, Internet access enabled mobile telephones, a bi-directional communication enabled pager, and a communication enabled personal digital assistant (PDA).
- the user terminals 1420 include an output unit such as a display and/or speakers, an input unit such as a keyboard or a touch-sensitive screen, as well as a controller such as a CPU for performing user instructed procedures at the user terminals 1420 .
- the user terminals 1420 may be configured to communicate with the data network 1430 using a wireless data communication protocol such as Bluetooth®, 801.11x, and ZigBee®. Additionally, the user terminal 1420 may also be configured to communicate with the testing or monitoring device 1440 via short range RF communication path, an IrDA communication path, or using Bluetooth® communication protocol. Additionally, the testing or monitoring device 1440 may also be configured to connect to the respective user terminals 1420 via a wired connection such as a USB connection, an RS-232 cable connection, an IEEE 1394 or FireWire connection, or an Ethernet cable connection.
- a wireless data communication protocol such as Bluetooth®, 801.11x, and ZigBee®.
- the user terminal 1420 may also be configured to communicate with the testing or monitoring device 1440 via short range RF communication path, an IrDA communication path, or using Bluetooth® communication protocol. Additionally, the testing or monitoring device 1440 may also be configured to connect to the respective user terminals 1420 via a wired connection such as a USB connection, an RS-232 cable
- the financial account terminal 1460 may be configured to communicate with the server terminal 1410 and the user terminals 1420 over the data network 1430 using either or a wired or wireless secure and encrypted connection.
- high level of security for data communication to and from the financial account terminal 1430 may be used such as an encryption level exceeding 128-key encryption, and the like.
- the financial account terminal 1460 may include one of a banking institution terminal, a credit card institution terminal, a brokerage institution terminal, and any other financial institution terminal which maintains a financial account of a user with which financial account transactions may be performed. This aspect of the present disclosure is discussed in further detail below.
- the server terminal 1410 in one embodiment may include a controller 1411 operatively coupled to an input/output (I/O) interface unit 1412 , a read-only memory (ROM) 1413 , a random access memory (RAM) 1414 , and a storage unit 1415 .
- the storage unit 1415 includes a server application 1416 and an operating system 1417 .
- the controller 1411 may in one embodiment be configured to communicate with the user terminals 1420 and the financial account terminal 1460 over the data network 1430 via the I/O interface unit 1412 , under the control of the various processes and routines stored in the ROM 1413 and the storage unit 1415 as well as user transmitted requests and information.
- the server application 1416 and the operating system 1417 of the storage unit may be configured to provide a proprietary interface for the users, to execute secure and encrypted data communication over the data network 1400 .
- the server terminal 1410 may be configured to provide a proprietary internet-based user interface at a predetermined URL for the users to login from the user terminals 1420 , for example, for communication with the server terminal 1410 .
- the data network 1430 may include the internet, and wherein the server application 1416 and the operating system 1417 of the server terminal 1410 are configured to provide a dedicated website for allowing the users to securely and easily log in to their respective accounts using the user terminals 1420 over the data network.
- the storage unit 1415 of the server terminal 1410 in one embodiment may be configured to store data and information related to the user accounts such as, but not limited to, user account login identification and password, user contact information such as telephone and/or facsimile numbers, email addresses, billing and shipping addresses, user account profile information such as replenishment level information, seasonality or periodicity of user use of the testing, monitoring, or dosing device, prescribed medication information, user financial account information (for example, a bank routing number and bank account number in the case of a banking institution), and user testing, monitoring, or medication dosing device data information such as the user strip order history, medication order history, health related monitoring data such as previously measured glucose levels, user specific basal profile information, bolus determination information, insulin sensitivity, trend information determined based on the measured glucose levels (and determined by the controller 1411 ), and healthcare provider information for the user such as contact information for the user's physician, hospital, and nursing facilities.
- user contact information such as telephone and/or facsimile numbers, email addresses, billing and shipping addresses
- user account profile information
- the storage unit 1415 may further be configured to store an expiration information and/or lot number associated with the consumable item, or to calculate expiration information from the lot number.
- the server terminal 1410 may be configured to determine the expiration information of the consumable item prior to or at the time of replenishment transaction (discussed in detail below), based on one or more of several factors, and further configured to transmit the expiration information to the user terminal 1420 associated with the replenishment transaction.
- the one or more of the several factors determining the expiration information associated with the consumable item includes the lot number associated with the consumable item, where each lot number has a unique expiration date associated therewith, a shipment date of the consumable item from the manufacturer, and a date of manufacture of the consumable item.
- the user requesting the replenishment transaction for the consumable item will be notified of the expiration information such as the expiration date associated with the consumable item, and will be alerted that the consumable item will not function as optimally beyond the expiration date.
- the expiration information such as the expiration date associated with the consumable item
- the consumable item will not function as optimally beyond the expiration date.
- glucose test strips to ensure the accuracy of the test results showing the measured glucose levels it is important that the user/patient be aware of such expiration date of the glucose test strips, so that the measured glucose levels are as accurate as possible.
- medication such as insulin
- the importance of a patient's awareness of the expiration date may be even more important than the expiration date of a consumable item, such as a glucose test strip.
- expired medication may not only have a diminished effectiveness, it may in fact have a severely detrimental effect on the patient's health.
- a warning signal may be generated and communicated to a healthcare professional or to the user in the case where the consumption of the test materials, as determined by the server terminal 1410 , is less or more than the consumption required to meet this frequency or threshold of testing, monitoring or dosing.
- the controller 1411 of the server terminal 1410 may be configured to determine trend information based on measured glucose levels so as to determine and correspondingly generate for the user terminal 1420 for display, a color coded indication of the user's glucose level projections including arrow indicators, color coded warning or notification indicators, and associated audible alerts.
- the server terminal 1410 may be configured to generate and transmit to the user terminal 1420 a color coded arrow indicator for display on the user terminal 1420 to visually and easily inform the user of the projected or anticipated trend in the glucose level based on the measured glucose levels.
- the controller 1411 of the server terminal 1410 may be configured to determine trend information based on insulin dosage information so as to determine and correspondingly generate for the user terminal 1420 for display, a color coded indication of the user's projected future insulin dosage information, including projected increase or decrease in insulin dosage.
- the controller 1411 may be configured to alert the patient if the rate of change of the insulin dosage information over a period of time is above a certain threshold, possibly indicating an advancement in a user's health condition, such as a worsening of a diabetic condition.
- a predetermined threshold it may be an indication that the user should visit their primary care physician in order to ascertain information relating to the health condition of the patient, and possibly determine a change in treatment or medication.
- the server application 1416 stored in the storage unit 1415 of the server terminal 1410 may be configured to perform, under the control of the controller 1411 , the various procedures and processes as discussed below in conjunction with FIGS. 15-19 , as well as to store any information related to the user accounts and profiles within the scope of the present disclosure.
- FIG. 15 is a flowchart illustrating user account registration setup and account subscription process in accordance with one embodiment of the present disclosure.
- the server terminal 1410 receives from a user terminal 1420 user account registration information.
- the received user account registration information may include, among others, the user name, user address, the user telephone number, the user testing, monitoring, or dosing device information such as model information of the testing, monitoring, or dosing device, and the user medication prescription information.
- the server terminal 1410 is configured to generate a user account profile and login information including password and login identification, all of which are stored in the storage unit 1415 of the server terminal 1410 . Then at step 1530 , the server terminal 1410 is configured to transmit the user login information including the generated login identification information and associated password to the user terminal 1420 . After transmitting the user login information or alternatively, substantially contemporaneously to the login information transmission, the server terminal 1410 is configured to transmit a prompt or request to the user terminal for the user desired subscription information for the consumable product replenishment.
- the user desired consumable product replenishment subscription information may include low product count threshold notification information and consumable product replenishment transaction option information.
- a low product count threshold information may be a low test strip count or a low medication, such as insulin, amount.
- the server terminal 1410 in one embodiment is configured to request from the user via the user terminal 1420 when the user wishes to be notified of a low consumable product count for performing a replenishment procedure, and also, the user's desired purchase transaction option such as establishing a link to the user's financial institution. For example, if the user wishes to be notified of a low test strip count level when the user has 150 or less strips for usage with the health monitor device, the user may specify 150 as the low strip count level at which point, the user desired notification by the server terminal 1410 that replenishment procedure would be necessary.
- the replenishment transaction option information provided to the user terminal 1420 by the server terminal 1410 may include one of establishing a link to the user's financial account institution for processing the purchase transaction for the purchase of the replenishment consumable product, prompting the user to allow purchase transactions over the data network 1430 , and a simple replenishment notification with option to perform the purchase transaction for the purchase of the replenishment product.
- the server terminal 1410 is configured to receive the user selected low consumable product count notification and the replenishment transaction information for the user account from the user terminal 1420 .
- the server terminal 1410 then stores the received information related to the user selected low consumable product count notification and the chosen replenishment transaction option in the storage unit 1415 associated with the user account information also stored therein.
- the server terminal 1410 may be configured to transmit a notification to the user terminal 1420 a confirmation of the receipt and the information which the user selected for the low consumable product count notification level and the product replenishment transaction that the user selected. Thereafter, the user account registration setup and account subscription process shown in FIG. 15 ends.
- FIG. 16 is a flowchart illustrating an overall replenishment procedure for the user account in accordance with one embodiment of the present disclosure.
- the server terminal 1410 ( FIG. 14 ) in one embodiment is configured to detect a user login transmission, including, for example, the detection of the user account login identification information and the corresponding password transmitted from the user terminal 1420 over the data network 1430 .
- the server terminal 1410 is configured to verify the received user account login identification information. That is, in one embodiment, the server terminal 1410 is configured to confirm the accuracy of the received account login identification information from the user terminal 1420 , and to correspond the received account login identification information to a corresponding stored user account.
- the server terminal 1410 may be configured to search the storage unit 1415 for a user account profile generated and which corresponds to the received user account login identification information.
- the procedure returns to step 1610 and waits for a subsequent transmission of the user account login identification information from the user terminal 1420 .
- the server terminal 1410 may be configured to generate and transmit a login fail notification corresponding to the failed verification of the user account login at step 1620 to the corresponding user terminal 1420 .
- the server terminal 1410 is configured to receive a consumable product usage information from the user terminal 1420 whose user is now logged into the corresponding user account profile.
- Consumable product usage information may include, among others, usage information for the number of test strips or dosage information for a medication, such as a long-acting and/or a fast-acting insulin.
- the server terminal 1410 at step 1640 is configured in one embodiment to retrieve the corresponding user account profile from the storage unit 1415 , for example, (such as in a database associated with the storage of the user account profiles in the storage unit 1415 ). Then, with the consumable product usage information received from the user terminal 1420 , and the corresponding user account profile retrieved from the storage unit 1415 , in one embodiment, the server terminal 1410 at step 1650 is configured to perform a consumable product replenishment procedure discussed in further detail below to replenish the consumable product supply associated with the user account profile.
- the server terminal 1410 at step 1660 may be configured to update the user account profile associated with the user by for example, updating the database stored in the storage unit 1415 of the server terminal 1410 associated with the user account profile for the user that is logged in.
- the database stored in the storage unit 1415 may also be linked to systems that are configured to track user demand, so as to forecast and anticipate demand, and also to track overall consumption patterns, preference, seasonal demand, geographic demand, and other similar demographic data for use in managing supply side activities more effectively and efficiently.
- the individual user data in the database stored in the storage unit 1415 may also include insurance or other individual reimbursement coverage rates of the individual user. This data may be used to determine a user co-pay and the amount that the insurance or other individual reimbursement coverage allows to the individual user.
- the results of these calculations on the user data in the database stored in the storage unit 1415 may be used as a basis for purchase or charge transaction to user for the co-pay amount, to charge the insurance or other individual reimbursement coverage for the amount so covered, and also to provide an alert signal in the case that the individual user may exceed the limits of payment coverage, as stored in the database in the storage unit 1415 , so that action may be taken based on the alert signal.
- FIG. 17 is a flowchart illustrating the replenishment procedure shown in FIG. 16 in further detail in accordance with one embodiment of the present disclosure. More specifically, the strip replenishment procedure of step 1650 ( FIG. 16 ) in one embodiment begins at step 1710 where the server terminal 1410 ( FIG. 14 ) in one embodiment is configured to compare the received consumable product usage level with a user selected threshold level.
- the user selected threshold level in one embodiment may correspond to the one or more of low consumable product count notification level which the user selected during the user account registration procedure as shown in FIG. 15 .
- the received consumable product usage level at step 1710 in one embodiment corresponds with the received consumable product usage information at step 1630 ( FIG. 16 ) received from the user terminal 1420 .
- the consumable product replenishment procedure at step 1720 determines whether the received consumable product usage level is below the user selected threshold level. If it is determined at step 1720 that the received consumable product usage level is above the user selected threshold level, then at step 1730 , the server terminal 1410 transmits a user notification to the corresponding user terminal 1420 notifying that replenishment is unnecessary, and thereafter, the consumable product replenishment procedure terminates.
- the server terminal is configured to determine the amount of the consumable product needed for replenishment. More specifically, the server terminal 1410 in one embodiment may be configured to not only determine whether consumable product replenishment is necessary for the associated user account, but also, what the amount of necessary replenishment should be based on one or more predetermined factors such as the desired or optimal consumable product level or count selected by the user (and previously stored in the storage unit 1415 , for example, of the server terminal 1410 ), and the time frame in which the consumable product replenishment procedure is triggered based upon the user account profile information (that is, based on the user's consumable product usage history profile, whether the triggered consumable product replenishment procedure is temporally closer to the most immediately preceding consumable product replenishment procedure).
- the server terminal 1410 in one embodiment may be configured to not only determine whether consumable product replenishment is necessary for the associated user account, but also, what the amount of necessary replenishment should be based on one or more predetermined factors such as the desired or optimal consumable product level or count selected by the user (and previously stored in
- such usage historical information determined by the server terminal 1410 may provide valuable information to the user as well as to the server terminal 1410 to maintain an efficient and reliable consumable product replenishment routine so as to not result in either over supply of products, or a supply of consumable products running dangerously low.
- the server terminal 1410 ( FIG. 14 ) in one embodiment is configured to perform a charge transaction to the financial account associated with the user account so as to charge the user's financial account for the purchase and shipping of the replenishment products to the user associated with the user account profile.
- the server terminal 1410 is configured to retrieve the financial account information stored and associated with the user account and performs the charge transaction over the data network 1430 with the corresponding financial account terminal 1460 .
- the financial account information in one embodiment may include one of a bank account, a credit card account, a debit account, a pre-paid financial account, or any other cash or cash equivalent account (such as the redemption of airline miles or vendor points) which the server terminal 1410 is configured to recognize with monetary value.
- the server terminal 1410 in one embodiment is configured to interact with the financial account terminal 1460 over the data network 1430 in order to perform the charge or debit transaction for the amount associated with the amount of replacement product. If the associated financial account terminal 1460 returns a failed transaction notification to the server terminal 1410 based on the server terminal 1410 transmission of the charge transaction over the data network 1430 , then at step 1770 , the server terminal 1410 in one embodiment is configured to generate and transmit a notification to the user terminal 1420 notifying the user at the user terminal 1420 that the consumable product replenishment procedure has failed.
- the server terminal 1410 is configured to notify the user that the reason for consumable product replenishment failure is due to inaccurate or outdated financial account information associated with the user account, and thus, is configured to prompt the user to update the user's financial account associated with the user's account profile stored in the server terminal 1410 .
- the server terminal 1410 is configured to retrieve the user shipping information associated with the user account profile, and executes the shipping procedure to ship the replenishment consumable products purchased by the user to the user's designated shipping location.
- the server terminal 1410 may be configured to prompt the user to verify or update the desired shipping location (such as destination address and time frame for shipping to include expedited shipping or custom shipping options, for example).
- the server terminal at step 1790 is configured to generate and transmit a notification to the user terminal 1420 associated with the user account confirming the shipment of the ordered products as well as the shipping and the fulfilled order details. Also, the server terminal 1410 is configured to update the associated user account based on the charge transaction and the shipping transaction performed. In this manner, in accordance with one embodiment of the present disclosure, the users may conveniently place a shipment order of products in advance of running low on the product, and rather then relying upon the user's manual calculation or determination of the needed products based upon the user's usage, such determination is automatically performed for the user, and the user can easily make the purchase transactions for the replenishment consumable products quickly and easily.
- FIG. 18 is a flowchart illustrating the replenishment procedure shown in FIG. 16 in further detail in accordance with another embodiment of the present disclosure.
- the server terminal 1410 is configured to transmit to the user terminal 1420 a predetermined or calculated amount of consumable products to be shipped at step 1810 .
- the server terminal 1410 may be configured to determine the amount of consumable products to be shipped based on one or more predetermined factors such as the user product usage level, the user selection of low consumable product notification information, the user's desired consumable product inventory, and the user's desired frequency of product replenishment.
- the user may confirm the received number of consumable products to be shipped as the number of products that the user wants to receive, and thus, may transmit an acceptance notification to the server terminal 1410 which the server terminal 1410 at step 1820 is configured to receive, for example, as an acceptance of the order associated with the amount of consumable products to be shipped to the user.
- the server terminal 1410 may be configured to receive order payment information for the purchase of the amount of consumable products that the user has accepted to be shipped to the user.
- the user may transmit from the user terminal 1420 to the server terminal 1410 over the data network 1430 , a user financial account information, such as a credit card information or a bank account information to be used to perform the purchase transaction.
- the server terminal 1410 having received the financial account information from the user terminal 1420 , performs and completes the order transaction for the purchase of the amount of consumable products accepted by the user and to be shipped to the user with the received payment information.
- the server terminal 1410 at step 1850 is configured in one embodiment to generate an order confirmation notification and to transmit the notification to the user.
- the order confirmation notification may include the amount of consumable products ordered, the shipping or mailing address where the ordered products are to be shipped, and the amount charged to the financial account associated with the payment information.
- the user is not required to provide the user's financial account information to have it stored, for example, in the user account profile at the server terminal 1410 .
- This approach would be particularly desirable for users who do not wish to have their financial account information disseminated and stored in vendor sites such as the server terminal 1410 configured to perform consumable product replenishment procedures.
- FIG. 19 is a flowchart illustrating a user account update and maintenance procedure in accordance with one embodiment of the present disclosure.
- a user account update procedure is prompted.
- This may be a server terminal 1410 ( FIG. 14 ) triggered procedure (for example, when it is determined that the user financial account information stored in the server terminal 1410 is outdated or no longer accurate), or alternatively, the user at the user terminal 1420 may initiate the user account update procedure of step 1910 based on the user's desire to modify one or more settings or parameters associated with the user account profile.
- the server terminal 1410 determines that the user account update is not needed, then at step 1920 , it is determined that the account update procedure is unnecessary and a corresponding notification is transmitted to the user terminal 1420 .
- the server terminal 1410 determines at step 1910 that the updated information with which the user wishes to update is the same at that which is stored in the server terminal 1410 , then, rather then expending the processing power of the server terminal 1410 to perform the user account update procedure, the server terminal 1410 is configured to generate and transmit the notification to the user terminal that the user specified account update is not necessary.
- the server terminal 1410 is configured to retrieve the stored user account associated with the user profile. Thereafter, at step 1940 , the server terminal 1410 is configured to detect the receipt of updated information associated with the user profile received from the user terminal 1420 . Thereafter, the server terminal 1410 at step 1950 is configured to update the user account with the updated information received from the user terminal 1420 . In one embodiment, the server terminal 1410 may be configured to update the database stored in the storage unit 1415 , and which is associated with the user account to be updated based on the account update information received from the user terminal 1420 . Upon completing the user account update with the received updated information, the server terminal 1410 at step 1960 is configured to transmit a notification to the user terminal 1420 to notify and confirm the update to the user account.
- the user's use of the account or access to the subscription based account profile serves to compare the number of remaining test strips with the desired minimum number of strips which the patient may have specified or the amount of remaining insulin with the desired minimum amount of insulin which the patient may have specified, and to automatically initiate and execute the purchase transaction of the test strips, insulin, or other consumables for the user to order, and deliver the products to the patient on time such that the patient does not run low on the item.
- an efficient system and method for the user to always maintain a minimum number of consumable items on order or to be ordered based on the user's rate of usage of the item is provided.
- the server terminal 1410 may be configured to provide a loyalty based rewards program such that based on a predetermined criteria, the users may be provided with a discounted price for the replenishment orders of the test strips or medication, such as insulin, and/or be offered a replacement health monitor device or medication delivery device based on the user's replenishment transaction history.
- the server terminal 1410 may be configured to flag a user account profile which has executed a threshold amount of replenishment transactions (whether based on the number of products ordered for replenishment, or based on the total value of the replenishment transactions sum), and to offer an incentive to continue to maintain the user account, and thus with the replenishment transactions.
- the server terminal 1410 may be configured to automatically offer to send a replacement health monitor device and/or medication delivery system, such as a syringe or injection pen, at every calendar year (or at a predetermined frequency) so long as the user's frequency and volume of replenishment transaction satisfies a threshold level.
- the server terminal 1410 may be configured to apply a price discount for future replenishment transactions based on the user satisfying the threshold level discussed above. In this manner, within the scope of the present disclosure, the users or patients are provided with an incentive to continue to maintain the user account and to continue performing the replenishment transactions.
- the server terminal 1410 may be configured to automatically provide the special commercial terms to the provider of insurance or other individual reimbursement, or to the government or authority.
- FIG. 20 is a flowchart illustrating modified therapy management procedure including medication dosage determination based on real time monitored analyte levels in accordance with one embodiment of the present disclosure.
- the current therapy parameters are retrieved 2010 and the retrieved current therapy parameters are analyzed based on the received real time data associated with the monitored or acquired analyte levels and/or updated analyte trend information 2020 .
- one or more preprogrammed medication delivery profiles or rates including, for example, but not limited to medication delivery rate or profiles including, for example, basal profiles, correction bolus amount, carbohydrate bolus amount, temporary basal profiles and associated parameters are retrieved and analyzed based on, for example, the received real time data associated with the monitored or acquired analyte levels and/or updated analyte trend information, and may further, factor in the insulin sensitivity level or related information of the patient as well as insulin on board information.
- one or more modified therapy profiles are calculated 2030 . That is, based upon the glucose levels monitored by the health monitor device with a medication dose calculation function 100 ( FIG. 1 ), a modification or adjustment to the programmed, pre-programmed or programmable basal profiles stored in the health monitor device with a medication dose calculation function 100 may be determined, and the modified therapy profile is output to the patient 2040 , for example on the display 120 of the health monitor device 100 .
- the modification or adjustment to the pre-programmed delivery profiles may be provided to the patient for review and/or execution to implement the recommended modification or adjustment to the programmed, pre-programmed or programmable therapy profiles (e.g., basal profiles).
- Embodiments of the present disclosure include current therapy parameters as discussed above including medication delivery rate information, frequency of medication dosing information, previously administered medication delivery rate, amount, delivery duration, and the like, as well as medication sensitivity information (unique to each user or patient) including, for example, insulin sensitivity.
- current therapy parameters further include exercise regimen, compliance to medication therapy information (for example, indications or confirmations that the recommended or programmed medication was administered, exercise regimen and/or diet profiles were followed or complied with, and the like).
- the patient may be provided with one or more adjustments to the existing or current therapy management profiles including for example, medication delivery profiles such as basal profiles and/or bolus dosage recommendation (amount or time period for administration) or any other programmed, pre-programmed or programmable therapy profiles based on monitored or acquired physiological levels of the patient such as analyte levels of the patient.
- medication delivery profiles such as basal profiles and/or bolus dosage recommendation (amount or time period for administration) or any other programmed, pre-programmed or programmable therapy profiles based on monitored or acquired physiological levels of the patient such as analyte levels of the patient.
- modification or adjustment to the programmed, pre-programmed or programmable therapy management profiles may be determined and provided to the patient for review and/or implementation or execution as desired by the patient.
- the user when provided with the therapy modification recommendation, may decide to execute or implement the recommended therapy modification for example, initiating one or more routines of functions for implementation of the same.
- a diabetic patient may improve the insulin therapy management and control of the variation in the glycemic levels within desired and/or acceptable range.
- therapy parameters may be associated with or tagged in conjunction with current or past analyte level measurements.
- a patient measures their current analyte level, for example utilizing a health monitor device such as those described in FIGS. 1 , 6 A and 7
- one or more therapy related parameter and/or associated analyte level measurements may be tagged or flagged and the corresponding tagged or flagged information stored in the database.
- Therapy parameters which may be associated with analyte level measurements may include, but are not limited to, events such as medication intake, carbohydrate intake, exercise, sleep, travel, work related events, and associated parameters such as the amount or time duration related to the corresponding events.
- analyte level data may be stored in a database including the associative one or more tags related to the therapy parameters.
- a patient or other healthcare professional may then be able to query the database based on particular therapy parameters, and optionally use the results for, for example, determination of a desired therapy profile.
- the database as described in further detail above, may be stored in the memory of the health monitor device, or alternatively or additionally be stored in a memory of an external peripheral device, computer, or server.
- the therapy parameter tag may be associated with a current analyte level manually or automatically.
- the health monitor may display a request to the patient to confirm if a therapy parameter is associated with the current analyte level measurement.
- the health monitor may display a request to the patient to choose from a selected list of available therapy parameter tags, the corresponding current therapy parameter to associate with the current analyte level.
- the patient may manually choose to associate a therapy parameter tag with the current analyte level measurement by, for example, entering a preprogrammed code or choosing a therapy parameter tag from a list.
- the health monitor device may be programmed to automatically determine if the current analyte level measurement should have a therapy parameter tag associated therewith.
- the health monitor device may compare the current time and analyte level with historical data saved in a database or memory, and determine based upon said historical data if the current analyte level measurement is likely associated with a therapy parameter tag. For example, if historical data indicated a carbohydrate intake within a preselected time range on each of a number of preceding days with a similar analyte level measurement as the current analyte level measurement, the health monitor may automatically tag the current analyte level measurement with a carbohydrate intake therapy parameter tag.
- the health monitor device may be programmed to associate analyte level measurements with corresponding therapy parameter tags during particular times of the day in accordance with the specified therapy regimen.
- the health monitor device may require a user confirmation prior to storing the data in a memory or database.
- the adjustment or modification to the therapy management profiles may include statistical analysis, including, linear regression, modified linear regression analysis, forecasting techniques, data mining and/or other suitable data analysis to determine customized therapy management modification based on the variation in the glycemic profiles of the patient or the user.
- routines and/or functionalities for data processing, analysis and display including user input and output of information may be performed by the health monitor devices ( 100 , 600 , 700 ) described above.
- software algorithm or programs may be stored in one or more memory devices or storage units of the health monitor devices that may be retrieved or accessed by microprocessors and/or control units including, for example, application specific integrated circuits that includes one or more state machines programmed to perform routines or logic based on the algorithm or programs retrieved from the one or more memory devices or storage units.
- FIG. 21 is a flowchart illustrating contextual based therapy management including medication dosage determination in accordance with one embodiment of the present disclosure.
- one or more user input parameter is received 2110 such as, for example, user's age, gender, physiological profile, existing medication (i.e., prescription or nonprescription medication consumed or ingested during a relevant time period), the amount of carbohydrate to ingest, type of exercise to perform, current time of day information, insulin on board information determined based on time and amount information of previously administered medication doses, frequency, type and amount of previously administered medication doses (for example, the frequency, time of day information, and/or amount of administered bolus doses over a predetermined time period (e.g., over a 24 hour period, over a 48 hour period, or all such information stored and/or available for use in the analysis) or any other appropriate information that may impact the determination of the suitable medication level.
- a predetermined time period e.g., over a 24 hour period, over a 48 hour period, or all such information stored and
- one or more database is queried 2120 .
- the database may be provided in the health monitor device with a medication dose calculation function 100 ( FIG. 1 ).
- the one or more databases may be provided in one or more remote locations such as a server or a remote user terminal.
- the database query in one embodiment may be configured to search or query for medication dosage levels that are associated with similar parameters as the received one or more user input parameters. Thereafter, the queried result is generated and provided to the user 2130 which may be acted upon by the user, for example, to administer the medication dosage amount based on the queried result.
- the user selection of the administered medication dosage level is stored in the database 2140 with the associated one or more user input parameters as well as the time and date information of when the user has administered the medication dosage amount.
- insulin dosages and associated contextual information may be stored in the one or more databases for retrieval, analysis, updating and/or modification.
- a bolus dose amount for a diabetic patient may be determined in the manner described above using the stored historical information without performing a mathematical calculation which takes into account of variables such as sensitivity factors varying with time and/or user's physiological conditions, and which may need to be estimated.
- embodiments include contextual medication dosage determination that includes analyzing the current profile of the user or the patient to determine the relevant or suitable physiological profile of the user or the patient, by comparing to one or more of the previously stored profiles including the various parameters associated with the user or the patient's physiology, medication history, diet, as well as other parameters to retrieve the corresponding medication dosage previously administered for recommendation to the user or the patient.
- the recommended dosage or the therapy or delivery profile may be further refined or modified by the patient or the user prior to administration or implementation.
- insulin dependent users may determine their appropriate insulin dosages by, for example, using historical dosage information as well as associated physiological condition information.
- the historical data may be stored in one or more databases to allow search or query based on one or more parameters such as the user's physiological condition and other contextual information associated with each prior bolus dosage calculated and administered.
- the user may be advised on the proper amount of insulin under the particular circumstances, the user may be provided with descriptive statistical information of insulin dosages under the various conditions, and the overall system may be configured to learn and customize the dosage determination for the particular user over an extended time period.
- contextual information may be stored with the insulin bolus value.
- the contextual data in one aspect may include one or more of blood glucose concentration, basal rate, type of insulin, exercise information, meal information, carbohydrate content estimate, insulin on board information, and any other parameters that may be used to determine the suitable or appropriate medication dosage level.
- Some or all of the contextual information may be provided by the user or may be received from another device or devices in the overall therapy management system such as receiving the basal rate information or blood glucose concentration from the health monitor device with a medication dose calculation function 100 ( FIG. 1 ).
- a contextually determined medication dosage level in one embodiment may be provided to the user along with a suitable or appropriate notification or message to the user that after a predetermined time period since the prior administration of the medication dosage level, the blood glucose level was still above a target level. That is, the queried result providing the suitable medication dosage level based on user input or other input parameters may be accompanied by other relevant physiological condition information associated with the administration of the prior medication dosage administration.
- the user when the user is provided with the contextually determined medication dosage level, the user is further provided with information associated with the effects of the determined medication dosage level to the user's physiological condition (for example, one hour after the administration of the particular medication dosage level determined, the user's blood glucose level changed by a given amount). Accordingly, the user may be better able to adjust or modify, as desired or needed, the contextually determined medication dosage level to the current physiological conditions.
- statistical determination of the suitable medication dosage based on contextual information may be determined using, one or more of mean dosage determination, using a standard deviation or other appropriate statistical analysis of the contextual information for medication dosages which the user has administered in the past. Further, in one aspect, in the case where no close match is found in the contextual query for the desired medication dosage level, the medication dosage level with the most similar contextual information may be used to interpolate an estimated medication dosage level.
- FIG. 22 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment.
- the current therapy profile of the user's medication delivery system such as an insulin pump
- the database is queried based on the input parameters and the current therapy profile at step 2230 , which results in one or more contextually determined bolus amount associated with the input parameters and the current therapy profile at step 2240 that is provided to the user.
- the determined bolus amount is then at step 2250 stored in the database with the associated input parameters and the current therapy profile and any other contextual information associated with the determined bolus amount.
- other relevant contextual information may be retrieved (for example, the current therapy profile such as basal rate, the current blood glucose level and/or glucose trend information from the health monitor device with a medication dose calculation function 100 ( FIG. 1 ), and the like) prior to the database query to determine the suitable bolus amount.
- the current therapy profile such as basal rate, the current blood glucose level and/or glucose trend information from the health monitor device with a medication dose calculation function 100 ( FIG. 1 ), and the like
- the contextual information including the user input parameters and other relevant information may be queried to determine the suitable medication dosage level based on one or more statistical analysis such as, for example, but not limited to, descriptive statistics with the use of numerical descriptors such as mean and standard deviation, or inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
- descriptive statistics with the use of numerical descriptors such as mean and standard deviation
- inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
- Embodiments further include querying the one or more databases or storage devices to perform statistical analysis including or based at least in part on a hierarchy of the therapy profile parameters that is either pre-programmed or stored in the database (based on for example, level of relevance, temporal occurrence, user identified ranking of importance, healthcare provider identified ranking of importance, similarity, dissimilarity, occurrence prior to another event, occurrence after another event, occurrence in conjunction with a predetermined physiological condition, etc).
- the patient when a diabetic patient plans to take insulin of a particular type, the patient enters contextual information such as that the patient has moderately exercised and is planning to consume a meal with a predetermined estimated carbohydrate content.
- the database in one embodiment may be queried for insulin dosages determined under similar circumstances in the past for the patient, and further, statistical information associated with the determined insulin dosage is provided to the user.
- the displayed statistical information associated with the determined insulin dosage may include, for example, an average amount of insulin dosage, a standard deviation or a median amount and the 25 th and the 75 th percentile values of the determined insulin dosage.
- the patient may consider the displayed statistical information associated with the determined insulin dosage, and determine the most suitable or desired insulin amount based on the information received.
- the patient programs the insulin pump to administer the desired insulin amount (or otherwise administer the desired insulin amount using other medication administration procedures such as injection (using a pen-type injection device or a syringe), intaking inhalable or ingestable insulin, and the like)
- the administered dosage level is stored in the database along with the associated contextual information and parameters.
- the database for use in the contextual based query may be continuously updated with each administration of the insulin dosage such that, each subsequent determination of appropriate insulin dosage level may be determined with more accuracy and is further customized to the physiological profile of the particular patient.
- the database queried may be used for other purposes, such as, for example, but not limited, to tracking medication information, providing electronic history of the patient related medical information, and the like.
- other medication dosage may be determined based on the contextual based database query approaches described herein.
- the contextual based medication dosage query and determination may be used in conjunction with the standard or available medication dosage determination (for example, standard bolus calculation algorithms) as a supplement to provide additional information or provide a double checking ability to insure that the estimated or calculated bolus or medication dosage level is appropriate for the particular patient under the physiological condition at the time of the dosage level determination.
- standard or available medication dosage determination for example, standard bolus calculation algorithms
- user or patient feedback on current or prior medication dosage levels may be used in conjunction with the contextual based medication dosage query and determination to improve the user or patient's therapy management.
- health monitor devices such as glucose meters and monitoring systems with improved and robust functionalities providing comprehensive and easy to use therapy management devices and/or systems.
- the health monitor devices may be configured to provide medication dosage calculation, such as single dose of rapid or fast acting insulin, long acting insulin, or combinations thereof, and further configured to incorporate additional features to improve the management of the management and/or treatment of medical conditions such as diabetes, for example.
- the program instructions and/or associated application for execution by the one or more processor driven devices such as, for example, the health monitor device 100 ( FIG. 1 ) may be transferred over data network for installation and subsequent execution by the devices that are downloading the applications, for example, the health monitor device 100 .
- the application associated with the various program instructions for implementing the medication dose calculation function may be downloadable over the air (OTA) over a cellular network and installed in one or more devices in communication in the cellular network.
- the executable program or application may be installed for execution in the one or more components of devices in the various systems described above, over a data network such as the internet, a local area network, a wide area network and the like.
- the various components of the overall systems described above including, for example, the health monitor device, data processing terminal or remote computing device (such as a personal computer terminal or server terminal) as described above may each be configured for bi-directional or uni-directional communication over one or more data communication networks to communicate with other devices and/or components, including, for example, infusion devices, analyte monitoring device such as continuous glucose monitoring system, computer terminals at a hospital or a healthcare provider's office, the patient or user's residence or office, or the device/component vendor/supplier or manufacturer (for example, the vendor or manufacturer of the test strips, insulin, and lancing device and the like) or any other location where the network component is capable of wired or wireless communication over a data network with other devices or components in data communication over the data network.
- secure encrypted data communication may be provided, including encryption based on public/private key pair, password protection and the like to maintain a desired level of security of the data transferred.
- a device may comprise, one or more processors, and a memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors, causes the one or more processors to detect an analyte sample, determine an analyte concentration associated with the detected analyte sample, retrieve stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determine a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, wherein the determined current dose level includes a predetermined type of medication classification.
- the medication classification may include one or more of long acting insulin and rapid acting insulin.
- the analyte concentration may be associated with a blood glucose concentration.
- the analyte concentration may be associated with a fasting blood glucose concentration.
- the retrieved prior dose determination information may include prior administered medication level information.
- the prior administered medication level information may include prior stored one or more of long acting insulin dose amount, or a rapid acting insulin dose amount.
- each of the retrieved one or more prior dose determination information may be associated with one or more of administered medication dose time information, administered dose frequency information over a predetermined time period, or administered medication dose amount.
- the device may include an output unit coupled to the one or more processors, wherein the memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors causes the one or more processors to output one or more of the determined current dose level, determined analyte concentration, retrieved stored one or more dose determination information, analyte concentration associated with the retrieved one or more dose determination information, or a request for one or more predetermined information.
- the output unit may include one or more of a visual output unit, an audible output unit, or a vibratory output unit, or one or more combinations thereof.
- the one or more predetermined information may include a request for an additional analyte sample, or a request to confirm the determined current dose level.
- the device may include an input unit coupled to the one or more processors, wherein the memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors causes the one or more processors to detect one or more input commands received from the input unit.
- the one or more input commands may include an acknowledgement confirming the determined current dose level.
- the one or more input commands may include a rejection of the determined current dose level.
- the one or more input commands may include a request to recalculate the current dose level.
- the device may include a communication module operatively coupled to the one or more processors, the communication module configured to transmit one or more of the determined current dose level or the determined analyte concentration to a remote location.
- the communication module may include one or more of an RF transmitter, an RF transceiver, a ZigBee® communication module, a WiFiTM communication module, a Bluetooth® communication module, an infrared communication module, or a wired communication module.
- a method may comprise detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, retrieving stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determining a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, wherein the determined current dose level includes a predetermined type of medication classification.
- the medication classification may include one or more of long acting insulin and rapid acting insulin.
- the analyte concentration may be associated with a blood glucose concentration.
- the analyte concentration may be associated with a fasting blood glucose concentration.
- the retrieved prior dose determination information may include prior administered medication level information.
- the prior administered medication level information may include prior stored one or more of long acting insulin dose amount, or a rapid acting insulin dose amount.
- Each of the retrieved one or more prior dose determination information may be associated with one or more of administered medication dose time information, administered dose frequency information over a predetermined time period, or administered medication dose amount.
- the method may include outputting one or more information associated with the one or more of the determined current dose level, determined analyte concentration, retrieved stored one or more dose determination information, analyte concentration associated with the retrieved one or more dose determination information, or a request for one or more predetermined information.
- the outputting of one or more information may include outputting a visual indication, an audible indication, a vibratory indication, or one or more combinations thereof.
- the one or more predetermined information may include a request for an additional analyte sample, or a request to confirm the determined current dose level.
- the method may include detecting one or more input commands received from the input unit.
- the one or more input commands may include an acknowledgement confirming the determined current dose level.
- the one or more input commands may include a rejection of the determined current dose level.
- the one or more input commands may include a request to recalculate the current dose level.
- the method may include transmitting one or more of the determined current dose level or the determined analyte concentration to a remote location.
- Transmitting may include transmitting over one or more of an RF transmission protocol, a ZigBee® transmission protocol, a WiFiTM transmission protocol, a Bluetooth® transmission protocol, an infrared transmission protocol, or a wired transmission protocol.
- a glucose meter may comprise a housing, a memory device coupled to the housing, a controller unit coupled to the housing and the memory device, an input unit coupled to the controller unit and the housing for inputting one or more commands or information, an output unit coupled to the controller unit and the housing for outputting one or more output data, and a strip port provided on the housing configured to receive an analyte test strip, the controller unit configured to determine an analyte concentration based at least in part on the analyte sample on the received analyte test strip, wherein the controller unit is configured to retrieve one or more routines stored in the memory device to determine a medication dose amount based at least in part on the determined analyte concentration.
- the determined medication dose amount may include a bolus dose amount.
- the determined medication dose amount may include an insulin dose amount or a glucagon dose amount.
- the determined medication dose amount may include one or more of a rapid acting insulin dose or a long acting insulin dose.
- the output unit may include one or more of a visual display unit, an audible output unit, or a vibratory output unit.
- the determined analyte concentration may include a blood glucose concentration.
- the controller unit may be configured to store one or more of the determined analyte concentration or the medication dose amount.
- the meter may include a communication module coupled to the controller unit, the communication module configured to, at least in part, communicate one or more of the determined analyte concentration or the medication dose amount to a remote location.
- the remote location may include a medication delivery device.
- the medication delivery device may include an insulin delivery device.
- a method of providing therapy management may include receiving a request for a therapy profile for treating a medical condition, determining using a processor a plurality of therapy profile parameters, assigning a weighted value to each therapy profile parameter based on a hierarchy determined by the medical condition, querying a database to identify a stored therapy profile with therapy profile parameters that most closely correspond to the determined plurality of therapy profile parameters based on the hierarchy, and generating an output data corresponding to the identified stored therapy profile, wherein the output data may include a medication dosage information.
- the outputted medication dosage information may include a medication delivery amount or duration or both for the treatment of the medical condition.
- Assigning the weighted value to each therapy profile parameter may include ranking the therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking.
- Querying the database may include matching each determined therapy profile parameter with a respective therapy profile parameter stored in the database and correlated with a stored therapy profile.
- Therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile.
- the therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile based on a temporal attribute.
- the temporal attribute may include a time of day information or time duration information corresponding to the stored therapy profile and the requested therapy profile.
- the time of day information may include a start time associated with the stored therapy profile and the requested therapy profile.
- the time duration information may include a duration information associated with the stored therapy profile and the requested therapy profile.
- one aspect may include storing the output data in the database.
- another aspect may include outputting the output data on a user interface component.
- the output data may include a medication dose recommendation information.
- the medication dose recommendation information may include a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
- the requested therapy profile may include the identified stored therapy profile.
- the hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a user defined hierarchy.
- the hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a predetermined order of importance of each therapy profile parameter.
- the predetermined order may be stored in the database.
- the stored therapy profiles may include one or more of a correction bolus amount delivered, a carbohydrate bolus amount delivered, a basal profile delivered, or one or more combinations thereof.
- Querying the database may include performing a statistical analysis based on the information stored in the database.
- the statistical analysis may include one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of the one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
- Another aspect may include receiving a test sample, wherein one or more of the plurality of therapy profile parameters are based at least in part on the received test sample.
- a glucose monitoring apparatus may include a housing, one or more processing units provided in the housing, and a memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to receive a request for a therapy profile for treating a medical condition, determine a plurality of therapy profile parameters, assign a weighted value to each therapy profile parameter based on a hierarchy determined by the medical condition, query the memory to identify a stored therapy profile with therapy profile parameters that most closely correspond to the determined plurality of therapy profile parameters based on the hierarchy, and generate an output data corresponding to the identified stored therapy profile, wherein the output data may include a medication dosage information.
- the outputted medication dosage information may include a medication delivery amount or duration or both for the treatment of the medical condition.
- the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to assign the weighted value to each therapy profile parameter which may include ranking the therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking.
- the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to match each determined therapy profile parameter with a respective therapy profile parameter stored in the memory and correlated with a stored therapy profile.
- Therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile.
- the therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile based on a temporal attribute.
- the temporal attribute may include a time of day information or time duration information corresponding to the stored therapy profile and the requested therapy profile.
- the time of day information may include a start time associated with the stored therapy profile and the requested therapy profile.
- the time duration information may include a duration information associated with the stored therapy profile and the requested therapy profile.
- the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to store the output data in the memory.
- a user interface component may be coupled to the housing, and wherein the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to output the output data on the user interface component.
- the output data may include a medication dose recommendation information.
- the medication dose recommendation information may include a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
- the requested therapy profile may include the identified stored therapy profile.
- the hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a user defined hierarchy.
- the hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a predetermined order of importance of each therapy profile parameter.
- the predetermined order may be stored in the memory.
- the stored therapy profiles may include one or more of a correction bolus amount delivered, a carbohydrate bolus amount delivered, a basal profile delivered, or one or more combinations thereof.
- the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to perform a statistical analysis based on the information stored in the memory.
- the statistical analysis may include one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of the one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
- test strip port provided on the housing, the test strip port configured to receive a test strip with a test sample provided thereon, wherein the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to determine one or more of the plurality of therapy profile parameters based at least in part on the test sample.
- the test strip may include an in vitro blood glucose test strip.
- the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to determine a blood glucose concentration based on the received test sample.
- the various processes described above including the processes operating in the software application execution environment overall systems described above performing the various functions including those routines described in conjunction with FIGS. 3-5 , 8 - 13 , and 15 - 22 , may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships.
- the software required to carry out the inventive process which may be stored in the storage unit of one or more components in the one or more overall system described above, may be developed by a person of ordinary skill in the art and may include one or more computer program products.
Abstract
Methods, device and systems including receiving a request for a therapy profile for treating a medical condition, determining using a processor a plurality of therapy profile parameters, assigning a weighted value to each therapy profile parameter based on a hierarchy determined by the medical condition, querying a database to identify a stored therapy profile with therapy profile parameters that most closely correspond to the determined plurality of therapy profile parameters based on the hierarchy, generating an output data corresponding to the identified stored therapy profile, the output data a medication dosage information are provided. Also provided are systems and kits.
Description
- The present application is a continuation of U.S. patent application Ser. No. 12/699,844 filed Feb. 3, 2010, which claims priority under 35 U.S.C. §119(e) to U.S. provisional application No. 61/149,989 filed Feb. 4, 2009 entitled “Multi-Function Analyte Test Device and Methods Therefor”, the disclosures of each of which are incorporated herein by reference for all purposes. The present application is also a continuation-in-part of U.S. patent application Ser. No. 12/032,617 filed Feb. 15, 2008, now U.S. Pat. No. 8,732,188, which claims priority to U.S. provisional application No. 60/890,492 filed Feb. 18, 2007, the disclosures of each of which are incorporated herein by reference for all purposes. The present application is related to U.S. patent application Ser. No. 12/699,653 concurrently filed on Feb. 3, 2010 entitled “Multi-Function Analyte Test Device and Methods Therefor”, which is assigned to the assignee of the present application, Abbott Diabetes Care Inc., and the disclosure of which is incorporated herein by reference for all purposes.
- In diabetes management, there exists devices which allow diabetic patients to measure their blood glucose levels. One such device is a hand-held electronic meter such as a blood glucose meter such as the Freestyle® blood glucose monitoring system available from Abbott Diabetes Care Inc., of Alameda, Calif. which receives blood samples via enzyme-based test strips. Typically, the patient lances a finger or alternate body site to obtain a blood sample, applies the drawn blood sample to the test strip, and inserts the test strip into a test strip opening or port in the meter housing for analysis and determination of the corresponding blood glucose value which is displayed or otherwise provided to the patient to show the level of glucose at the time of testing.
- With the decreasing cost of electronic components and a corresponding increase in data processing capabilities of microprocessors, computational capability of electronic devices have been rapidly increasing. However, currently available glucose meters are generally configured with limited functionalities related to glucose testing. Additionally, patients who rely on the usage of glucose meters or other health related devices to monitor and treat health conditions, such as diabetes, also rely on a supply of consumable products employed by said glucose meters or other health related devices.
- For patients who are frequent users of the health related devices, such as diabetics that test glucose levels and possibly administer insulin several times daily, having a sufficient supply of the test strips and insulin is critical. More often than not, it is the case that patients run out of the test strips or insulin, which necessitates a trip to the drugstore or healthcare professional office, which in some cases, may not be practical or convenient. Furthermore, it is also inconvenient to consistently maintain a log or keep track of the number of test strips and amount of insulin that remains until replenishment strips and insulin are purchased. On the other hand, it is wasteful to simply purchase a large quantity of test strips and insulin for storage, which may eventually be lost, that take up storage space, may have an expiration date after which use of the item may be undesirable to the health of the patient, and include an up front cost. This is also true for many other medical testing or monitoring devices, including, for example, measurement of blood coagulation times, cholesterol and lipids, and other diagnostic monitoring tests.
- In view of the foregoing, in accordance with the various embodiments of the present disclosure, there are provided methods, devices and/or systems for providing a medication dosage calculation function into a health monitor device, such as a blood glucose meter, configured to perform data analysis and management based on, for example, the glucose level detected using the health monitor device. More specifically, in accordance with the various aspects of the present disclosure, methods, systems and devices for detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, retrieving stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determining a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, where the determined current dose level includes a predetermined type of medication classification are provided.
- These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.
-
FIG. 1 is a health monitor device with a medication dose calculation function in accordance with one embodiment of the present disclosure; -
FIG. 2 is a block diagram of the health monitor device with a medication dose calculation function ofFIG. 1 in one embodiment of the present disclosure; -
FIG. 3 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with one embodiment of the present disclosure; -
FIG. 4 is a flowchart illustrating the medication dose calculation procedure ofFIG. 3 in accordance with one embodiment of the present disclosure; -
FIG. 5 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with another embodiment of the present disclosure; -
FIG. 6A shows a health monitor device with medication dose calculation function in accordance with another embodiment of the present disclosure; -
FIG. 6B is a block diagram of a configuration of the health monitor device shown inFIG. 6A in one embodiment; -
FIG. 6C is an illustration of a display of the health monitor device shown inFIG. 6A in one embodiment; -
FIG. 7 shows a touch-screen health monitor device in accordance with one embodiment of the present disclosure; -
FIG. 8 is a flow chart illustrating a medication dosage calculation procedure for use in one or more embodiments of the present disclosure; -
FIG. 9 is a flow chart illustrating an analyte concentration determination and medication dosage calculation in one embodiment of the present disclosure; -
FIG. 10 is a flow chart illustrating a procedure for determining a recommended update to a long-acting insulin dosage regimen in one embodiment; -
FIG. 11 is a flow chart illustrating a procedure for calculating a dosage recommendation for a long-acting insulin and a fast-acting insulin in one embodiment; -
FIG. 12 is a flow chart illustrating a means for calculating a dosage recommendation for one or more selectable medication types; -
FIG. 13 is a flow chart illustrating a means for calculating insulin dosage information for more than one type of insulin in another embodiment; -
FIG. 14 illustrates a block diagram of a replenishment management system in accordance with one embodiment of the present disclosure; -
FIG. 15 is a flowchart illustrating user account registration setup and account subscription process in accordance with one embodiment of the present disclosure; -
FIG. 16 is a flowchart illustrating an overall replenishment procedure for the user account in accordance with one embodiment of the present disclosure; -
FIG. 17 is a flowchart illustrating the replenishment procedure shown inFIG. 16 in further detail in accordance with one embodiment of the present disclosure; -
FIG. 18 is a flowchart illustrating the replenishment procedure shown inFIG. 16 in further detail in accordance with another embodiment of the present disclosure; -
FIG. 19 is a flowchart illustrating a user account update and maintenance procedure in accordance with one embodiment of the present disclosure; -
FIG. 20 is a flowchart illustrating modified therapy management procedure based on real time monitored analyte levels in accordance with one embodiment of the present disclosure; -
FIG. 21 is a flowchart illustrating contextual based therapy management in accordance with one embodiment of the present disclosure; and -
FIG. 22 is a flowchart illustrating contextual based therapy management in accordance with another embodiment of the present disclosure. - The following patents, applications and/or publications are incorporated herein by reference for all purposes: U.S. Pat. Nos. 4,545,382; 4,711,245; 5,262,035; 5,262,305; 5,264,104; 5,320,715; 5,356,786; 5,509,410; 5,543,326; 5,593,852; 5,601,435; 5,628,890; 5,820,551; 5,822,715; 5,899,855; 5,918,603; 6,071,391; 6,103,033; 6,120,676; 6,121,009; 6,134,461; 6,143,164; 6,144,837; 6,161,095; 6,175,752; 6,270,455; 6,284,478; 6,299,757; 6,338,790; 6,377,894; 6,461,496; 6,503,381; 6,514,460; 6,514,718; 6,540,891; 6,560,471; 6,579,690; 6,591,125; 6,592,745; 6,600,997; 6,605,200; 6,605,201; 6,616,819; 6,618,934; 6,650,471; 6,654,625; 6,676,816; 6,730,200; 6,736,957; 6,746,582; 6,749,740; 6,764,581; 6,773,671; 6,881,551; 6,893,545; 6,932,892; 6,932,894; 6,942,518; 7,041,468; 7,167,818; and 7,299,082; U.S. Published Application Nos. 2004/0186365; 2005/0182306; 2006/0025662; 2006/0091006; 2007/0056858; 2007/0068807; 2007/0095661; 2007/0108048; 2007/0199818; 2007/0227911; 2007/0233013; 2008/0066305; 2008/0081977; 2008/0102441; 2008/0148873; 2008/0161666; 2008/0267823; and 2009/0054748; U.S. patent application Ser. No. 11/461,725, now U.S. Pat. No. 7,866,026; Ser. Nos. 12/131,012; 12/242,823, now U.S. Pat. No. 8,219,173; Ser. No. 12/363,712, now U.S. Pat. No. 8,346,335; Ser. Nos. 12/495,709; and 12/698,124; and U.S. Provisional Application Ser. Nos. 61/149,639; 61/155,889; 61/155,891; 61/155,893; 61/165,499; 61/230,686; 61/227,967 and 61/238,461.
- As described in further detail below, in accordance with the various embodiments of the present disclosure, there are provided health monitor devices, such as blood glucose meter devices, that include therapy management including for example, medication dosage calculation functions, such as a single-dose calculation function for administration of rapid acting insulin and/or long acting insulin, and/or related data analysis capabilities incorporated in the health monitor devices. In certain aspects of the present disclosure, method, device or system are provided to determine therapy management profile, recommended medication dose information based on, for example, fast or rapid acting and/or long acting insulin, to treat physiological conditions associated with diabetes or other appropriate conditions. In the manner described, in aspects of the present disclosure, patients with Type-1 or Type-2 diabetic conditions may improve their diabetes management, and further, the patients, users or healthcare providers may be provided with tools to improve the treatment of such conditions.
-
FIG. 1 shows a health monitor device with a medication dose calculation function in accordance with one embodiment of the present disclosure. Health monitor device with a medicationdose calculation function 100 includes ahousing 110 with adisplay unit 120 provided thereon. Also shown inFIG. 1 is a plurality ofinput buttons 130, each configured to allow the user of the health monitor device with a medicationdose calculation function 100 to input or enter data or relevant information associated with the operation of the health monitor device with a medicationdose calculation function 100. For example, the user of the health monitor device with a medication dose calculation function may operate the one ormore input buttons 130 to enter a calibration code associated with atest strip 160, or other fluid sample reception means, for use in conjunction with the health monitor device with a medicationdose calculation function 100. - In one embodiment, the health monitor device with a medication
dose calculation function 100 may include a blood glucose meter with bolus calculation function configured to calculate a single dose bolus dosage of a medication such as insulin such as long acting, fast acting or rapid acting insulin. Thetest strip 160 for use in conjunction with the health monitor device with a medicationdose calculation function 100, may be a blood glucose test strip configured to receive a blood sample thereon, in order to determine a blood glucose level of the received blood sample. Additionally, the user may operate the one ormore input buttons 130 to adjust time and/or date information, as well as other features or settings associated with the operation of the health monitor device with a medicationdose calculation function 100. - In aspects of the present disclosure, the strip port for receiving the
test strip 160 may be integrated with the housing of thehealth monitor device 100, or alternatively, may be provided in a separate housing or as a separate component that may be physically or electrically coupled to thehealth monitoring device 100. In one aspect, a component including the strip port may be provided in a separate snap-on type housing which physically snaps onto the housing of thehealth monitor device 100. Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Method” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination”, the disclosure of each of which is incorporated herein by reference for all purposes. - Referring back to
FIG. 1 , also shown isinput unit 140 which, in one embodiment, may be configured as a jog dial, or the like, and provided on thehousing 110 of the health monitor device with a medicationdose calculation function 100. In one embodiment, as discussed in further detail below, the user or the patient may operate theinput unit 140 to perform calculations and determinations associated with one or more medication dose estimation functions, such as a bolus dose estimation function, of the health monitor device with a medicationdose calculation function 100. Also shown inFIG. 1 is astrip port 150 which is configured to receive the test strip 160 (with fluid sample provided thereon) substantially in the direction as shown by thedirectional arrow 170. - In operation, when the
test strip 160 with the patient's fluid sample such as a blood sample is inserted into thestrip port 150 of the health monitor device with a medicationdose calculation function 100, a microprocessor or a controller unit 210 (FIG. 2 ) of the health monitor device with a medicationdose calculation function 100 may be configured to determine the associated analyte level in the fluid sample, and display the determined analyte level on thedisplay unit 120. - In addition, in accordance with the various embodiments of the present disclosure, the health monitor device with a medication
dose calculation function 100 may be configured to automatically enter into a medication dosage calculation mode to, for example, estimate a medication dosage amount based on information stored in the health monitor device with a medication dose calculation function 100 (such as the patient's insulin sensitivity, for example), and/or prompt the patient to provide additional information, such as the amount of carbohydrate to be ingested by the patient for determination of, for example, a carbohydrate bolus dosage determination. The patient may operate theinput unit 140 in conjunction with the user interface menu provided on thedisplay unit 120 to provide the appropriate information. - In another embodiment, the health monitor device with a medication
dose calculation function 100 may be configured to prompt the patient to select whether to retrieve a predetermined or preprogrammed medication dosage amount such as, for example, a correction bolus or a carbohydrate bolus, following the display of the determined analyte level from thetest strip 160. In this manner, in one embodiment of the present disclosure, the health monitor device with a medicationdose calculation function 100 may be configured to automatically prompt the user or patient to select whether a medication dosage determination is desired following an analyte test using thetest strip 160. - Example embodiments of the present disclosure are directed mainly toward measuring the levels of glucose, such as a blood glucose level, however it is to be understood that the present embodiments may also be configured to measure the levels of other analytes, drugs, or physiological conditions. For example, analyte levels that may be determined include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones (e.g., ketone bodies), lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. Assays suitable for determining the concentration of DNA and/or RNA are disclosed in U.S. Pat. No. 6,281,006 and U.S. Pat. No. 6,638,716, the disclosures of each of which are incorporated by reference herein. Furthermore, the concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be determined.
-
FIG. 2 is a block diagram of the health monitor device with a medication dose calculation function ofFIG. 1 in one embodiment of the present disclosure. Referring toFIG. 2 , the health monitor device with a medication dose calculation function 100 (FIG. 1 ) includes acontroller unit 210 operatively coupled to acommunication interface 220 and configured for bidirectional communication. Thecontroller unit 210 is further operatively coupled to atest strip interface 230, an input section 240 (which, for example, may include theinput unit 140 and the plurality ofinput buttons 130 as shown inFIG. 1 ), anoutput unit 250, and adata storage unit 260. - Referring to
FIG. 2 , in one embodiment of the present disclosure, thetest strip interface 230 is configured for signal communication with the inserted test strip 160 (FIG. 1 ) for determination of the fluid sample on thetest strip 160. In addition, thetest strip interface 230 may include an illumination segment which may be configured to illuminate the strip port 150 (FIG. 1 ) using a light emitting diode (LED), for example, during thetest strip 160 insertion process to assist the user in properly and accurately inserting thetest strip 160 into thestrip port 150. - Moreover, in a further aspect of the present disclosure, the
test strip interface 230 may be additionally configured with a physical latch or securement mechanism internally provided within thehousing 110 of the health monitor device with a medication dose calculation function 100 (FIG. 1 ) such that when thetest strip 160 is inserted into thestrip port 150, thetest strip 160 is retained in the received position within thestrip port 150 until the sample analysis is completed. Examples of such physical latch or securement mechanism may include a uni-directionally biased anchor mechanism, or a pressure application mechanism to retain thetest strip 160 in place by applying pressure on one or more surfaces of thetest strip 160 within thestrip port 150. - Referring back to
FIG. 2 , theoutput unit 250 may be configured to output display data or information including the determined analyte level on the display unit 120 (FIG. 1 ) of the health monitor device with a medicationdose calculation function 100. In addition, in still a further aspect of the present disclosure, theoutput unit 250 and theinput section 240 may be integrated, for example, in the case where thedisplay unit 120 is configured as a touch sensitive display where the patient may enter information or commands via the display area using, for example, a finger or stylus or any other suitable input device, and where, the touch sensitive display is configured as the user interface in an icon or motion driven environment, for example. - Referring yet again to
FIG. 2 , thecommunication interface 220 in one embodiment of the present disclosure includes a wireless communication section configured for bi-directional radio frequency (RF) communication with other devices to transmit and/or receive data to and from the health monitor device with a medicationdose calculation function 100. In addition, thecommunication interface 220 may also be configured to include physical ports or interfaces such as a USB port, an RS-232 port, or any other suitable electrical connection port to allow data communication between the health monitor device with a medicationdose calculation function 100 and other external devices such as a computer terminal (for example, at a physician's office or in a hospital environment), an external medical device, such as an infusion device or including an insulin delivery device, or other devices that are configured for similar complementary data communication. - In one embodiment, the wireless communication section of the
communication interface 220 may be configured for infrared communication, Bluetooth® communication, or any other suitable wireless communication mechanism to enable the health monitor device with a medicationdose calculation function 100 for communication with other devices such as infusion devices, analyte monitoring devices, computer terminals, communication enabled mobile telephones, personal digital assistants, or any other communication devices which the patient or user of the health monitor device with a medicationdose calculation function 100 may use in conjunction therewith, in managing the treatment of a health condition, such as diabetes. -
FIG. 3 is a flowchart illustrating the analyte level determination and medical dose calculation procedure in accordance with one embodiment of the present disclosure. Referring toFIG. 3 , atest strip 160 is detected by the controller unit 210 (or the test strip interface 230) (310) of the health monitor device with a medication dose calculation function 100 (FIG. 1 ). Thereafter, the fluid sample, such as a blood sample, received from the insertedtest strip 160 is analyzed (320) to determine the corresponding analyte level, such as a glucose level, and the determined analyte level is output (330) on the display unit 120 (FIG. 1 ) for example, in units of mg/dL. - Referring back to
FIG. 3 , after determining the analyte level and displaying the measured analyte level to the patient (330), a prompt command is generated and output to the patient to select if the medication dosage calculation is desired (340). More specifically, in one embodiment of the present disclosure, the controller unit 210 (FIG. 2 ) is configured to generate a command and display in thedisplay unit 120 to query the user as to whether a medication dosage calculation determination is desired by the patient. Thereafter, a determination of whether or not the patient has selected to have the medication dosage calculation performed by thecontroller unit 210 is made (350). In one embodiment, the patient may operate one or more of theinput buttons 130 or theinput unit 140 to select whether or not to have the medication dosage calculation performed. - Referring again to
FIG. 3 , if it is determined that the patient has selected not to have the medication dosage determination performed, then the determined analyte value is displayed and/or stored (360), e.g., in memory of the health monitor device, and the routine terminates. For example, in one embodiment, the controller unit 210 (FIG. 2 ) may be configured to store the determined analyte value in thedata storage unit 260 with associated time and/or date information of when the analyte value determination is performed. In an alternate embodiment, the measured analyte value may be stored substantially concurrently with the display of the analyte value. - On the other hand, if it is determined that the patient has selected to have the medication dosage calculation performed, the health monitor device with a medication
dose calculation function 100 is configured to enter the medication dosage determination mode (370), described in further detail below in conjunction withFIG. 4 , where the desired type of medication dosage is determined and provided to the patient. In another embodiment, the health monitor device with a medicationdose calculation function 100 may be configured to store the glucose data even in the event the user selects to perform the medication dose calculation. -
FIG. 4 is a flowchart illustrating the medication dose calculation procedure ofFIG. 3 in accordance with one embodiment of the present disclosure. Referring toFIG. 4 , when the health monitor device with a medication dose calculation function 100 (FIG. 1 ) enters the medication dosage determination mode as described above, the controller unit 210 (FIG. 2 ) is configured to prompt the patient (for example, by displaying the options to the patient on the display unit 120 (FIG. 1 )) to select the type of desired medication dosage calculation 410. For example, thecontroller unit 210 may be configured to output a list of available medication dosage calculation options including, for example, bolus calculation options such as a carbohydrate bolus, a correction bolus, a dual or extended bolus, a square wave bolus, or any other suitable medication calculation function which may be programmed into the health monitor device with a medication dose calculation function 100 (and for example, stored in the data storage unit 260). - Referring back to
FIG. 4 , after the patient selects the desired medication dosage calculation in response to the prompt for medication type selection (410), the selected medication dosage calculation routine is retrieved (420) from thedata storage unit 260, and thereafter executed (430). In one embodiment, the execution of the selected medication dosage calculation (430) may include one or more input prompts to the patient to enter additional information as may be required to perform the selected medication dosage calculation. - For example, in the case of calculating a carbohydrate bolus, the patient may be prompted to provide or enter an estimate of the carbohydrate amount that the patient is planning on ingesting. In this regard, a food database may be stored in the
data storage unit 260 or elsewhere for easy access (e.g., personal computers (PCs), personal digital assistants (PDAs), mobile telephones, or the like and to which the health monitor device may be coupled (e.g., wirelessly or by physical connection) to easily retrieve such information) to conveniently determine the corresponding carbohydrate amount associated with the type of food which the patient will be ingesting. Alternatively, the patient may provide the actual estimated carbohydrate count if such information is readily available by the patient. - Alternatively, in the case of calculating a dual bolus of insulin, the patient is prompted to provide, in addition to a dose amount, a time duration information for the extended portion of the bolus dosage to be infused or otherwise delivered to the patient. Similarly, the patient may further be prompted to provide insulin sensitivity information, and any other information as may be necessary to determine the selected bolus dosage amount in conjunction with other relevant information such as insulin on board information, and the time of the most recently administered bolus (so as to provide a warning to the patient if a bolus dosage has been administered within a predetermined time period, and a subsequent administration of the additional bolus dosage may potentially be harmful).
- Referring back to
FIG. 4 , after the execution of the selected medication dosage calculation routine (430), the calculated medication dosage amount is stored (440) in thedata storage unit 260, and the calculated medication dosage amount is output displayed to the patient (450) on thedisplay unit 120 of the health monitor device with a medicationdose calculation function 100, or audibly if the health monitor device is so configured. In certain embodiments, storing and output displaying the calculated medication dosage amount may be substantially concurrently performed, rather than sequentially. -
FIG. 5 is a flowchart illustrating the analyte level determination and medication dose calculation procedure in accordance with another embodiment of the present disclosure. Referring toFIG. 5 , atest strip 160 is inserted into thestrip port 150 of the health monitor device with a medicationdose calculation function 100 and detected (510), the fluid sample on thetest strip 160 is analyzed to determine the corresponding analyte level (520), and thereafter, output displayed (530). - Referring back to
FIG. 5 , after the analyte level from the fluid sample received from thetest strip 160 is determined (530), a medication dosage calculation routine is retrieved (540). The controller unit 210 (FIG. 2 ) is configured to enter into the medication dosage determination mode, and to execute pre-programmed or predetermined medication calculation routine (550), and thereafter, output display the calculated medication dosage amount (560). In this manner, in one embodiment of the present disclosure, the health monitor device with a medicationdose calculation function 100 may be programmed or configured to automatically enter into the medication determination mode upon completion of the fluid sample analysis for analyte level determination. - In one embodiment of the present disclosure, the health monitor device with a medication
dose calculation function 100 may be configured to execute different types of medication dosage calculation based on the patient specified parameters. For example, the health monitor device with a medicationdose calculation function 100 may be configured to perform a carbohydrate bolus determination when the test strip sample analysis is performed within a predetermined time period of a meal event. For example, the health monitor device with a medicationdose calculation function 100 may be programmed by the patient to automatically select the carbohydrate bolus determination if the test strip fluid sample analysis is performed within one hour prior to a meal time (which may be programmed into the health monitor device with a medication dose calculation function 100). -
FIG. 6A shows a health monitor device with medication dose calculation function in accordance with another embodiment of the present disclosure. Ahealth monitor device 600 in accordance with one or more embodiments may be used for determining a concentration of an analyte in blood or interstitial fluid. In one embodiment, thehealth monitor device 600 may be an analyte test meter, such as a glucose test meter that may be used for determining an analyte concentration, such as a blood glucose concentration, of a sample for determination of a blood glucose level of a patient, such as a patient with Type-1 or Type-2 diabetes. - Referring to
FIG. 6A , in one embodiment, thehealth monitor device 600 may be a small portable device designed to be palm-sized and/or adapted to fit into, for example, a pocket or purse of a patient. The portablehealth monitor device 600 may have the appearance of a personal electronic device, such as a mobile phone or personal digital assistant (PDA), so that the user may not be identified as a person using a medical device. Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Method” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination”, the disclosure of each of which is incorporated herein by reference for all purposes. - In another embodiment, the
health monitor device 600 may be a larger unit for home use and designed to sit on a shelf or nightstand. In yet another embodiment, thehealth monitor device 600 may be designed for use in a hospital or doctor's office. The larger healthmonitor device units 600 may have the same functionality as the portablehealth monitor device 600 as described in further detail below. - Referring back to
FIGS. 6A and 6B , ahealth monitor device 600 includes ahousing 610 and adisplay unit 620 provided thereon. In one embodiment, thedisplay unit 620 may be a dot-matrix display. In other embodiments, other display types, such as liquid-crystal displays (LCD), plasma displays, light-emitting diode (LED) displays, or seven-segment displays, among others, may alternatively be used. Thedisplay unit 620 may display, in numerical or graphical form, for example, information related to, among others, a patient's current analyte concentration. Also incorporated within thehousing 610 of thehealth monitor device 600 may be a processor 660 (FIG. 6B ) and a memory device 670 (FIG. 6B ). The memory device 670 (FIG. 6B ) may store raw and/or analyzed data as well as store instructions which, when executed by the processor 660 (FIG. 6B ), may provide, among others, instructions to thedisplay unit 620, and may be used for analysis functions, such as analyte concentration analysis and medication dosage calculations. - In embodiments of the present disclosure, the memory device 670 (
FIG. 6B ) may include a readable and/or writable memory device such as, for example, but not limited to a read only memory (ROM), random access memory (RAM), flash memory device, or static random access memory (SRAM). In another embodiment, an optional transmitter/receiver unit 680 (FIG. 6B ) may be incorporated into thehousing 610 of thehealth monitor device 600. The transmitter/receiver unit 680 (FIG. 6B ) may be used to transmit and/or receive analyzed or raw data or instructions to/from, for example, optional peripheral devices, such as a data analysis unit or a medication administration unit in a data network. - In another embodiment, the transmitter/receiver unit 680 (
FIG. 6B ) is a transceiver capable of both transmitting and receiving data. The transmitter/receiver unit 680 (FIG. 6B ) may be configured for wired or wireless transmission, including, but not limited to, radio frequency (RF) communication, RFID (radio frequency identification) communication, WiFi™ or Bluetooth® communication protocols, and cellular communication, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM). In another embodiment, thehealth monitor device 600 may include a rechargeable power supply 690 (FIG. 6B ), such as a rechargeable battery. - Referring back to
FIG. 6A , in one embodiment, thehealth monitor device 600 may also include a plurality ofinput buttons 630. Each of the plurality ofinput buttons 630 may be designated for a specific task, or alternatively, each of the plurality ofinput buttons 630 may be ‘soft buttons’. In the case that the plurality of input buttons are ‘soft buttons’, each of the plurality of buttons may be used for a variety of functions. The variety of functions may be determined based on the current mode of thehealth monitor device 600, and may be distinguishable to a user by the use of button instructions shown on thedisplay unit 620. Other input methods may also be incorporated including, but not limited to, a touch-pad, jog-wheel, or capacitive sensing slider inputs. Yet another input method may be a touch-sensitive display unit, as described further below and shown inFIG. 7 . - Referring back to
FIG. 6A , thehealth monitor device 600 may also include astrip port 640 which may be configured for receiving atest strip 650. Thetest strip 650 is configured to receive a fluid sample, such as a blood sample, from a patient. Thetest strip 650 may then be inserted into thestrip port 640, whereby thehealth monitor device 600 may analyze the sample and determine the concentration of an analyte, such as glucose, in the sample. The analyte concentration of the sample may then be displayed on thedisplay unit 620 as the analyte level of the patient. In another aspect, thehealth monitor device 600 may use a conversion function to convert a measured analyte concentration of a sample to a blood analyte concentration of a host. In another embodiment, the analyte concentration of the analyzed sample may be stored in the memory 670 (FIG. 6B ) of thehealth monitor device 600. The stored analyte concentration data may additionally be tagged with date and/or time data related to the date and/or time the fluid sample was taken and analyzed. In another embodiment, the analyte concentration data may be transmitted via the transmitter/receiver unit 680 (FIG. 6B ) to one or more peripheral devices for storage and/or further analysis. - As discussed above, in certain embodiments, strip port to receive the test strip may be provided as a separate component that is configured to physically or electrically couple to the
health monitoring device 600. Additional information is provided in U.S. Pat. No. 7,041,468 issued on May 9, 2006 titled “Blood Glucose Tracking Apparatus and Methods” and in US Patent Application Publication No. US2004/0254434 published Dec. 16, 2004 titled “Glucose Measuring Module and Insulin Pump Combination” the disclosures of each of which are incorporated herein by reference for all purposes. - In another embodiment, the
health monitor device 600 may include instructions for calculating a medication dosage. The medication dosage may be, for example, a dosage of insulin in response to a blood glucose concentration data determined from the fluid sample on thetest strip 650 received at thestrip port 640. In one aspect, the medication dosage calculation may be based, at least in part, on a current patient analyte concentration data averaged with stored values of previous analyte concentration data. - In another aspect, the instructions for calculating a medication dosage may include instructions for calculating a dosage for a variety of types of medication, such as a variety of types of insulin. Insulin types may include, but are not limited to, long-acting insulin types such as LANTUS® (insulin glargine), available from Sanofi-Aventis, and LEVEMIR®, available from NovoNordisk, intermediate-acting insulin types such as Neutral Protamine Hagedorn (NPH), and LENTE insulin, fast-acting insulin types including recombinant human insulin such as HUMULIN®, available from Eli Lilly and Company, and NOVALIN®, available from NovoNordisk, bovine insulin, and porcine insulin, rapid-acting insulin types such as HUMALOG® (Lysine-Proline insulin), available from Eli Lilly and Company, APIDRA® (glulisine insulin), available from Sanofi-Aventis, and NOVOLOG® (aspart insulin), available from NovoNordisk, and very-rapid-acting insulin types such as VIAJECT™, available from Biodel, Inc.
- In another embodiment, the instructions for calculating a medication dosage may be instructions for calculating a recommended update to an existing medication dosage regimen. Data related to a current medication dosage regimen may be stored in the
memory 670 of thehealth monitor device 600, including current prescribed medication types and dosages and an algorithm for calculating recommended medication dosage changes. Calculated medication dosage recommendations may be displayed to the patient on thedisplay unit 620 of thehealth monitor device 600 for patient intervention, or further may be transmitted directly to a medication administration device, such as an insulin pump, for a medication dosage regimen update. - In another embodiment, the
health monitor device 600 may include programming for alarm functions. Alarms may be used to inform patients when current analyte concentrations are outside threshold levels, when medication dosage regimens need to be updated, or when an error is detected. Alarms may be in the form of a visual, auditory, or vibratory alarm. - In yet another embodiment, the
health monitor device 600 may include an integrated medication delivery system (not shown). Additional information is provided in US Patent Publication No. US2006/0224141 published on Oct. 5, 2006, titled “Method and System for Providing Integrated Medication Infusion and Analyte Monitoring System”, the disclosure of which is incorporated by reference for all purposes. - The integrated medication delivery system may be in the form of a drug delivery injection pen such as a pen-type injection device incorporated within the
housing 610 of thehealth monitor device 600. Additional information is provided in U.S. Pat. Nos. 5,536,249 and 5,925,021, disclosure of each of which are incorporated herein by reference for all purposes. - The integrated medication delivery system may be used for injecting a dose of medication, such as insulin, into a patient based on a prescribed medication dosage, and may be automatically updated with dosage information received from the medication dosage calculator described above. In another embodiment, the medication dosage of the medication delivery system may include manual entry of dosage changes made through, for example, the
input buttons 630 of thehealth monitor device 600. Medication dosage information associated with the medication delivery system may be displayed on thedisplay unit 620 of thehealth monitor device 600. -
FIG. 6C is an illustration of a display of the health monitor device shown inFIG. 6A in one embodiment. Referring toFIG. 6C , thedisplay unit 620 of the health monitor device 600 (FIG. 6A ) may display a variety of data values to a patient. In one embodiment, thedisplay unit 620 may display a current analyte concentration, such as the current blood glucose concentration of a patient, a recommended update to the patient's medication dosage regimen, such as insulin dosage updates, and the date and/or time of the current or most recent analyte test. Further, if thehealth monitor device 600 includes ‘soft buttons’, thedisplay unit 620 may show the current function of said ‘soft buttons’ for the particular current operational mode of thehealth monitor device 600. Other information that may be displayed on thedisplay unit 620 may include, but is not limited to, current medication dosage regimen data, recommended medication type, and historical patient analyte concentration data. - Information on the
display unit 620 may be displayed in a variety of manners or format including, for example, numerical data, graphical data, symbols, pictures, and/or animations. In one aspect, the user may be able to choose the display style, for example, by pushing one of theinput buttons 630. Thedisplay unit 620 may be a black and white display unit, or may alternatively be a color display unit, whereby, information may be displayed in a variety of colors. Colors may be used as indicators to a patient of changes in the current displayed information, or may be used for aesthetic purposes to allow for easier navigation of the data and/or menus. In another aspect, the brightness, contrast, tint, and/or color settings of thedisplay unit 620 may be adjustable. - In another embodiment, the health monitor device 600 (
FIG. 6 ) may incorporate a continuous analyte monitoring device, where a transcutaneously implanted sensor may continually or substantially continually measure an analyte concentration of a bodily fluid. Examples of such sensors and continuous analyte monitoring devices include systems and devices described in U.S. Pat. Nos. 6,175,752, 6,560,471, 5,262,305, 5,356,786, U.S. patent application Ser. No. 12/698,124 and U.S. provisional application No. 61/149,639 titled “Compact On-Body Physiological Monitoring Device and Methods Thereof”, the disclosures of each of which are incorporated herein by reference for all purposes. - Accordingly, in certain embodiments, the
health monitor device 600 may be configured to operate or function as a data receiver or controller to receive analyte related data from a transcutaneously positioned in vivo analyte sensor such as an implantable glucose sensor. The analyte monitoring system may include a sensor, for example an in vivo analyte sensor configured for continuous or substantially continuous measurement of an analyte level of a body fluid, a data processing unit (e.g., sensor electronics) connectable to the sensor, and thehealth monitor device 600 configured to communicate with the data processing unit via a communication link. In aspects of the present disclosure, the sensor and the data processing unit (sensor electronics) may be configured as a single integrated assembly. In certain embodiments, the integrated sensor and sensor electronics assembly may be configured as a compact, low profile on-body patch device assembled in a single integrated housing and positioned on a skin surface of the user or the patient with a portion of the analyte sensor maintained in fluid contact with a bodily fluid such as an interstitial fluid during the sensor life time period (for example, sensor life time period including about 5 days or more, or about 7 days or more, or about 14 days or more, or in certain embodiments, about 30 days or more). In such embodiments, the on-body patch device may be configured for, for example, RFID or RF communication with thehealth monitor device 600 to wirelessly provide monitored or detected analyte related data to thehealth monitor device 600 based on a predetermined transmission schedule or when requested from thehealth monitor device 600. Predetermined transmission schedule may be programmed or configured to coincide with the analyte sample detection by the analyte sensor (for example, but not limited to including once every minute, once every 5 minutes, once every 15 minutes). Alternatively, thehealth monitor device 600 may be programmed or programmable to acquire the sampled analyte data (real time information and/or stored historical data) in response to one or more requests transmitted from thehealth monitor device 600 to the on-body patch device. - As discussed, embodiments include the on-body patch device including the data processing unit coupleable to the analyte sensor so that both devices are positioned in or on the user's body, with at least a portion of the analyte sensor positioned transcutaneously. The data processing unit in certain embodiments may include a portion of the sensor (proximal section of the sensor in electrical communication with the data processing unit) which is encapsulated within or on the printed circuit board of the data processing unit with, for example, potting material or other protective material. The data processing unit performs data processing functions, where such functions may include but are not limited to, filtering and encoding of analyte related signals, for transmission to the
health monitor device 600. In certain embodiments, the sensor or the data processing unit or a combined sensor/data processing unit may be wholly implantable under the skin layer of the user. - In certain embodiments, transmitter/
receiver section 680 of thehealth monitor device 600 includes an RF receiver and an antenna that is configured to communicate with the data processing unit, and theprocessor 660 of thehealth monitor device 600 is configured for processing the received data from the data processing unit such as data decoding, error detection and correction, data clock generation, and/or data bit recovery. - In operation, the
health monitor device 600 in certain embodiments is configured to synchronize with the data processing unit to uniquely identify the data processing unit, based on, for example, an identification information of the data processing unit, and thereafter, to periodically receive signals transmitted from the data processing unit associated with the monitored analyte levels detected by the sensor. - As described, in aspects of the present disclosure, the analyte monitoring system may include an on-body patch device with a thin profile that may be comfortably worn on the arm or other locations on the body (under clothing worn by the user or the patient, for example), the on-body patch device including an analyte sensor and circuitry and components for operating the sensor and processing and storing signals received from the sensor as well as for communication with the
health monitor device 600. For example, one aspect of the on-body patch device may include electronics to sample the voltage signal received from the analyte sensor in fluid contact with the body fluid, and to process the sampled voltage signals into the corresponding glucose values and/or store the sampled voltage signal as raw data. - The on-body patch device in one aspect may further include an antenna such as a loop antenna to receive RF power from an external device such as the
health monitor device 600 described above, electronics to convert the RF power received via the antenna into DC (direct current) power for the on-body patch device circuitry, communication module or electronics to detect commands received from thehealth monitor device 600, and communication component such as an RF transmitter to transmit data to thehealth monitor device 600, a low capacity battery for providing power to sensor sampling circuitry (for example, the analog front end circuitry of the on-body patch device in signal communication with the analyte sensor), one or more non-volatile memory or storage device to store data including raw signals from the sensor or processed data based on the raw sensor signals. - In certain embodiments, the
health monitor device 600 may also be configured to operate as a data logger, interacting or communicating with the on-body patch device by, for example, periodically transmitting requests for analyte level information from the on-body patch device, and storing the received analyte level information from the on-body patch device in one ormore memory components 670. - The various processes described above including the processes operating in the software application execution environment in the analyte monitoring system including the on-body patch device and/or the
health monitor device 600 performing one or more routines described above may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. The software required to carry out the inventive process, which may be stored in a memory or storage device of the storage unit of the various components of the analyte monitoring system described above in conjunction to the Figures including the on-body patch device or thehealth monitor device 600 may be developed by a person of ordinary skill in the art and may include one or more computer program products. - In one embodiment, an apparatus for bi-directional communication with an analyte monitoring system may comprise a storage device having stored therein one or more routines, a processing unit operatively coupled to the storage device and configured to retrieve the stored one or more routines for execution, a data transmission component operatively coupled to the processing unit and configured to transmit data based at least in part on the one or more routines executed by the processing unit, and a data reception component operatively coupled to the processing unit and configured to receive analyte related data from a remote location and to store the received analyte related data in the storage device for retransmission, wherein the data transmission component is programmed to transmit a query to a remote location, and further wherein the data reception component receives the analyte related data from the remote location in response to the transmitted query when one or more electronics in the remote location transitions from an inactive state to an active state upon detection of the query from the data transmission component.
- Embodiments also include the on-body patch device including sensor electronics coupled to an analyte sensor is positioned on a skin surface of a patient or a user. In one aspect, an introducer mechanism may be provided for the transcutaneous placement of the analyte sensor such that when the on-body patch device is positioned on the skin surface, a portion of the sensor is inserted through the skin surface and in fluid contact with a body fluid of the patient or the user under the skin layer.
- In certain embodiments, when the
health monitor device 600 is positioned or placed in close proximity or within a predetermined range of the on-body patch device, the RF power supply in thehealth monitor device 600 may be configured to provide the necessary power to operate the electronics in the on-body patch device, and accordingly, the on-body patch device may be configured to, upon detection of the RF power from thehealth monitor device 600, perform preprogrammed routines including, for example, transmitting one or more signals to thehealth monitor device 600 indicative of the sampled analyte level measured by the analyte sensor. In one embodiment, communication and/or RF power transfer between thehealth monitor device 600 and the on-body patch device may be automatically initiated when thehealth monitor device 600 is placed in close proximity to the on-body patch device. Alternatively, thehealth monitor device 600 may be configured such that user intervention, such as a confirmation request and subsequent confirmation by the user using, for example, thedisplay 620 and/orinput components 630 of thehealth monitor device 600, may be required prior to the initiation of communication and/or RF power transfer between thehealth monitor device 600 and the on-body patch device. In a further embodiment, thehealth monitor device 600 may be user configurable between multiple modes, such that the user may choose whether the communication between thehealth monitor device 600 and on-body patch device is performed automatically or requires a user confirmation. - As discussed, some or all of the electronics in the on-body patch device in one embodiment may be configured to rely on the RF power received from the
health monitor device 600 to perform analyte data processing and/or transmission of the processed analyte information to thehealth monitor device 600. That is, the on-body patch device may be discreetly worn on the body of the user or the patient, and under clothing, for example, and when desired, by positioning thehealth monitor device 600 within a predetermined distance from the on-body patch device, real time glucose level information may be received by thehealth monitor device 600. This routine may be repeated as desired by the patient (or on-demand or upon request, for example) to acquire monitored real time glucose levels at any time during the time period that the on-body patch device is worn by the user or the patient. - In another embodiment, the
health monitor device 600 may include an integrated analyte test meter and lancing device for lancing a bodily fluid sample, such as a blood sample, and measuring an analyte concentration, such as a blood glucose concentration. Examples of such integrated devices include systems and devices described in US Published Application Nos. 2007/0149897 and 2008/0167578, the disclosures of each of which are incorporated herein by reference for all purposes. -
FIG. 7 shows a touch-screen health monitor device in accordance with one embodiment of the present disclosure. Referring toFIGS. 7 and 6A , a touch-screenhealth monitor device 700 may include the same functions and basic design as ahealth monitor device 600 without a touch-screen. Typically, a touch-screenhealth monitor device 700 would include alarger display unit 720 compared to thedisplay unit 620 of ahealth monitor device 600 without a touch-screen in order to accommodate the extra area required for any touch-screen buttons 730 that may be used. Similar to ahealth monitor device 600 without a touch-screen, a touch-screenhealth monitor device 700 includes ahousing 710, thereon which lies the touch-screen display unit 720. The touch-screenhealth monitor device 700 may also include astrip port 740 for receiving atest strip 750, which may include a fluid sample for analysis, such as a blood sample for a blood glucose concentration analysis. -
FIG. 8 is a flow chart illustrating a medication dosage calculation procedure for use in one or more embodiments of the present disclosure. Referring toFIG. 8 , a device, such as a health monitor device 600 (FIG. 6A ), receives an analyte concentration (810) for the current analyte level of a patient. The analyte level is compared to a predetermined threshold analyte level (820). For example, if the analyte is glucose and the analyte level is a blood glucose level of a patient, the threshold blood glucose level may be between 80 mg/dL and 120 mg/dL, or a tailored threshold determined by a healthcare professional. If the current analyte concentration level is above the predetermined threshold, a list of available medication types may be displayed (830) on thedisplay unit 620 of ahealth monitor device 600. For example, if the analyte concentration level is a blood glucose concentration level for a patient suffering from, for example, diabetes, the list of available medication types may be a list of available insulin types. From the list of available medication types, a medication type is selected (840) and a recommended dosage for the selected medication type based upon the current analyte concentration level is calculated (850) and displayed (860). -
FIG. 9 is a flow chart illustrating an analyte concentration determination and medication dosage calculation in one embodiment of the present disclosure. Referring toFIGS. 9 and 6A , a fluid sample is detected (910), for example, by applying the fluid sample to atest strip 650 and inserting thetest strip 650 into astrip port 640 of thehealth monitor device 600. Upon detection of the fluid sample, a current analyte concentration is calculated (920) based on analysis of the fluid sample. In one embodiment, thehealth monitor device 600 may include adisplay unit 620, such as a dot-matrix display, and the current analyte concentration is displayed (930) on thedisplay unit 620. - Still referring to
FIGS. 9 and 6A , in one embodiment, thehealth monitor device 600 may include instructions or routines to perform a long-acting medication dosage calculation function. A long-acting medication may be a medication wherein a single dose may last for up to 12 hours, 24 hours, or longer. The instructions for a long-acting medication dosage calculation function may be in the form of software stored on the memory device 670 (FIG. 6B ) and executed by the processor 660 (FIG. 6B ) of thehealth monitor device 600. In one aspect, the long-acting medication dosage calculation function may be an algorithm based on the current concentration of an analyte of a patient, wherein the long-acting medication dosage calculation function compares the current analyte concentration value to a predetermined threshold (940), which may be based on clinically determined threshold levels for a particular analyte, or may be tailored for individual patients by a doctor or other treating professional. If the current analyte concentration is above the predetermined threshold, the long-acting medication dosage calculation function may use the current analyte concentration value to calculate a recommended dosage of a long-acting medication (950). Once calculated, the recommended medication dosage may be displayed (960) on thedisplay unit 620 of thehealth monitor device 600. - In one embodiment, the
health monitor device 600 may be configured to measure the blood glucose concentration of a patient and include instructions for a long-acting insulin dosage calculation function. Periodic injection or administration of long-acting insulin may be used to maintain a baseline blood glucose concentration in a patient with Type-1 or Type-2 diabetes. In one aspect, the long-acting medication dosage calculation function may include an algorithm or routine based on the current blood glucose concentration of a diabetic patient, to compare the current measured blood glucose concentration value to a predetermined threshold or an individually tailored threshold as determined by a doctor or other treating professional to determine the appropriate dosage level for maintaining the baseline glucose level. - In one embodiment, the long-acting insulin dosage calculation function may be based upon LANTUS® insulin, available from Sanofi-Aventis, also known as insulin glargine. LANTUS® is a long-acting insulin that has up to a 24 hour duration of action. Further information of LANTUS® insulin is available at www.lantus.com. Other types of long-acting insulin include LEVEMIR® insulin available from NovoNordisk (www.levemir-us.com).
-
FIG. 10 is a flow chart illustrating a procedure for determining a recommended update to a long-acting insulin dosage regimen in one embodiment. Some patients with diabetes, including patients with type-1 diabetes and patients with type-2 diabetes, may require or be recommended to take insulin as a method for maintaining a safe blood glucose level. In some cases, a medical professional may determine that a dosage regimen of long-acting insulin, such as LANTUS® insulin, may be beneficial to a patient for maintaining a safe baseline blood glucose level. Long-acting insulin may be taken as, for example, a daily bolus dosage, and may have up to a 24 hour duration of action. Long-acting insulin may be used as an alternative for patients who may not wish to use an insulin pump, which provides a patient with a steady basal glucose level throughout the day. In some cases, a patient may require only the long-acting insulin dose to maintain a safe baseline blood glucose level, and may not require periodic doses of a fast or rapid acting insulin to correct for spikes in blood glucose levels resulting from, for example, carbohydrate intake. In one embodiment, among others, long-acting insulin may be taken as an injection by, for example, a syringe or injection pen, as an oral stimulant from, for example, an inhaler, or as a transdermal patch delivery system. - Patients using long-acting insulin may have different sensitivity to insulin. As such, it may be desirable for patients to periodically adjust their daily bolus dosage of long-acting insulin. Referring to
FIG. 10 , a glucose measuring device, such as thehealth monitor device 600 described above in conjunction withFIG. 6A , may prompt for a fasting blood sample (1010) to measure a fasting blood glucose level. A fasting blood sample may be a blood sample of a patient taken after a predetermined period of time without food, such as 8 hours without food typically obtained in the morning after a period of sleep. The fasting blood sample may be received on atest strip 650, which may be inserted into astrip port 640 of thehealth monitor device 600 for analysis. - Referring back to
FIG. 10 , in one embodiment, to ensure an accurate blood glucose reading, thehealth monitor device 600 may request and await confirmation that the provided blood sample is a fasting sample (1020). The confirmation that the provided blood sample is a fasting sample may be provided by the patient to thehealth monitor device 600 through, for example, theinput buttons 630 of thehealth monitor device 600. Alternatively, thehealth monitor device 600 may determine whether the provided blood sample is a fasting sample by determining if the current time is in the morning following what would typically be a predetermined period of sleep, or comparing the current time to stored past data and basing whether the sample is a fasting sample or not based upon trends of what time during the day that previous provided fasting samples were obtained. In the event that the provided blood sample is not a fasting sample, thehealth monitor device 600 may calculate and display the current blood glucose level of the provided sample with a warning that the displayed value is not a fasting blood glucose level (1030). In one aspect, if the provided blood sample is not a fasting sample, no recommended long-acting insulin dosage regimen update is calculated or displayed. - Still referring to
FIG. 10 , if the received blood sample is confirmed to be a fasting blood sample, a fasting blood glucose level may be determined by analyzing the blood glucose level of the received blood sample (1040). Once the fasting blood glucose level is determined, the value may be stored (1050) in amemory 670 of thehealth monitor device 600, or alternatively, the value may be transmitted for storage in a memory of a secondary device or computer. In one embodiment, the stored fasting blood glucose level data may be time and/or date stamped. Once the fasting blood glucose level data is stored in thememory 670, the data may be compared to a predetermined threshold value. In another embodiment, the current fasting blood glucose level may be averaged with stored fasting blood glucose level data from preceding days (1060), for example, the preceding, one, two, or four days, for comparison to the predetermined threshold value (1070). - If the current fasting blood glucose level or the averaged fasting blood glucose level are above the predetermined threshold, a dosage recommendation algorithm may be implemented based on the fasting blood glucose level. The dosage recommendation algorithm may be stored in the
memory 670 in thehealth monitor device 600 and executed by theprocessor 660 in thehealth monitor device 600, to calculate and display on a display unit 620 a recommended long-acting insulin dosage (1080). Alternatively, the dosage recommendation algorithm may be stored in a peripheral device containing a memory, and data may be transmitted to one or more peripheral devices over a data network for analysis and the results transmitted back to thehealth monitor device 600 for display. - The severity of the symptoms of diabetes for patients may vary from individual to individual. For some diabetic patients, it may be advantageous to use insulin to maintain a stable baseline blood glucose level, and additionally to use fast-acting insulin injections to compensate for periodic blood glucose level fluctuations resulting from, for example, carbohydrate intake. For such patients, it may be advantageous to have a method of calculating adjustments to daily insulin dosages to maintain a safe baseline blood glucose level, as well as on-the-spot dosage recommendations to correct for periodic blood glucose level fluctuations.
- Insulin used to maintain a stable baseline blood glucose level may be administered through, among others, the use of an insulin pump in the form of a basal insulin infusion (small dosages of insulin injected into the body at periodic intervals throughout the day), or may be administered through the use of single daily injections of long-acting insulin, such as LANTUS® insulin. In other embodiments, long-acting insulin may be administered at various other intervals, such as twice a day, or every other day. Fast-acting and rapid-acting insulin, for example, are more often used as single dose bolus injections for immediate correction to periodic blood glucose level fluctuations, which may be used in conjunction with the long-acting insulin used to maintain the baseline blood glucose level. Accurate calculation and administration of insulin to a diabetic patient is used as a measure for maintaining safe blood glucose levels in order to avoid incidents of hyperglycemia.
-
FIG. 11 is a flow chart illustrating a procedure for calculating a dosage recommendation for a long-acting insulin and a fast-acting insulin in one embodiment. Typically, long-acting insulin dosage regimens are calculated and adjusted based upon a patient's fasting blood glucose level, or the blood glucose level of a patient after a predetermined length of time, such as 8 hours, without food (or after 8 hours of sleep). The fasting glucose level may be considered to be the baseline glucose level of a patient, and is further used for determining a long-acting insulin dosage calculation, which is typically used for controlling the baseline glucose level of a patient. On the other hand, fast-acting insulin bolus dosages are typically calculated based upon a current or future blood glucose level regardless of activities such as eating and exercise, as fast-acting insulin bolus dosages are typically used to correct a current on-the-spot blood glucose level fluctuation. - Referring to
FIG. 11 , a glucose measuring device, such as thehealth monitor device 600 described above in conjunction withFIG. 6A , may prompt for a fluid sample (1110) to measure a blood glucose level. The fluid sample may be received (1120) at astrip port 640 of thehealth monitor device 600 in the form of a blood sample applied to atest strip 650. The received sample may then be analyzed in order to measure a blood glucose concentration level (1130). The measured blood glucose concentration level may then be compared to a predetermined threshold level (1140) for determination of whether an insulin dosage may be required in order to adjust the blood glucose concentration level to a safe or optimal level. - In the case that an insulin dosage is determined to be required or recommended, the
health monitor device 600 may calculate a recommended dosage of long-acting insulin (1150) as well as a recommended dosage of a fast-acting insulin (1160). The dosages may be calculated based upon one or more software algorithms stored within amemory unit 670 and executed by theprocessor 660 of thehealth monitor device 600. Once calculated, the recommended dosages of long-acting and fast-acting may be displayed on adisplay unit 620 of the health monitor device 600 (1170). - In one embodiment, the
health monitor device 600 may only recommend a long-acting insulin dosage when the received blood sample is a fasting blood sample. In another embodiment, thehealth monitor device 600 may determine whether to recommend a long-acting insulin dosage or a fast-acting insulin dosage or both, based upon the current time of day, whereby the time of day consideration may be determined by analyzing trends of previous data stored in thememory 670 of thehealth monitor device 600. - It is to be understood that the procedures described above in conjunction with
FIG. 11 are not limited to only the calculation of a long-acting insulin and a fast-acting insulin, but may be applicable to any combination of one or more medications used to treat a number of physiological conditions, including, among others, various analyte concentrations, heart-rate, breathing rate, or blood pressure, whereby some or all of the medications may be configured for dosage updates based upon a variety of mitigating factors, such as carbohydrate intake or physical activity. - In one embodiment, a health monitor device 600 (
FIG. 6A ) with a medication dosage calculator may include a medication type selector function. The medication type selector function may allow a patient to request a recommended dosage for a variety of medication types.FIG. 12 is a flow chart illustrating a means for calculating a dosage recommendation for one or more selectable medication types. Referring toFIG. 12 , ahealth monitor device 600 may prompt for a fluid sample (1210) and subsequently analyze the fluid sample to ascertain an analyte concentration (1220). In one embodiment, thehealth monitor device 600 may be a blood glucose measuring device, and may receive a fluid sample in the form of a blood sample applied to atest strip 650 and inserted into astrip port 640 of thehealth monitor device 600. The blood sample may be analyzed to discern a blood glucose concentration, which may be used as an indicator for the blood glucose level of a patient from which the sample was obtained. - Once an analyte concentration is ascertained, a medication type selection is received (1230). The medication type selection may be established via a number of different methods, including providing a list of available medication types for which the
health monitor device 600 is programmed to calculate dosage information. For example, if thehealth monitor device 600 is a glucose measuring device intended for the measurement of a patient's blood glucose level, the corresponding medication for dosage calculation may be insulin. In this case, the glucose measuring device may include programming or algorithms for calculating insulin dosage information for a variety of insulin types, including long-acting insulin, intermediate acting insulin, fast-acting insulin, rapid-acting insulin, and very-rapid acting insulin. Further, programming or algorithms may be exclusive to specific insulin compositions, even amongst the general categories of insulin types. In another aspect, the medication type may be selected automatically by thehealth monitor device 600 based on, for example, a pre-programmed treatment regimen. - Referring back to
FIG. 12 , once a medication type is chosen, the program or algorithm associated with the selected medication type may be applied to the ascertained analyte concentration in order to calculate a recommended medication dosage (1240). The recommended medication dosage and the ascertained analyte concentration may then be displayed on adisplay unit 620 of the health monitor device 600 (1250). In another embodiment, the selected medication type may also be displayed on thedisplay unit 620 to allow for confirmation that the recommended medication dosage is meant for the correct medication type. - In another embodiment, a list of available medication types for display and for selection may be limited to a predetermined list of available medications as indicated by the user, or alternatively by a doctor or other treating professional. In this manner, in one aspect of the present disclosure, a list or subset of available medication types for selection (and subsequent dosage calculation, for example) may be limited to a predetermined list of available (or pre-stored) or permitted medication stored in the
health monitor device 600. The list of available or permitted medication may be stored in thememory 670 of thehealth monitor device 600. Alternatively, thehealth monitor device 600 may include programming or software instructions which, when a particular medication is selected, other medication known or determined to be incompatible with the selected medication (for example, due to potential adverse reactions when mixed with the selected medication), may automatically be removed from the list of available medication types before providing the list to the user of thehealth monitor device 600. - In another embodiment, the
memory 670 of thehealth monitor device 600 may store information related to a patient's medical history, for example, information related to medications the patient has been previously determined to cause allergic or undesirable reactions. Accordingly, thememory 670 may store, for example, a dynamic list of available medications that are appropriate for the medication dose determination in response to or based on a selection of a type of the medication selected for dosage calculation, or alternatively, based on one or more other characteristics based on the physiological condition of the user or the medication composition. - In some instances, it may be advantageous for a patient to make use of more than one medication to control a disease or health condition. For example, diabetic patients, including patients with Type-1 and severe Type-2 diabetes, may benefit from using more than one type of insulin to help control their blood glucose level. For example, it may be advantageous to use long-acting insulin to maintain a stable baseline blood glucose level, and additionally to use fast-acting insulin injections to compensate for periodic blood glucose level fluctuations resulting from, for example, carbohydrate intake. Accordingly, in one aspect there is provided techniques for calculating adjustments to daily insulin dosages to maintain a safe baseline blood glucose level, as well as on-the-spot dosage recommendations to correct for periodic blood glucose level fluctuations.
-
FIG. 13 is a flow chart illustrating a means for calculating insulin dosage information for more than one type of insulin. In one embodiment, the more than one type of insulin may include a combination of a long-acting insulin and a rapid-acting insulin. In one aspect, dosages of the long-acting insulin may be calculated based upon a fasting blood glucose level of a patient. Referring toFIG. 13 , a health monitor device 600 (FIG. 6A ) may prompt for a fasting blood sample (1310). The fasting blood sample may be a blood sample taken from a patient after a predetermined length of time, such as at least 8 hours, without food and applied to atest strip 650 to be inserted into astrip port 640 of thehealth monitor device 600 for analysis. As a fasting blood sample is taken after at least 8 hours without food, often the blood sample is taken in the morning following 8 hours of sleep. In one aspect, in order to discern a consistent fasting blood glucose level, thehealth monitor device 600 may prompt for the fasting blood sample at the same time every morning. Once the fasting blood sample is received by thehealth monitor device 600, the sample may then be analyzed in order to ascertain a blood glucose concentration (1320) of the patient from which the sample was obtained. Once ascertained, the blood glucose concentration may be stored (1330) in amemory 670 of thehealth monitor device 600. In one aspect, the stored blood glucose concentration may be date and/or time stamped. An algorithm for calculating a long-acting insulin dosage recommendation may then be applied to the ascertained blood glucose concentration in order to calculate a recommended long-acting insulin dosage (1340) to be displayed on adisplay unit 620 of the health monitor device 600 (1350). - The algorithm or routine for determining a long-acting insulin dosage recommendation may be a dosage update algorithm based upon initial settings as determined by, for example, a healthcare professional or an insulin manufacturer specification. In one embodiment, an initial daily prescribed dosage of long-acting insulin, such as LANTUS® insulin (which has up to a 24 hour active time), may be 10 IU (International Unit) of insulin per day. One International Unit (IU) of insulin is the biological equivalent of 45.5 micrograms (μg) pure crystalline insulin. 10 IU/day of LANTUS® insulin may be the starting dosage of a long-acting insulin regimen. The fasting blood glucose concentration may be measured on a daily basis, and each measurement stored in a memory. By taking a mean average of the stored fasting blood glucose concentrations, the fasting blood glucose concentration average may be compared to a predetermined target fasting blood glucose concentration threshold. In one aspect, a recommended update to the daily dosage of long acting insulin may be calculated weekly, based upon the average glucose concentration of the preceding two or more days, and follow the below dosage schedule:
-
Average Glucose Concentration Increase in Insulin Dose(IU/day) ≧180 mg/dL +8 140-179 mg/dL +6 120-139 mg/dL +4 100-119 mg/ dL + 2 - In another embodiment, the algorithm for calculating a long-acting insulin dosage recommendation may be a daily dosage update. The algorithm may compare a fasting blood glucose concentration to a predetermined threshold level, for example, a target threshold level as determined by a healthcare professional. If the fasting blood glucose concentration is greater than the target threshold level, the algorithm may recommend an increase of 1 IU/day of long-acting insulin. This may continue each day until the fasting blood glucose concentration is at or below the target threshold level.
- In other embodiments, the target threshold level of fasting blood glucose concentration may be set by the user or may be a customized target threshold as determined by a healthcare professional.
- In another embodiment, the algorithm for calculating a long-acting insulin dosage recommendation may be based on both an upper and lower threshold value. For example, a healthcare professional may recommend a safe fasting blood glucose concentration between a predefined range. In such a case, the algorithm may update the long-acting insulin dosage on a daily basis. In one aspect, if the fasting blood glucose concentration is greater than the upper threshold, the algorithm may recommend an increase to the current long-acting insulin dosage by 1 IU/day, while if the fasting blood glucose concentration is less than the lower threshold, the algorithm may recommend a decrease to the current long-acting insulin dosage by 1 IU/day. Furthermore, if the fasting blood glucose concentration is between the upper and lower threshold, the algorithm may recommend no change to the current long-acting insulin dosage regimen.
- In another embodiment, the algorithm for calculating a long-acting insulin dosage recommendation may be based upon past and present fasting blood glucose concentration values. In one aspect, the algorithm may not recommend an update to a current glucose dosage unless the fasting blood glucose concentration is above or below a certain upper and lower threshold. In a further aspect, the algorithm may not recommend an update to a current glucose dosage unless the fasting blood glucose concentration is outside a certain threshold for a certain number of consecutive days, such as, for example, for two or more straight days.
- In another embodiment, if the difference between a current fasting blood glucose concentration and a preceding day's fasting blood glucose concentration is outside a predetermined threshold level, a software program for calculating the insulin dosage update may be programmed to not recommend an update to an insulin dosage regimen for safety measures in the case that the current fasting blood glucose concentration is in error or is not an acceptable value. Furthermore, the algorithm may be programmed to not recommend an update to an insulin dosage regimen if the insulin dosage regimen was recently updated, for example, if the insulin dosage regimen was updated within the preceding two days.
- In another aspect, if it is determined that current measured values are found to be outside threshold values, such as if the difference between a current fasting blood glucose concentration and a preceding day's fasting blood glucose concentration is outside a predetermined threshold, an alarm system may activate. The alarm system may be in the form of an auditory, visual, and/or vibratory alarm, or may be an alarm notification transmitted over a data network to, for example, a healthcare professional. Other values that may activate the alarm system may include, an upper or lower threshold current blood glucose value, a threshold number of consecutive days wherein the fasting blood glucose value increased or decreased, a missed expected sample time, or if an error is detected.
- Referring back to
FIG. 13 , thehealth monitor device 600 may also include programming to calculate a fast-acting insulin dosage. In one embodiment, while the dosage calculation for a long-acting insulin is used to maintain a stable safe baseline glucose concentration, a fast-acting insulin injection may be used to help stabilize blood glucose concentration fluctuations throughout the day due to, for example, carbohydrate intake. To that end, thehealth monitor device 600 may prompt for a non-fasting bodily fluid sample (1360), which may be in the form of a blood sample applied to atest strip 650 and received at thestrip port 640 of thehealth monitor device 600. - Non-fasting blood samples may be taken periodically throughout the day at regular intervals or at irregular intervals depending upon a patient's physical state, such as when a patient determines that his/her blood glucose level is lower or higher than one or more predetermined threshold or desired level. Furthermore, events may also define when a patient takes a non-fasting blood sample, such as before or after meals, exercise, or after taking other medications.
- Once the non-fasting blood sample is received at the
strip port 640 of thehealth monitor device 600, the blood sample may then be analyzed and a blood glucose concentration is determined (1370). An algorithm for calculating a fast-acting insulin dosage recommendation may then be applied to the ascertained blood glucose concentration in order to calculate a recommended fast-acting insulin dosage (1380) to be displayed on adisplay unit 620 of the health monitor device 600 (1390). In other embodiments, the algorithm may be designed for calculating a dosage recommendation for an intermediate, rapid, or very-rapid acting insulin type or a combination thereof. - In other embodiments, a
health monitor device 600 including programming for calculating a medication dosage or therapy profile recommendation may further include an integrated medication delivery system. In one embodiment the integrated medication delivery system may automatically deliver the medication dosage as recommended by thehealth monitor device 600. In one aspect, thehealth monitor device 600 may be preprogrammed with information related to the medication of the medication delivery system thus eliminating any possible errors resulting from a patient's accidental entry of a wrong medication in a medication selector function of thehealth monitor device 600. In another aspect, the medication delivery system may be detachable from thehealth monitor device 600. - In another embodiment, a
health monitor device 600 including programming for calculating medication dosages for two or more medication types may further include an integrated medication delivery system. In one aspect, the medication delivery system may include two or more reservoirs, each designated for storing one of the two or more medication types, and each with an individual delivery mechanism. In another aspect, the two or more reservoirs may share a single delivery mechanism. In one aspect, the medication delivery system may automatically deliver each medication in doses as recommended by thehealth monitor device 600. - In another embodiment, the
health monitor device 600 may include a corresponding docking station or one or more other peripheral devices. The docking station may include, among others, a transmitter whereby when thehealth monitor device 600 is docked to the docking station, thehealth monitor device 600 and docking station may communicate over a data network with, for example, a healthcare provider, for the transfer of data or receipt of instructions or new dosage regimens. The docking station transmitter may be configured for transmission protocols including, but not limited to, cellular telephone transmission, such as code division multiple access (CDMA) or Global System for Mobile communications (GSM), internet communication, facsimile communications, and/or telephone communication. In another aspect, the docking station may also be configured to provide power for recharging a rechargeable battery of thehealth monitor device 600. In another aspect, the docking station may be configured for communication with a personal computer for additional storage, programming, and/or communication. - In another embodiment, the
health monitor device 600 may include software for monitoring and ordering replacements for consumable products associated with thehealth monitor device 600. Consumable products may include, among others, analyte test strips, lancing devices, types of medication, such as types of long-acting and fast-acting insulin, medication deliver devices, such as syringes or injection pens, integrated lancet and testing striplet devices, sensors for an implantable sensor glucose monitoring system, or batteries. -
FIG. 14 illustrates a block diagram of a replenishment management system in accordance with one embodiment of the present disclosure. Referring toFIG. 14 , thereplenishment management system 1400 includes aserver terminal 1410 operatively coupled to one ormore user terminals 1420 via adata network 1430. As can be seen from the Figure, each of theuser terminals 1420 are also configured to be operatively connected to a respective one or more testing ormonitoring devices 1440. As will be discussed in further detail below, there is also provided afinancial account terminal 1460 operatively coupled to thedata network 1430 for communication with theserver terminal 1410 and a corresponding one of theuser terminals 1420. - In one embodiment, the testing or
monitoring device 1440 may include a health monitor device as described above in conjunction withFIG. 6A , which may be configured to automatically and wirelessly transmit the measured analyte data to theserver terminal 1410 at a predetermined frequency over the wireless connection 1451. In this case, theserver terminal 1410 may be configured to detect and receive the measured analyte data from the health monitor device and to store the received data in a corresponding user account associated with the health monitor device. Furthermore, in another embodiment, the health monitor device is configured to transmit medication dosage information, such as insulin dosage information, to theserver terminal 1410. The medication dosage information may be information related to periodic dosages of long-acting and/or fast-acting insulin. - Referring back to
FIG. 14 , it can be seen that each of theuser terminals 1420, thefinancial account terminal 1460, and theserver terminal 1410 are operatively coupled to thedata network 1430 via a correspondingdata communication link 1450. Within the scope of the present disclosure, thedata communication link 1450 may include a wired or wireless communication path which may be configured for secure, encrypted bi-directional data exchange over thedata network 1430. In particular, thedata communication link 1450 in one embodiment may include Wi-Fi data communication, infrared data communication (for example Infrared Data Association (IrDA) communication), Bluetooth® data communication, ZigBee® data communication, USB or FireWire cable based data communication, Ethernet cable based data communication, and dial up modem data communication. - For example, in one embodiment, the
user terminals 1420 may include, among others, one of a personal computer (including a desktop or a laptop computer) or a handheld communication device such as an iPhone, Blackberry, Internet access enabled mobile telephones, a bi-directional communication enabled pager, and a communication enabled personal digital assistant (PDA). In one embodiment, theuser terminals 1420 include an output unit such as a display and/or speakers, an input unit such as a keyboard or a touch-sensitive screen, as well as a controller such as a CPU for performing user instructed procedures at theuser terminals 1420. Moreover, within the scope of the present disclosure, theuser terminals 1420 may be configured to communicate with thedata network 1430 using a wireless data communication protocol such as Bluetooth®, 801.11x, and ZigBee®. Additionally, theuser terminal 1420 may also be configured to communicate with the testing ormonitoring device 1440 via short range RF communication path, an IrDA communication path, or using Bluetooth® communication protocol. Additionally, the testing ormonitoring device 1440 may also be configured to connect to therespective user terminals 1420 via a wired connection such as a USB connection, an RS-232 cable connection, an IEEE 1394 or FireWire connection, or an Ethernet cable connection. - Referring again to
FIG. 14 , thefinancial account terminal 1460 may be configured to communicate with theserver terminal 1410 and theuser terminals 1420 over thedata network 1430 using either or a wired or wireless secure and encrypted connection. As is generally the case, because financial account related information is very sensitive, high level of security for data communication to and from thefinancial account terminal 1430 may be used such as an encryption level exceeding 128-key encryption, and the like. Within the scope of the present disclosure, thefinancial account terminal 1460 may include one of a banking institution terminal, a credit card institution terminal, a brokerage institution terminal, and any other financial institution terminal which maintains a financial account of a user with which financial account transactions may be performed. This aspect of the present disclosure is discussed in further detail below. - Referring yet again to
FIG. 14 , theserver terminal 1410 in one embodiment may include acontroller 1411 operatively coupled to an input/output (I/O)interface unit 1412, a read-only memory (ROM) 1413, a random access memory (RAM) 1414, and astorage unit 1415. In one embodiment, thestorage unit 1415 includes aserver application 1416 and anoperating system 1417. In this manner, thecontroller 1411 may in one embodiment be configured to communicate with theuser terminals 1420 and thefinancial account terminal 1460 over thedata network 1430 via the I/O interface unit 1412, under the control of the various processes and routines stored in theROM 1413 and thestorage unit 1415 as well as user transmitted requests and information. - In one embodiment, the
server application 1416 and theoperating system 1417 of the storage unit may be configured to provide a proprietary interface for the users, to execute secure and encrypted data communication over thedata network 1400. More specifically, theserver terminal 1410 may be configured to provide a proprietary internet-based user interface at a predetermined URL for the users to login from theuser terminals 1420, for example, for communication with theserver terminal 1410. Alternatively, within the scope of the present disclosure, thedata network 1430 may include the internet, and wherein theserver application 1416 and theoperating system 1417 of theserver terminal 1410 are configured to provide a dedicated website for allowing the users to securely and easily log in to their respective accounts using theuser terminals 1420 over the data network. - Referring still again to
FIG. 14 , thestorage unit 1415 of theserver terminal 1410 in one embodiment may be configured to store data and information related to the user accounts such as, but not limited to, user account login identification and password, user contact information such as telephone and/or facsimile numbers, email addresses, billing and shipping addresses, user account profile information such as replenishment level information, seasonality or periodicity of user use of the testing, monitoring, or dosing device, prescribed medication information, user financial account information (for example, a bank routing number and bank account number in the case of a banking institution), and user testing, monitoring, or medication dosing device data information such as the user strip order history, medication order history, health related monitoring data such as previously measured glucose levels, user specific basal profile information, bolus determination information, insulin sensitivity, trend information determined based on the measured glucose levels (and determined by the controller 1411), and healthcare provider information for the user such as contact information for the user's physician, hospital, and nursing facilities. - In addition, within the scope of the present disclosure, the
storage unit 1415 may further be configured to store an expiration information and/or lot number associated with the consumable item, or to calculate expiration information from the lot number. For example, theserver terminal 1410 may be configured to determine the expiration information of the consumable item prior to or at the time of replenishment transaction (discussed in detail below), based on one or more of several factors, and further configured to transmit the expiration information to theuser terminal 1420 associated with the replenishment transaction. The one or more of the several factors determining the expiration information associated with the consumable item includes the lot number associated with the consumable item, where each lot number has a unique expiration date associated therewith, a shipment date of the consumable item from the manufacturer, and a date of manufacture of the consumable item. - In this manner, in one embodiment, the user requesting the replenishment transaction for the consumable item will be notified of the expiration information such as the expiration date associated with the consumable item, and will be alerted that the consumable item will not function as optimally beyond the expiration date. In the case of glucose test strips, to ensure the accuracy of the test results showing the measured glucose levels it is important that the user/patient be aware of such expiration date of the glucose test strips, so that the measured glucose levels are as accurate as possible. In the case of medication, such as insulin, the importance of a patient's awareness of the expiration date may be even more important than the expiration date of a consumable item, such as a glucose test strip. In the case of medication, expired medication may not only have a diminished effectiveness, it may in fact have a severely detrimental effect on the patient's health.
- Moreover, in the case where there is a physician or treatment advised, or other guideline as to frequency or threshold of testing, monitoring, or dosing, a warning signal may be generated and communicated to a healthcare professional or to the user in the case where the consumption of the test materials, as determined by the
server terminal 1410, is less or more than the consumption required to meet this frequency or threshold of testing, monitoring or dosing. - Referring back to
FIG. 14 , in one embodiment of the present disclosure, based on the measured glucose levels for a given patient from arespective user terminal 1420, thecontroller 1411 of theserver terminal 1410 may be configured to determine trend information based on measured glucose levels so as to determine and correspondingly generate for theuser terminal 1420 for display, a color coded indication of the user's glucose level projections including arrow indicators, color coded warning or notification indicators, and associated audible alerts. For example, based on the user's measured glucose level for a predetermined period of time contemporaneously received from theuser terminal 1420, theserver terminal 1410 may be configured to generate and transmit to the user terminal 1420 a color coded arrow indicator for display on theuser terminal 1420 to visually and easily inform the user of the projected or anticipated trend in the glucose level based on the measured glucose levels. - In another embodiment, based on the insulin dosage information for a given patient from a
respective user terminal 1420, thecontroller 1411 of theserver terminal 1410 may be configured to determine trend information based on insulin dosage information so as to determine and correspondingly generate for theuser terminal 1420 for display, a color coded indication of the user's projected future insulin dosage information, including projected increase or decrease in insulin dosage. In one aspect, thecontroller 1411 may be configured to alert the patient if the rate of change of the insulin dosage information over a period of time is above a certain threshold, possibly indicating an advancement in a user's health condition, such as a worsening of a diabetic condition. When the change of insulin dosage over a period of time is above a predetermined threshold, it may be an indication that the user should visit their primary care physician in order to ascertain information relating to the health condition of the patient, and possibly determine a change in treatment or medication. - Referring still again to
FIG. 14 , theserver application 1416 stored in thestorage unit 1415 of theserver terminal 1410 may be configured to perform, under the control of thecontroller 1411, the various procedures and processes as discussed below in conjunction withFIGS. 15-19 , as well as to store any information related to the user accounts and profiles within the scope of the present disclosure. -
FIG. 15 is a flowchart illustrating user account registration setup and account subscription process in accordance with one embodiment of the present disclosure. Referring to the Figure, atstep 1510, the server terminal 1410 (FIG. 14 ) receives from auser terminal 1420 user account registration information. The received user account registration information may include, among others, the user name, user address, the user telephone number, the user testing, monitoring, or dosing device information such as model information of the testing, monitoring, or dosing device, and the user medication prescription information. - Thereafter at
step 1520, theserver terminal 1410 is configured to generate a user account profile and login information including password and login identification, all of which are stored in thestorage unit 1415 of theserver terminal 1410. Then at step 1530, theserver terminal 1410 is configured to transmit the user login information including the generated login identification information and associated password to theuser terminal 1420. After transmitting the user login information or alternatively, substantially contemporaneously to the login information transmission, theserver terminal 1410 is configured to transmit a prompt or request to the user terminal for the user desired subscription information for the consumable product replenishment. In one embodiment, the user desired consumable product replenishment subscription information may include low product count threshold notification information and consumable product replenishment transaction option information. A low product count threshold information may be a low test strip count or a low medication, such as insulin, amount. - More specifically, at step 1540, the
server terminal 1410 in one embodiment is configured to request from the user via theuser terminal 1420 when the user wishes to be notified of a low consumable product count for performing a replenishment procedure, and also, the user's desired purchase transaction option such as establishing a link to the user's financial institution. For example, if the user wishes to be notified of a low test strip count level when the user has 150 or less strips for usage with the health monitor device, the user may specify 150 as the low strip count level at which point, the user desired notification by theserver terminal 1410 that replenishment procedure would be necessary. Furthermore, in one embodiment, the replenishment transaction option information provided to theuser terminal 1420 by theserver terminal 1410 may include one of establishing a link to the user's financial account institution for processing the purchase transaction for the purchase of the replenishment consumable product, prompting the user to allow purchase transactions over thedata network 1430, and a simple replenishment notification with option to perform the purchase transaction for the purchase of the replenishment product. - Referring again to
FIG. 15 , atstep 1550, theserver terminal 1410 is configured to receive the user selected low consumable product count notification and the replenishment transaction information for the user account from theuser terminal 1420. Theserver terminal 1410 then stores the received information related to the user selected low consumable product count notification and the chosen replenishment transaction option in thestorage unit 1415 associated with the user account information also stored therein. - Then, as can be seen from
FIG. 15 , atstep 1560, theserver terminal 1410 may be configured to transmit a notification to the user terminal 1420 a confirmation of the receipt and the information which the user selected for the low consumable product count notification level and the product replenishment transaction that the user selected. Thereafter, the user account registration setup and account subscription process shown inFIG. 15 ends. -
FIG. 16 is a flowchart illustrating an overall replenishment procedure for the user account in accordance with one embodiment of the present disclosure. Referring to the Figure, atstep 1610, the server terminal 1410 (FIG. 14 ) in one embodiment is configured to detect a user login transmission, including, for example, the detection of the user account login identification information and the corresponding password transmitted from theuser terminal 1420 over thedata network 1430. Thereafter at step 1620, theserver terminal 1410 is configured to verify the received user account login identification information. That is, in one embodiment, theserver terminal 1410 is configured to confirm the accuracy of the received account login identification information from theuser terminal 1420, and to correspond the received account login identification information to a corresponding stored user account. In one embodiment, theserver terminal 1410 may be configured to search thestorage unit 1415 for a user account profile generated and which corresponds to the received user account login identification information. - Referring to
FIG. 16 , if at step 1620 the received user account login identification information verification fails, the procedure returns to step 1610 and waits for a subsequent transmission of the user account login identification information from theuser terminal 1420. Optionally, theserver terminal 1410 may be configured to generate and transmit a login fail notification corresponding to the failed verification of the user account login at step 1620 to thecorresponding user terminal 1420. On the other hand, if at step 1620 it is determined that the received user account login identification is verified, and thus, a corresponding user account profile is recognized by theserver terminal 1410, then atstep 1630, theserver terminal 1410 is configured to receive a consumable product usage information from theuser terminal 1420 whose user is now logged into the corresponding user account profile. Consumable product usage information may include, among others, usage information for the number of test strips or dosage information for a medication, such as a long-acting and/or a fast-acting insulin. - Thereafter, the
server terminal 1410 at step 1640 is configured in one embodiment to retrieve the corresponding user account profile from thestorage unit 1415, for example, (such as in a database associated with the storage of the user account profiles in the storage unit 1415). Then, with the consumable product usage information received from theuser terminal 1420, and the corresponding user account profile retrieved from thestorage unit 1415, in one embodiment, theserver terminal 1410 atstep 1650 is configured to perform a consumable product replenishment procedure discussed in further detail below to replenish the consumable product supply associated with the user account profile. - While the present embodiment is mainly described in conjunction with glucose test strips to be used for the periodic glucose level testing and with insulin medication to be used for controlling a patient's blood glucose level, the present disclosure may be applied and would equally cover any procedure which is configured to replenish a given quantity of consumables (for example, medications to be consumed at a predetermined time interval). Referring back to the Figure, upon completing the consumable product replenishment procedure at
step 1650, theserver terminal 1410 atstep 1660 may be configured to update the user account profile associated with the user by for example, updating the database stored in thestorage unit 1415 of theserver terminal 1410 associated with the user account profile for the user that is logged in. - Furthermore, within the scope of the present disclosure, the database stored in the
storage unit 1415 may also be linked to systems that are configured to track user demand, so as to forecast and anticipate demand, and also to track overall consumption patterns, preference, seasonal demand, geographic demand, and other similar demographic data for use in managing supply side activities more effectively and efficiently. The individual user data in the database stored in thestorage unit 1415 may also include insurance or other individual reimbursement coverage rates of the individual user. This data may be used to determine a user co-pay and the amount that the insurance or other individual reimbursement coverage allows to the individual user. The results of these calculations on the user data in the database stored in thestorage unit 1415 may be used as a basis for purchase or charge transaction to user for the co-pay amount, to charge the insurance or other individual reimbursement coverage for the amount so covered, and also to provide an alert signal in the case that the individual user may exceed the limits of payment coverage, as stored in the database in thestorage unit 1415, so that action may be taken based on the alert signal. -
FIG. 17 is a flowchart illustrating the replenishment procedure shown inFIG. 16 in further detail in accordance with one embodiment of the present disclosure. More specifically, the strip replenishment procedure of step 1650 (FIG. 16 ) in one embodiment begins at step 1710 where the server terminal 1410 (FIG. 14 ) in one embodiment is configured to compare the received consumable product usage level with a user selected threshold level. Referring back toFIG. 14 , the user selected threshold level in one embodiment may correspond to the one or more of low consumable product count notification level which the user selected during the user account registration procedure as shown inFIG. 15 . Moreover, the received consumable product usage level at step 1710 in one embodiment corresponds with the received consumable product usage information at step 1630 (FIG. 16 ) received from theuser terminal 1420. - Referring back to
FIG. 17 , after the comparing step at step 1710 (or as a result of the comparison step of step 1710), the consumable product replenishment procedure at step 1720 determines whether the received consumable product usage level is below the user selected threshold level. If it is determined at step 1720 that the received consumable product usage level is above the user selected threshold level, then atstep 1730, theserver terminal 1410 transmits a user notification to thecorresponding user terminal 1420 notifying that replenishment is unnecessary, and thereafter, the consumable product replenishment procedure terminates. - On the other hand, if at step 1720 it is determined that the received consumable product usage level is below the user selected threshold level, then, at
step 1740, the server terminal is configured to determine the amount of the consumable product needed for replenishment. More specifically, theserver terminal 1410 in one embodiment may be configured to not only determine whether consumable product replenishment is necessary for the associated user account, but also, what the amount of necessary replenishment should be based on one or more predetermined factors such as the desired or optimal consumable product level or count selected by the user (and previously stored in thestorage unit 1415, for example, of the server terminal 1410), and the time frame in which the consumable product replenishment procedure is triggered based upon the user account profile information (that is, based on the user's consumable product usage history profile, whether the triggered consumable product replenishment procedure is temporally closer to the most immediately preceding consumable product replenishment procedure). - Within the scope of the present disclosure, such usage historical information determined by the
server terminal 1410, for example, may provide valuable information to the user as well as to theserver terminal 1410 to maintain an efficient and reliable consumable product replenishment routine so as to not result in either over supply of products, or a supply of consumable products running dangerously low. - Referring back to
FIG. 17 , after determining the number of consumable products that are needed for replenishment atstep 1740 associated with the user account profile, at step 1750, the server terminal 1410 (FIG. 14 ) in one embodiment is configured to perform a charge transaction to the financial account associated with the user account so as to charge the user's financial account for the purchase and shipping of the replenishment products to the user associated with the user account profile. In one embodiment, as discussed above, theserver terminal 1410 is configured to retrieve the financial account information stored and associated with the user account and performs the charge transaction over thedata network 1430 with the correspondingfinancial account terminal 1460. As discussed above, the financial account information in one embodiment may include one of a bank account, a credit card account, a debit account, a pre-paid financial account, or any other cash or cash equivalent account (such as the redemption of airline miles or vendor points) which theserver terminal 1410 is configured to recognize with monetary value. - Referring again to
FIG. 17 , at step 1760, it is determined whether the charge transaction performed at step 1750 is successful. More specifically, theserver terminal 1410 in one embodiment is configured to interact with thefinancial account terminal 1460 over thedata network 1430 in order to perform the charge or debit transaction for the amount associated with the amount of replacement product. If the associatedfinancial account terminal 1460 returns a failed transaction notification to theserver terminal 1410 based on theserver terminal 1410 transmission of the charge transaction over thedata network 1430, then at step 1770, theserver terminal 1410 in one embodiment is configured to generate and transmit a notification to theuser terminal 1420 notifying the user at theuser terminal 1420 that the consumable product replenishment procedure has failed. Also, theserver terminal 1410 is configured to notify the user that the reason for consumable product replenishment failure is due to inaccurate or outdated financial account information associated with the user account, and thus, is configured to prompt the user to update the user's financial account associated with the user's account profile stored in theserver terminal 1410. - On the other hand, referring back to
FIG. 17 , if at step 1760, it is determined that the consumable product replenishment charge transaction is successful, then at step 1780, theserver terminal 1410 is configured to retrieve the user shipping information associated with the user account profile, and executes the shipping procedure to ship the replenishment consumable products purchased by the user to the user's designated shipping location. In one embodiment, theserver terminal 1410 may be configured to prompt the user to verify or update the desired shipping location (such as destination address and time frame for shipping to include expedited shipping or custom shipping options, for example). - Referring again to
FIG. 17 , upon executing the shipping procedure at step 1780, the server terminal at step 1790 is configured to generate and transmit a notification to theuser terminal 1420 associated with the user account confirming the shipment of the ordered products as well as the shipping and the fulfilled order details. Also, theserver terminal 1410 is configured to update the associated user account based on the charge transaction and the shipping transaction performed. In this manner, in accordance with one embodiment of the present disclosure, the users may conveniently place a shipment order of products in advance of running low on the product, and rather then relying upon the user's manual calculation or determination of the needed products based upon the user's usage, such determination is automatically performed for the user, and the user can easily make the purchase transactions for the replenishment consumable products quickly and easily. -
FIG. 18 is a flowchart illustrating the replenishment procedure shown inFIG. 16 in further detail in accordance with another embodiment of the present disclosure. Referring to the Figure, in one embodiment of the present disclosure, theserver terminal 1410 is configured to transmit to the user terminal 1420 a predetermined or calculated amount of consumable products to be shipped atstep 1810. In one embodiment, theserver terminal 1410 may be configured to determine the amount of consumable products to be shipped based on one or more predetermined factors such as the user product usage level, the user selection of low consumable product notification information, the user's desired consumable product inventory, and the user's desired frequency of product replenishment. - Responsive to the amount of consumable products to be shipped notification received from the
server terminal 1410, the user may confirm the received number of consumable products to be shipped as the number of products that the user wants to receive, and thus, may transmit an acceptance notification to theserver terminal 1410 which theserver terminal 1410 atstep 1820 is configured to receive, for example, as an acceptance of the order associated with the amount of consumable products to be shipped to the user. Thereafter atstep 1830, theserver terminal 1410 may be configured to receive order payment information for the purchase of the amount of consumable products that the user has accepted to be shipped to the user. In one embodiment, the user may transmit from theuser terminal 1420 to theserver terminal 1410 over thedata network 1430, a user financial account information, such as a credit card information or a bank account information to be used to perform the purchase transaction. - Referring back to
FIG. 18 , thereafter atstep 1840, theserver terminal 1410, having received the financial account information from theuser terminal 1420, performs and completes the order transaction for the purchase of the amount of consumable products accepted by the user and to be shipped to the user with the received payment information. Upon performing and successfully confirming the order transaction atstep 1840, theserver terminal 1410 atstep 1850 is configured in one embodiment to generate an order confirmation notification and to transmit the notification to the user. In one embodiment, the order confirmation notification may include the amount of consumable products ordered, the shipping or mailing address where the ordered products are to be shipped, and the amount charged to the financial account associated with the payment information. - In this embodiment, it can be seen that the user is not required to provide the user's financial account information to have it stored, for example, in the user account profile at the
server terminal 1410. This approach would be particularly desirable for users who do not wish to have their financial account information disseminated and stored in vendor sites such as theserver terminal 1410 configured to perform consumable product replenishment procedures. -
FIG. 19 is a flowchart illustrating a user account update and maintenance procedure in accordance with one embodiment of the present disclosure. Referring to the Figure, atstep 1910, a user account update procedure is prompted. This may be a server terminal 1410 (FIG. 14 ) triggered procedure (for example, when it is determined that the user financial account information stored in theserver terminal 1410 is outdated or no longer accurate), or alternatively, the user at theuser terminal 1420 may initiate the user account update procedure ofstep 1910 based on the user's desire to modify one or more settings or parameters associated with the user account profile. - Referring to the Figure, in the case where the
server terminal 1410 determines that the user account update is not needed, then atstep 1920, it is determined that the account update procedure is unnecessary and a corresponding notification is transmitted to theuser terminal 1420. For example, in the case where the user prompts a parameter which the user wishes to modify (such as by modifying the shipping information), if theserver terminal 1410 determines atstep 1910 that the updated information with which the user wishes to update is the same at that which is stored in theserver terminal 1410, then, rather then expending the processing power of theserver terminal 1410 to perform the user account update procedure, theserver terminal 1410 is configured to generate and transmit the notification to the user terminal that the user specified account update is not necessary. - On the other hand, if it is determined that the user account update is to be performed at
step 1910, then atstep 1930, theserver terminal 1410 is configured to retrieve the stored user account associated with the user profile. Thereafter, atstep 1940, theserver terminal 1410 is configured to detect the receipt of updated information associated with the user profile received from theuser terminal 1420. Thereafter, theserver terminal 1410 at step 1950 is configured to update the user account with the updated information received from theuser terminal 1420. In one embodiment, theserver terminal 1410 may be configured to update the database stored in thestorage unit 1415, and which is associated with the user account to be updated based on the account update information received from theuser terminal 1420. Upon completing the user account update with the received updated information, theserver terminal 1410 atstep 1960 is configured to transmit a notification to theuser terminal 1420 to notify and confirm the update to the user account. - In the manner described above, in accordance with the various embodiments of the present disclosure, there is provided method and system for providing subscription based transaction for consumable items such as glucose test strips or insulin, which diabetic patients may effectively use to easily replenish glucose test strips or insulin when the patient is running low on such items. In one embodiment, the user's use of the account or access to the subscription based account profile serves to compare the number of remaining test strips with the desired minimum number of strips which the patient may have specified or the amount of remaining insulin with the desired minimum amount of insulin which the patient may have specified, and to automatically initiate and execute the purchase transaction of the test strips, insulin, or other consumables for the user to order, and deliver the products to the patient on time such that the patient does not run low on the item.
- In this manner, in accordance with the various embodiments of the present disclosure, an efficient system and method for the user to always maintain a minimum number of consumable items on order or to be ordered based on the user's rate of usage of the item is provided.
- Furthermore, within the scope of the present disclosure, the server terminal 1410 (
FIG. 14 ) may be configured to provide a loyalty based rewards program such that based on a predetermined criteria, the users may be provided with a discounted price for the replenishment orders of the test strips or medication, such as insulin, and/or be offered a replacement health monitor device or medication delivery device based on the user's replenishment transaction history. - For example, the
server terminal 1410 may be configured to flag a user account profile which has executed a threshold amount of replenishment transactions (whether based on the number of products ordered for replenishment, or based on the total value of the replenishment transactions sum), and to offer an incentive to continue to maintain the user account, and thus with the replenishment transactions. In one embodiment, theserver terminal 1410 may be configured to automatically offer to send a replacement health monitor device and/or medication delivery system, such as a syringe or injection pen, at every calendar year (or at a predetermined frequency) so long as the user's frequency and volume of replenishment transaction satisfies a threshold level. Alternatively, theserver terminal 1410 may be configured to apply a price discount for future replenishment transactions based on the user satisfying the threshold level discussed above. In this manner, within the scope of the present disclosure, the users or patients are provided with an incentive to continue to maintain the user account and to continue performing the replenishment transactions. - Additionally, in a further embodiment of the present disclosure, where there are existing contracts with a provider of insurance or other individual reimbursement, or with a government or authority which provides group discounts when certain conditions are met, such as group price discounts or other special commercial terms, the
server terminal 1410 may be configured to automatically provide the special commercial terms to the provider of insurance or other individual reimbursement, or to the government or authority. -
FIG. 20 is a flowchart illustrating modified therapy management procedure including medication dosage determination based on real time monitored analyte levels in accordance with one embodiment of the present disclosure. Referring toFIG. 20 , in one embodiment, the current therapy parameters are retrieved 2010 and the retrieved current therapy parameters are analyzed based on the received real time data associated with the monitored or acquired analyte levels and/or updatedanalyte trend information 2020. For example, one or more preprogrammed medication delivery profiles or rates including, for example, but not limited to medication delivery rate or profiles including, for example, basal profiles, correction bolus amount, carbohydrate bolus amount, temporary basal profiles and associated parameters are retrieved and analyzed based on, for example, the received real time data associated with the monitored or acquired analyte levels and/or updated analyte trend information, and may further, factor in the insulin sensitivity level or related information of the patient as well as insulin on board information. - Referring to
FIG. 20 , based upon the analysis of the current therapy parameters, one or more modified therapy profiles are calculated 2030. That is, based upon the glucose levels monitored by the health monitor device with a medication dose calculation function 100 (FIG. 1 ), a modification or adjustment to the programmed, pre-programmed or programmable basal profiles stored in the health monitor device with a medicationdose calculation function 100 may be determined, and the modified therapy profile is output to thepatient 2040, for example on thedisplay 120 of thehealth monitor device 100. That is, the modification or adjustment to the pre-programmed delivery profiles (e.g., basal profiles) may be provided to the patient for review and/or execution to implement the recommended modification or adjustment to the programmed, pre-programmed or programmable therapy profiles (e.g., basal profiles). - Embodiments of the present disclosure include current therapy parameters as discussed above including medication delivery rate information, frequency of medication dosing information, previously administered medication delivery rate, amount, delivery duration, and the like, as well as medication sensitivity information (unique to each user or patient) including, for example, insulin sensitivity. Moreover, current therapy parameters further include exercise regimen, compliance to medication therapy information (for example, indications or confirmations that the recommended or programmed medication was administered, exercise regimen and/or diet profiles were followed or complied with, and the like).
- In this manner, the patient may be provided with one or more adjustments to the existing or current therapy management profiles including for example, medication delivery profiles such as basal profiles and/or bolus dosage recommendation (amount or time period for administration) or any other programmed, pre-programmed or programmable therapy profiles based on monitored or acquired physiological levels of the patient such as analyte levels of the patient. Indeed, in one embodiment of the present disclosure, using monitored glucose levels of the patient, modification or adjustment to the programmed, pre-programmed or programmable therapy management profiles may be determined and provided to the patient for review and/or implementation or execution as desired by the patient. That is, in one aspect, as may be appropriate or suitable, the user, when provided with the therapy modification recommendation, may decide to execute or implement the recommended therapy modification for example, initiating one or more routines of functions for implementation of the same. In this manner, for example, a diabetic patient may improve the insulin therapy management and control of the variation in the glycemic levels within desired and/or acceptable range.
- In one or more embodiments, therapy parameters may be associated with or tagged in conjunction with current or past analyte level measurements. In this manner, when a patient measures their current analyte level, for example utilizing a health monitor device such as those described in
FIGS. 1 , 6A and 7, one or more therapy related parameter and/or associated analyte level measurements may be tagged or flagged and the corresponding tagged or flagged information stored in the database. Therapy parameters which may be associated with analyte level measurements may include, but are not limited to, events such as medication intake, carbohydrate intake, exercise, sleep, travel, work related events, and associated parameters such as the amount or time duration related to the corresponding events. - For example, analyte level data may be stored in a database including the associative one or more tags related to the therapy parameters. A patient or other healthcare professional may then be able to query the database based on particular therapy parameters, and optionally use the results for, for example, determination of a desired therapy profile. The database, as described in further detail above, may be stored in the memory of the health monitor device, or alternatively or additionally be stored in a memory of an external peripheral device, computer, or server.
- The therapy parameter tag may be associated with a current analyte level manually or automatically. In one aspect, the health monitor may display a request to the patient to confirm if a therapy parameter is associated with the current analyte level measurement. Furthermore, the health monitor may display a request to the patient to choose from a selected list of available therapy parameter tags, the corresponding current therapy parameter to associate with the current analyte level. In another aspect, the patient may manually choose to associate a therapy parameter tag with the current analyte level measurement by, for example, entering a preprogrammed code or choosing a therapy parameter tag from a list. In yet another embodiment, the health monitor device may be programmed to automatically determine if the current analyte level measurement should have a therapy parameter tag associated therewith. In one aspect, the health monitor device may compare the current time and analyte level with historical data saved in a database or memory, and determine based upon said historical data if the current analyte level measurement is likely associated with a therapy parameter tag. For example, if historical data indicated a carbohydrate intake within a preselected time range on each of a number of preceding days with a similar analyte level measurement as the current analyte level measurement, the health monitor may automatically tag the current analyte level measurement with a carbohydrate intake therapy parameter tag. In another aspect, if the patient is currently on a specific therapy regimen, including a medication, exercise, and/or diet regimen, the health monitor device may be programmed to associate analyte level measurements with corresponding therapy parameter tags during particular times of the day in accordance with the specified therapy regimen. In one aspect, when the determination of an association of therapy parameter tags is automated by the health monitor device, the health monitor device may require a user confirmation prior to storing the data in a memory or database.
- As discussed below, the adjustment or modification to the therapy management profiles may include statistical analysis, including, linear regression, modified linear regression analysis, forecasting techniques, data mining and/or other suitable data analysis to determine customized therapy management modification based on the variation in the glycemic profiles of the patient or the user. In certain aspects, routines and/or functionalities for data processing, analysis and display including user input and output of information may be performed by the health monitor devices (100, 600, 700) described above. That is, software algorithm or programs may be stored in one or more memory devices or storage units of the health monitor devices that may be retrieved or accessed by microprocessors and/or control units including, for example, application specific integrated circuits that includes one or more state machines programmed to perform routines or logic based on the algorithm or programs retrieved from the one or more memory devices or storage units.
-
FIG. 21 is a flowchart illustrating contextual based therapy management including medication dosage determination in accordance with one embodiment of the present disclosure. Referring to the Figure, one or more user input parameter is received 2110 such as, for example, user's age, gender, physiological profile, existing medication (i.e., prescription or nonprescription medication consumed or ingested during a relevant time period), the amount of carbohydrate to ingest, type of exercise to perform, current time of day information, insulin on board information determined based on time and amount information of previously administered medication doses, frequency, type and amount of previously administered medication doses (for example, the frequency, time of day information, and/or amount of administered bolus doses over a predetermined time period (e.g., over a 24 hour period, over a 48 hour period, or all such information stored and/or available for use in the analysis) or any other appropriate information that may impact the determination of the suitable medication level. Based on the one or more user input parameters, one or more database is queried 2120. In one embodiment, the database may be provided in the health monitor device with a medication dose calculation function 100 (FIG. 1 ). Alternatively or in addition, the one or more databases may be provided in one or more remote locations such as a server or a remote user terminal. - Referring back to
FIG. 21 , the database query in one embodiment may be configured to search or query for medication dosage levels that are associated with similar parameters as the received one or more user input parameters. Thereafter, the queried result is generated and provided to theuser 2130 which may be acted upon by the user, for example, to administer the medication dosage amount based on the queried result. The user selection of the administered medication dosage level is stored in thedatabase 2140 with the associated one or more user input parameters as well as the time and date information of when the user has administered the medication dosage amount. - In this manner, in one embodiment, insulin dosages and associated contextual information (e.g., user input parameters) may be stored in the one or more databases for retrieval, analysis, updating and/or modification. For example, a bolus dose amount for a diabetic patient may be determined in the manner described above using the stored historical information without performing a mathematical calculation which takes into account of variables such as sensitivity factors varying with time and/or user's physiological conditions, and which may need to be estimated.
- In particular, embodiments include contextual medication dosage determination that includes analyzing the current profile of the user or the patient to determine the relevant or suitable physiological profile of the user or the patient, by comparing to one or more of the previously stored profiles including the various parameters associated with the user or the patient's physiology, medication history, diet, as well as other parameters to retrieve the corresponding medication dosage previously administered for recommendation to the user or the patient. The recommended dosage or the therapy or delivery profile may be further refined or modified by the patient or the user prior to administration or implementation.
- In particular, in one embodiment of the present disclosure, insulin dependent users may determine their appropriate insulin dosages by, for example, using historical dosage information as well as associated physiological condition information. For example, the historical data may be stored in one or more databases to allow search or query based on one or more parameters such as the user's physiological condition and other contextual information associated with each prior bolus dosage calculated and administered. In this manner, the user may be advised on the proper amount of insulin under the particular circumstances, the user may be provided with descriptive statistical information of insulin dosages under the various conditions, and the overall system may be configured to learn and customize the dosage determination for the particular user over an extended time period.
- For example, in one aspect, contextual information may be stored with the insulin bolus value. The contextual data in one aspect may include one or more of blood glucose concentration, basal rate, type of insulin, exercise information, meal information, carbohydrate content estimate, insulin on board information, and any other parameters that may be used to determine the suitable or appropriate medication dosage level. Some or all of the contextual information may be provided by the user or may be received from another device or devices in the overall therapy management system such as receiving the basal rate information or blood glucose concentration from the health monitor device with a medication dose calculation function 100 (
FIG. 1 ). - By way of an example, a contextually determined medication dosage level in one embodiment may be provided to the user along with a suitable or appropriate notification or message to the user that after a predetermined time period since the prior administration of the medication dosage level, the blood glucose level was still above a target level. That is, the queried result providing the suitable medication dosage level based on user input or other input parameters may be accompanied by other relevant physiological condition information associated with the administration of the prior medication dosage administration. In this manner, when the user is provided with the contextually determined medication dosage level, the user is further provided with information associated with the effects of the determined medication dosage level to the user's physiological condition (for example, one hour after the administration of the particular medication dosage level determined, the user's blood glucose level changed by a given amount). Accordingly, the user may be better able to adjust or modify, as desired or needed, the contextually determined medication dosage level to the current physiological conditions.
- In this manner, in one embodiment, to determine and provide the user with proper medication dosage levels, the present or current context including the patient's current physiological condition (such as current blood glucose level, current glucose trend information, insulin on board information, the current basal profile, and so on) is considered and the database is queried for one or more medication dosage levels which correlate (for example, within a predetermined range of closeness or similarity) to the one or more current contextual information associated with the user's physiological condition, among others.
- Accordingly, in one embodiment, statistical determination of the suitable medication dosage based on contextual information may be determined using, one or more of mean dosage determination, using a standard deviation or other appropriate statistical analysis of the contextual information for medication dosages which the user has administered in the past. Further, in one aspect, in the case where no close match is found in the contextual query for the desired medication dosage level, the medication dosage level with the most similar contextual information may be used to interpolate an estimated medication dosage level.
- In still another aspect, the database query may be configured to provide time based weighing of prior medication dosage level determinations such that, for example, more recent dosage level determination in which similar contextual information may be weighed heavier than aged dosage level determination under similar conditions. For example, older or more aged bolus amounts determined may be weighed less heavily than the more recent bolus amounts. Also, over an extended period of time, in one aspect, the older or aged bolus amounts may be aged out or weighed with a value parameter that minimally impacts the current contextual based bolus determination. In this manner, in one aspect, a highly personalized and individualistic profile for medication dosage determination may be developed and stored in the database with the corresponding contextual information associated therewith.
-
FIG. 22 is a flowchart illustrating contextual based dosage determination in accordance with one embodiment. Referring toFIG. 22 , in one aspect, when the user input parameters are received at step 2210, the current therapy profile of the user's medication delivery system, such as an insulin pump, is determined atstep 2220. Thereafter, the database is queried based on the input parameters and the current therapy profile atstep 2230, which results in one or more contextually determined bolus amount associated with the input parameters and the current therapy profile atstep 2240 that is provided to the user. The determined bolus amount is then atstep 2250 stored in the database with the associated input parameters and the current therapy profile and any other contextual information associated with the determined bolus amount. - In this manner, in one aspect, in addition to the user provided input parameters, other relevant contextual information may be retrieved (for example, the current therapy profile such as basal rate, the current blood glucose level and/or glucose trend information from the health monitor device with a medication dose calculation function 100 (
FIG. 1 ), and the like) prior to the database query to determine the suitable bolus amount. - As discussed above, optionally, the contextual information including the user input parameters and other relevant information may be queried to determine the suitable medication dosage level based on one or more statistical analysis such as, for example, but not limited to, descriptive statistics with the use of numerical descriptors such as mean and standard deviation, or inferential statistics including, for example, estimation or forecasting, correlation of parameters, modeling of relationships between parameters (for example, regression), as well as other modeling approaches such as time series analysis (for example, autoregressive modeling, integrated modeling and moving average modeling), data mining, and probability.
- Embodiments further include querying the one or more databases or storage devices to perform statistical analysis including or based at least in part on a hierarchy of the therapy profile parameters that is either pre-programmed or stored in the database (based on for example, level of relevance, temporal occurrence, user identified ranking of importance, healthcare provider identified ranking of importance, similarity, dissimilarity, occurrence prior to another event, occurrence after another event, occurrence in conjunction with a predetermined physiological condition, etc).
- By way of a further non-limiting example, when a diabetic patient plans to take insulin of a particular type, the patient enters contextual information such as that the patient has moderately exercised and is planning to consume a meal with a predetermined estimated carbohydrate content. The database in one embodiment may be queried for insulin dosages determined under similar circumstances in the past for the patient, and further, statistical information associated with the determined insulin dosage is provided to the user. In one aspect, the displayed statistical information associated with the determined insulin dosage may include, for example, an average amount of insulin dosage, a standard deviation or a median amount and the 25th and the 75th percentile values of the determined insulin dosage.
- The patient may consider the displayed statistical information associated with the determined insulin dosage, and determine the most suitable or desired insulin amount based on the information received. When the patient programs the insulin pump to administer the desired insulin amount (or otherwise administer the desired insulin amount using other medication administration procedures such as injection (using a pen-type injection device or a syringe), intaking inhalable or ingestable insulin, and the like) the administered dosage level is stored in the database along with the associated contextual information and parameters.
- In this manner, the database for use in the contextual based query may be continuously updated with each administration of the insulin dosage such that, each subsequent determination of appropriate insulin dosage level may be determined with more accuracy and is further customized to the physiological profile of the particular patient. Additionally, the database queried may be used for other purposes, such as, for example, but not limited, to tracking medication information, providing electronic history of the patient related medical information, and the like. Further, while the above example is provided in the context of determining an insulin level determination, within the scope of the present disclosure, other medication dosage may be determined based on the contextual based database query approaches described herein.
- In a further aspect, the contextual based medication dosage query and determination may be used in conjunction with the standard or available medication dosage determination (for example, standard bolus calculation algorithms) as a supplement to provide additional information or provide a double checking ability to insure that the estimated or calculated bolus or medication dosage level is appropriate for the particular patient under the physiological condition at the time of the dosage level determination.
- In still a further aspect, user or patient feedback on current or prior medication dosage levels may be used in conjunction with the contextual based medication dosage query and determination to improve the user or patient's therapy management. In this manner, in aspects of the present disclosure, there are provided health monitor devices, such as glucose meters and monitoring systems with improved and robust functionalities providing comprehensive and easy to use therapy management devices and/or systems. In a certain aspect, the health monitor devices may be configured to provide medication dosage calculation, such as single dose of rapid or fast acting insulin, long acting insulin, or combinations thereof, and further configured to incorporate additional features to improve the management of the management and/or treatment of medical conditions such as diabetes, for example.
- In accordance with aspects of the present disclosure, the program instructions and/or associated application for execution by the one or more processor driven devices such as, for example, the health monitor device 100 (
FIG. 1 ) may be transferred over data network for installation and subsequent execution by the devices that are downloading the applications, for example, thehealth monitor device 100. For example, the application associated with the various program instructions for implementing the medication dose calculation function may be downloadable over the air (OTA) over a cellular network and installed in one or more devices in communication in the cellular network. In addition, the executable program or application may be installed for execution in the one or more components of devices in the various systems described above, over a data network such as the internet, a local area network, a wide area network and the like. - Moreover, in aspects of the present disclosure, the various components of the overall systems described above including, for example, the health monitor device, data processing terminal or remote computing device (such as a personal computer terminal or server terminal) as described above may each be configured for bi-directional or uni-directional communication over one or more data communication networks to communicate with other devices and/or components, including, for example, infusion devices, analyte monitoring device such as continuous glucose monitoring system, computer terminals at a hospital or a healthcare provider's office, the patient or user's residence or office, or the device/component vendor/supplier or manufacturer (for example, the vendor or manufacturer of the test strips, insulin, and lancing device and the like) or any other location where the network component is capable of wired or wireless communication over a data network with other devices or components in data communication over the data network. Additionally, secure encrypted data communication may be provided, including encryption based on public/private key pair, password protection and the like to maintain a desired level of security of the data transferred.
- In one embodiment, a device may comprise, one or more processors, and a memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors, causes the one or more processors to detect an analyte sample, determine an analyte concentration associated with the detected analyte sample, retrieve stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determine a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, wherein the determined current dose level includes a predetermined type of medication classification.
- The medication classification may include one or more of long acting insulin and rapid acting insulin.
- The analyte concentration may be associated with a blood glucose concentration.
- The analyte concentration may be associated with a fasting blood glucose concentration.
- The retrieved prior dose determination information may include prior administered medication level information.
- The prior administered medication level information may include prior stored one or more of long acting insulin dose amount, or a rapid acting insulin dose amount.
- Further, each of the retrieved one or more prior dose determination information may be associated with one or more of administered medication dose time information, administered dose frequency information over a predetermined time period, or administered medication dose amount.
- In one aspect, the device may include an output unit coupled to the one or more processors, wherein the memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors causes the one or more processors to output one or more of the determined current dose level, determined analyte concentration, retrieved stored one or more dose determination information, analyte concentration associated with the retrieved one or more dose determination information, or a request for one or more predetermined information.
- The output unit may include one or more of a visual output unit, an audible output unit, or a vibratory output unit, or one or more combinations thereof.
- The one or more predetermined information may include a request for an additional analyte sample, or a request to confirm the determined current dose level.
- In another aspect, the device may include an input unit coupled to the one or more processors, wherein the memory for storing instructions coupled to the one or more processors which, when executed by the one or more processors causes the one or more processors to detect one or more input commands received from the input unit.
- The one or more input commands may include an acknowledgement confirming the determined current dose level.
- The one or more input commands may include a rejection of the determined current dose level.
- The one or more input commands may include a request to recalculate the current dose level.
- In yet another aspect, the device may include a communication module operatively coupled to the one or more processors, the communication module configured to transmit one or more of the determined current dose level or the determined analyte concentration to a remote location.
- The communication module may include one or more of an RF transmitter, an RF transceiver, a ZigBee® communication module, a WiFi™ communication module, a Bluetooth® communication module, an infrared communication module, or a wired communication module.
- In another embodiment, a method may comprise detecting an analyte sample, determining an analyte concentration associated with the detected analyte sample, retrieving stored one or more dose determination information and associated analyte concentration associated with the retrieved one or more dose determination information, and determining a current dose level based at least in part on the determined analyte concentration and the retrieved prior dose determination information, wherein the determined current dose level includes a predetermined type of medication classification.
- The medication classification may include one or more of long acting insulin and rapid acting insulin.
- The analyte concentration may be associated with a blood glucose concentration.
- The analyte concentration may be associated with a fasting blood glucose concentration.
- The retrieved prior dose determination information may include prior administered medication level information.
- Further, the prior administered medication level information may include prior stored one or more of long acting insulin dose amount, or a rapid acting insulin dose amount.
- Each of the retrieved one or more prior dose determination information may be associated with one or more of administered medication dose time information, administered dose frequency information over a predetermined time period, or administered medication dose amount.
- In one aspect, the method may include outputting one or more information associated with the one or more of the determined current dose level, determined analyte concentration, retrieved stored one or more dose determination information, analyte concentration associated with the retrieved one or more dose determination information, or a request for one or more predetermined information.
- The outputting of one or more information may include outputting a visual indication, an audible indication, a vibratory indication, or one or more combinations thereof.
- The one or more predetermined information may include a request for an additional analyte sample, or a request to confirm the determined current dose level.
- In another aspect, the method may include detecting one or more input commands received from the input unit.
- The one or more input commands may include an acknowledgement confirming the determined current dose level.
- The one or more input commands may include a rejection of the determined current dose level.
- The one or more input commands may include a request to recalculate the current dose level.
- In yet another aspect, the method may include transmitting one or more of the determined current dose level or the determined analyte concentration to a remote location.
- Transmitting may include transmitting over one or more of an RF transmission protocol, a ZigBee® transmission protocol, a WiFi™ transmission protocol, a Bluetooth® transmission protocol, an infrared transmission protocol, or a wired transmission protocol.
- In another embodiment, a glucose meter may comprise a housing, a memory device coupled to the housing, a controller unit coupled to the housing and the memory device, an input unit coupled to the controller unit and the housing for inputting one or more commands or information, an output unit coupled to the controller unit and the housing for outputting one or more output data, and a strip port provided on the housing configured to receive an analyte test strip, the controller unit configured to determine an analyte concentration based at least in part on the analyte sample on the received analyte test strip, wherein the controller unit is configured to retrieve one or more routines stored in the memory device to determine a medication dose amount based at least in part on the determined analyte concentration.
- The determined medication dose amount may include a bolus dose amount.
- The determined medication dose amount may include an insulin dose amount or a glucagon dose amount.
- The determined medication dose amount may include one or more of a rapid acting insulin dose or a long acting insulin dose.
- The output unit may include one or more of a visual display unit, an audible output unit, or a vibratory output unit.
- The determined analyte concentration may include a blood glucose concentration.
- The controller unit may be configured to store one or more of the determined analyte concentration or the medication dose amount.
- In one aspect, the meter may include a communication module coupled to the controller unit, the communication module configured to, at least in part, communicate one or more of the determined analyte concentration or the medication dose amount to a remote location.
- The remote location may include a medication delivery device.
- The medication delivery device may include an insulin delivery device.
- In one embodiment, a method of providing therapy management may include receiving a request for a therapy profile for treating a medical condition, determining using a processor a plurality of therapy profile parameters, assigning a weighted value to each therapy profile parameter based on a hierarchy determined by the medical condition, querying a database to identify a stored therapy profile with therapy profile parameters that most closely correspond to the determined plurality of therapy profile parameters based on the hierarchy, and generating an output data corresponding to the identified stored therapy profile, wherein the output data may include a medication dosage information.
- The outputted medication dosage information may include a medication delivery amount or duration or both for the treatment of the medical condition.
- Assigning the weighted value to each therapy profile parameter may include ranking the therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking.
- Querying the database may include matching each determined therapy profile parameter with a respective therapy profile parameter stored in the database and correlated with a stored therapy profile.
- Therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile.
- The therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile based on a temporal attribute.
- The temporal attribute may include a time of day information or time duration information corresponding to the stored therapy profile and the requested therapy profile.
- The time of day information may include a start time associated with the stored therapy profile and the requested therapy profile.
- The time duration information may include a duration information associated with the stored therapy profile and the requested therapy profile.
- Furthermore, one aspect may include storing the output data in the database.
- Moreover, another aspect may include outputting the output data on a user interface component.
- The output data may include a medication dose recommendation information.
- The medication dose recommendation information may include a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
- The requested therapy profile may include the identified stored therapy profile.
- The hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a user defined hierarchy.
- The hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a predetermined order of importance of each therapy profile parameter.
- The predetermined order may be stored in the database.
- The stored therapy profiles may include one or more of a correction bolus amount delivered, a carbohydrate bolus amount delivered, a basal profile delivered, or one or more combinations thereof.
- Querying the database may include performing a statistical analysis based on the information stored in the database.
- The statistical analysis may include one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of the one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
- Another aspect may include receiving a test sample, wherein one or more of the plurality of therapy profile parameters are based at least in part on the received test sample.
- In another embodiment, a glucose monitoring apparatus may include a housing, one or more processing units provided in the housing, and a memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to receive a request for a therapy profile for treating a medical condition, determine a plurality of therapy profile parameters, assign a weighted value to each therapy profile parameter based on a hierarchy determined by the medical condition, query the memory to identify a stored therapy profile with therapy profile parameters that most closely correspond to the determined plurality of therapy profile parameters based on the hierarchy, and generate an output data corresponding to the identified stored therapy profile, wherein the output data may include a medication dosage information.
- The outputted medication dosage information may include a medication delivery amount or duration or both for the treatment of the medical condition.
- The memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to assign the weighted value to each therapy profile parameter which may include ranking the therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking.
- The memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to match each determined therapy profile parameter with a respective therapy profile parameter stored in the memory and correlated with a stored therapy profile.
- Therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile.
- The therapy profile parameters of the identified stored therapy profile may most closely match the respective therapy profile parameters of the requested therapy profile based on a temporal attribute.
- The temporal attribute may include a time of day information or time duration information corresponding to the stored therapy profile and the requested therapy profile.
- The time of day information may include a start time associated with the stored therapy profile and the requested therapy profile.
- The time duration information may include a duration information associated with the stored therapy profile and the requested therapy profile.
- The memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to store the output data in the memory.
- Furthermore, in one aspect a user interface component may be coupled to the housing, and wherein the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to output the output data on the user interface component.
- The output data may include a medication dose recommendation information.
- The medication dose recommendation information may include a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
- The requested therapy profile may include the identified stored therapy profile.
- The hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a user defined hierarchy.
- The hierarchy determined by the medical condition for assigning the weighted value to each therapy profile parameter may include a predetermined order of importance of each therapy profile parameter.
- The predetermined order may be stored in the memory.
- The stored therapy profiles may include one or more of a correction bolus amount delivered, a carbohydrate bolus amount delivered, a basal profile delivered, or one or more combinations thereof.
- The memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to perform a statistical analysis based on the information stored in the memory.
- The statistical analysis may include one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of the one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
- Another aspect may include a test strip port provided on the housing, the test strip port configured to receive a test strip with a test sample provided thereon, wherein the memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to determine one or more of the plurality of therapy profile parameters based at least in part on the test sample.
- The test strip may include an in vitro blood glucose test strip.
- The memory coupled to the one or more processing units and provided in the housing for storing instructions which, when executed by the one or more processing units, may cause the one or more processing units to determine a blood glucose concentration based on the received test sample.
- The various processes described above including the processes operating in the software application execution environment overall systems described above performing the various functions including those routines described in conjunction with
FIGS. 3-5 , 8-13, and 15-22, may be embodied as computer programs developed using an object oriented language that allows the modeling of complex systems with modular objects to create abstractions that are representative of real world, physical objects and their interrelationships. The software required to carry out the inventive process, which may be stored in the storage unit of one or more components in the one or more overall system described above, may be developed by a person of ordinary skill in the art and may include one or more computer program products. - Various other modifications and alterations in the structure and method of operation of the present disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with specific preferred embodiments, it should be understood that the present disclosure as claimed should not be unduly limited to such specific embodiments.
Claims (20)
1. A method, comprising:
assigning, using one or more computing processors, a weighted value to a plurality of therapy profile parameters including ranking each of the plurality of therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking; and
querying, using the one or more processors, a database to identify a stored therapy profile with one or more therapy profile parameters that corresponds to one or more of the plurality of therapy profile parameters based on a hierarchy.
2. The method of claim 1 , further including generating, using the one or more processors, an output data corresponding to the identified stored therapy profile, wherein the output data includes a medication dosage information including a medication delivery amount or a medication delivery duration or both the medication delivery amount and the medication delivery duration.
3. The method of claim 1 , wherein querying the database includes matching the one or more of the plurality of therapy profile parameters with a respective one or more therapy profile parameters stored in the database.
4. The method of claim 2 , wherein the output data includes a medication dose recommendation information.
5. The method of claim 4 , wherein the medication dose recommendation information includes a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
6. The method of claim 1 , wherein the hierarchy determined by a medical condition for assigning the weighted value to the one or more therapy profile parameters includes a user defined hierarchy.
7. The method of claim 1 , wherein the hierarchy determined by a medical condition for assigning the weighted value to the one or more therapy profile parameters includes the predetermined order of importance of each therapy profile parameter.
8. The method of claim 1 , wherein querying the database includes performing a statistical analysis based on a medication dosage information stored in the database.
9. The method of claim 8 , wherein the statistical analysis includes one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
10. The method of claim 1 , further including determining the hierarchy of the plurality of therapy profile parameters.
11. The method of claim 10 , wherein determining the hierarchy of the plurality of therapy profile parameters is based on at least one of a level of relevance, a temporal occurrence, a user identified ranking of importance, a healthcare provider identified ranking of importance, a similarity, a dissimilarity, an occurrence prior to another event, an occurrence after another event, and an occurrence in conjunction with a predetermined physiological condition.
12. A glucose monitoring apparatus, comprising:
one or more computing processing units; and
a memory coupled to the one or more processing units for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to assign a weighted value to a plurality of therapy profile parameters including ranking each of the plurality of therapy profile parameters in a predetermined order and assigning a respective weighted value based on the ranking, query the memory to identify a stored therapy profile with one or more therapy profile parameters that corresponds to one or more of the plurality of therapy profile parameters based on a hierarchy.
13. The apparatus of claim 12 , wherein the memory coupled to the one or more processing units for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to generate an output data corresponding to the identified stored therapy profile, wherein an outputted medication dosage information includes a medication delivery amount or a medication delivery duration or both the medication delivery amount and the medication delivery duration.
14. The apparatus of claim 12 , wherein a medication dose recommendation information includes a medication dose amount information, a medication dose administration time duration information, a medication dose administration time information, or one or more combinations thereof.
15. The apparatus of claim 12 , wherein the hierarchy determined by a medical condition for assigning the weighted value to each therapy profile parameter includes a user defined hierarchy.
16. The apparatus of claim 12 , wherein the hierarchy determined by a medical condition for assigning the weighted value to each therapy profile parameter includes the predetermined order of importance of each therapy profile parameter.
17. The apparatus of claim 12 , wherein the memory coupled to the one or more processing units for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to perform a statistical analysis based on the medication dosage information stored in the memory.
18. The apparatus of claim 17 , wherein the statistical analysis includes one or more of mean deviation analysis, standard deviation analysis, estimation analysis, forecasting analysis, correlation of one or more parameters, modeling of one or more relationships among the one or more parameters, regression analysis, time series analysis, autoregressive modeling, integrated modeling, moving average modeling, data mining, or probability analysis.
19. The apparatus of claim 12 , wherein the memory coupled to the one or more processing units for storing instructions which, when executed by the one or more processing units, causes the one or more processing units to determine the hierarchy of the plurality of therapy profile parameters.
20. The apparatus of claim 19 , wherein determining the hierarchy of the plurality of therapy profile parameters is based on at least one of a level of relevance, a temporal occurrence, a user identified ranking of importance, a healthcare provider identified ranking of importance, a similarity, a dissimilarity, an occurrence prior to another event, an occurrence after another event, and an occurrence in conjunction with a predetermined physiological condition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/292,557 US20140275910A1 (en) | 2007-02-18 | 2014-05-30 | Multi-Function Analyte Test Device and Methods Therefor |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89049207P | 2007-02-18 | 2007-02-18 | |
US12/032,617 US8732188B2 (en) | 2007-02-18 | 2008-02-15 | Method and system for providing contextual based medication dosage determination |
US14998909P | 2009-02-04 | 2009-02-04 | |
US12/699,844 US8930203B2 (en) | 2007-02-18 | 2010-02-03 | Multi-function analyte test device and methods therefor |
US14/292,557 US20140275910A1 (en) | 2007-02-18 | 2014-05-30 | Multi-Function Analyte Test Device and Methods Therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/699,844 Continuation US8930203B2 (en) | 2007-02-18 | 2010-02-03 | Multi-function analyte test device and methods therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140275910A1 true US20140275910A1 (en) | 2014-09-18 |
Family
ID=42540969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/699,844 Active 2029-07-10 US8930203B2 (en) | 2007-02-18 | 2010-02-03 | Multi-function analyte test device and methods therefor |
US14/292,557 Abandoned US20140275910A1 (en) | 2007-02-18 | 2014-05-30 | Multi-Function Analyte Test Device and Methods Therefor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/699,844 Active 2029-07-10 US8930203B2 (en) | 2007-02-18 | 2010-02-03 | Multi-function analyte test device and methods therefor |
Country Status (1)
Country | Link |
---|---|
US (2) | US8930203B2 (en) |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
ES2817503T3 (en) | 2007-04-14 | 2021-04-07 | Abbott Diabetes Care Inc | Procedure and apparatus for providing data processing and control in a medical communication system |
CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
EP2146625B1 (en) | 2007-04-14 | 2019-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
EP2257646A1 (en) * | 2008-02-29 | 2010-12-08 | ISIS Innovation Limited | Diagnostic methods |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
US8483967B2 (en) * | 2009-04-29 | 2013-07-09 | Abbott Diabetes Care Inc. | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
EP3936032A1 (en) | 2009-07-23 | 2022-01-12 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
DK3689237T3 (en) | 2009-07-23 | 2021-08-16 | Abbott Diabetes Care Inc | Method of preparation and system for continuous analyte measurement |
ES2912584T3 (en) | 2009-08-31 | 2022-05-26 | Abbott Diabetes Care Inc | A glucose monitoring system and method |
EP3923295A1 (en) | 2009-08-31 | 2021-12-15 | Abbott Diabetes Care, Inc. | Medical devices and methods |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
CN102469941B (en) | 2010-04-16 | 2016-04-13 | 艾伯特糖尿病护理公司 | Analyze thing surveillance equipment and method |
US8726266B2 (en) | 2010-05-24 | 2014-05-13 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US11213226B2 (en) | 2010-10-07 | 2022-01-04 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
US8615366B2 (en) | 2010-10-15 | 2013-12-24 | Roche Diagnostics Operations, Inc. | Handheld diabetes management device with bolus calculator |
US10458973B2 (en) | 2010-12-22 | 2019-10-29 | Roche Diabetes Care, Inc. | Handheld diabetes management device with bolus calculator |
US9786024B2 (en) | 2010-12-22 | 2017-10-10 | Roche Diabetes Care, Inc. | Graphical user interface for a handheld diabetes management device with bolus calculator |
US10251583B2 (en) | 2010-12-22 | 2019-04-09 | Roche Diabetes Care, Inc. | Insulin pump and methods for operating the insulin pump |
US9445757B2 (en) | 2010-12-29 | 2016-09-20 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
US10390740B2 (en) * | 2010-12-29 | 2019-08-27 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
CA3123171A1 (en) | 2011-01-12 | 2012-07-19 | The Regents Of The University Of California | System and method for closed-loop patient-adaptive hemodynamic management |
CN103619255B (en) | 2011-02-28 | 2016-11-02 | 雅培糖尿病护理公司 | The device that associates with analyte monitoring device, system and method and combine their device |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
US20120306628A1 (en) * | 2011-05-31 | 2012-12-06 | Tara Chand Singhal | Integrated blood glucose measurement device with a test strip count system |
US20130018356A1 (en) * | 2011-07-13 | 2013-01-17 | Crisi Medical Systems, Inc. | Characterizing medication container preparation, use, and disposal within a clinical workflow |
US9852407B2 (en) * | 2011-08-31 | 2017-12-26 | First Data Corporation | Systems and methods for routing debit transactions |
CA2851838A1 (en) | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
WO2013078426A2 (en) | 2011-11-25 | 2013-05-30 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
TW201333870A (en) | 2011-12-21 | 2013-08-16 | 艾登工具股份有限公司 | Systems and methods for determining insulin therapy for a patient |
US9136939B2 (en) | 2011-12-29 | 2015-09-15 | Roche Diabetes Care, Inc. | Graphical user interface pertaining to a bolus calculator residing on a handheld diabetes management device |
US11871901B2 (en) | 2012-05-20 | 2024-01-16 | Cilag Gmbh International | Method for situational awareness for surgical network or surgical network connected device capable of adjusting function based on a sensed situation or usage |
EP2881912A4 (en) * | 2012-07-30 | 2016-03-02 | Sony Corp | Information processing device, method, and program |
AR092077A1 (en) * | 2012-08-10 | 2015-03-18 | Sanofi Aventis Deutschland | MEDICAL SYSTEM |
EP3395252A1 (en) | 2012-08-30 | 2018-10-31 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US20140120559A1 (en) | 2012-10-26 | 2014-05-01 | Boston Heart Diagnostics Corporation | Diabetes panel |
US9787568B2 (en) * | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9486578B2 (en) * | 2012-12-07 | 2016-11-08 | Animas Corporation | Method and system for tuning a closed-loop controller for an artificial pancreas |
WO2014099629A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Rapid blood testing platform for use with mobile electronic devices |
WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
EP2967344A4 (en) | 2013-03-15 | 2016-11-23 | Abbott Diabetes Care Inc | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
CN109222991B (en) | 2013-04-30 | 2022-04-19 | 雅培糖尿病护理公司 | Method for supplying power in living body analyte monitoring environment and monitoring system |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
US9063146B2 (en) * | 2013-10-25 | 2015-06-23 | Roche Diagnostics Operations, Inc. | System and method for display type detection of a handheld medical device |
CA2933166C (en) | 2013-12-31 | 2020-10-27 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
EP4151150A1 (en) | 2014-03-30 | 2023-03-22 | Abbott Diabetes Care, Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US9459089B2 (en) * | 2014-04-09 | 2016-10-04 | Qualcomm Incorporated | Method, devices and systems for detecting an attachment of an electronic patch |
US11504192B2 (en) | 2014-10-30 | 2022-11-22 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
EP3220810A4 (en) | 2014-11-17 | 2018-05-16 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
WO2017011346A1 (en) | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
US10382407B1 (en) * | 2017-03-31 | 2019-08-13 | EMC IP Holding Company LLC | Encryption and decryption of time series data using a digital filter array |
US10856750B2 (en) | 2017-04-28 | 2020-12-08 | Masimo Corporation | Spot check measurement system |
CN110582231B (en) | 2017-05-05 | 2023-05-16 | 伊莱利利公司 | Closed loop control of physiological glucose |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
US11911045B2 (en) | 2017-10-30 | 2024-02-27 | Cllag GmbH International | Method for operating a powered articulating multi-clip applier |
US11291510B2 (en) | 2017-10-30 | 2022-04-05 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
US11311342B2 (en) | 2017-10-30 | 2022-04-26 | Cilag Gmbh International | Method for communicating with surgical instrument systems |
US11229436B2 (en) | 2017-10-30 | 2022-01-25 | Cilag Gmbh International | Surgical system comprising a surgical tool and a surgical hub |
US11026687B2 (en) | 2017-10-30 | 2021-06-08 | Cilag Gmbh International | Clip applier comprising clip advancing systems |
US11317919B2 (en) | 2017-10-30 | 2022-05-03 | Cilag Gmbh International | Clip applier comprising a clip crimping system |
US11564756B2 (en) | 2017-10-30 | 2023-01-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
US11129636B2 (en) | 2017-10-30 | 2021-09-28 | Cilag Gmbh International | Surgical instruments comprising an articulation drive that provides for high articulation angles |
US11801098B2 (en) | 2017-10-30 | 2023-10-31 | Cilag Gmbh International | Method of hub communication with surgical instrument systems |
US11510741B2 (en) | 2017-10-30 | 2022-11-29 | Cilag Gmbh International | Method for producing a surgical instrument comprising a smart electrical system |
US11901060B2 (en) | 2017-12-21 | 2024-02-13 | Ypsomed Ag | Closed loop control of physiological glucose |
US11464535B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Detection of end effector emersion in liquid |
US11744604B2 (en) | 2017-12-28 | 2023-09-05 | Cilag Gmbh International | Surgical instrument with a hardware-only control circuit |
US11311306B2 (en) | 2017-12-28 | 2022-04-26 | Cilag Gmbh International | Surgical systems for detecting end effector tissue distribution irregularities |
US11132462B2 (en) | 2017-12-28 | 2021-09-28 | Cilag Gmbh International | Data stripping method to interrogate patient records and create anonymized record |
US11464559B2 (en) | 2017-12-28 | 2022-10-11 | Cilag Gmbh International | Estimating state of ultrasonic end effector and control system therefor |
US11109866B2 (en) | 2017-12-28 | 2021-09-07 | Cilag Gmbh International | Method for circular stapler control algorithm adjustment based on situational awareness |
US11389164B2 (en) | 2017-12-28 | 2022-07-19 | Cilag Gmbh International | Method of using reinforced flexible circuits with multiple sensors to optimize performance of radio frequency devices |
US11832899B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical systems with autonomously adjustable control programs |
US11304745B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical evacuation sensing and display |
US11896322B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Sensing the patient position and contact utilizing the mono-polar return pad electrode to provide situational awareness to the hub |
US11410259B2 (en) | 2017-12-28 | 2022-08-09 | Cilag Gmbh International | Adaptive control program updates for surgical devices |
US10987178B2 (en) | 2017-12-28 | 2021-04-27 | Ethicon Llc | Surgical hub control arrangements |
US11096693B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Adjustment of staple height of at least one row of staples based on the sensed tissue thickness or force in closing |
US11308075B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Surgical network, instrument, and cloud responses based on validation of received dataset and authentication of its source and integrity |
US11202570B2 (en) | 2017-12-28 | 2021-12-21 | Cilag Gmbh International | Communication hub and storage device for storing parameters and status of a surgical device to be shared with cloud based analytics systems |
US11589888B2 (en) | 2017-12-28 | 2023-02-28 | Cilag Gmbh International | Method for controlling smart energy devices |
US20190201146A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Safety systems for smart powered surgical stapling |
US11576677B2 (en) | 2017-12-28 | 2023-02-14 | Cilag Gmbh International | Method of hub communication, processing, display, and cloud analytics |
US20190201039A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Situational awareness of electrosurgical systems |
US11069012B2 (en) | 2017-12-28 | 2021-07-20 | Cilag Gmbh International | Interactive surgical systems with condition handling of devices and data capabilities |
US11304720B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Activation of energy devices |
US11266468B2 (en) | 2017-12-28 | 2022-03-08 | Cilag Gmbh International | Cooperative utilization of data derived from secondary sources by intelligent surgical hubs |
US11257589B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Real-time analysis of comprehensive cost of all instrumentation used in surgery utilizing data fluidity to track instruments through stocking and in-house processes |
US11612444B2 (en) | 2017-12-28 | 2023-03-28 | Cilag Gmbh International | Adjustment of a surgical device function based on situational awareness |
US11857152B2 (en) | 2017-12-28 | 2024-01-02 | Cilag Gmbh International | Surgical hub spatial awareness to determine devices in operating theater |
US10943454B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Detection and escalation of security responses of surgical instruments to increasing severity threats |
US11818052B2 (en) | 2017-12-28 | 2023-11-14 | Cilag Gmbh International | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
US11937769B2 (en) | 2017-12-28 | 2024-03-26 | Cilag Gmbh International | Method of hub communication, processing, storage and display |
US11291495B2 (en) | 2017-12-28 | 2022-04-05 | Cilag Gmbh International | Interruption of energy due to inadvertent capacitive coupling |
US11273001B2 (en) | 2017-12-28 | 2022-03-15 | Cilag Gmbh International | Surgical hub and modular device response adjustment based on situational awareness |
US11253315B2 (en) | 2017-12-28 | 2022-02-22 | Cilag Gmbh International | Increasing radio frequency to create pad-less monopolar loop |
US11559308B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method for smart energy device infrastructure |
US11786251B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
US20190200981A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Method of compressing tissue within a stapling device and simultaneously displaying the location of the tissue within the jaws |
US11147607B2 (en) | 2017-12-28 | 2021-10-19 | Cilag Gmbh International | Bipolar combination device that automatically adjusts pressure based on energy modality |
US11571234B2 (en) | 2017-12-28 | 2023-02-07 | Cilag Gmbh International | Temperature control of ultrasonic end effector and control system therefor |
US11419667B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Ultrasonic energy device which varies pressure applied by clamp arm to provide threshold control pressure at a cut progression location |
US11166772B2 (en) | 2017-12-28 | 2021-11-09 | Cilag Gmbh International | Surgical hub coordination of control and communication of operating room devices |
US11424027B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Method for operating surgical instrument systems |
US10932872B2 (en) | 2017-12-28 | 2021-03-02 | Ethicon Llc | Cloud-based medical analytics for linking of local usage trends with the resource acquisition behaviors of larger data set |
US11540855B2 (en) | 2017-12-28 | 2023-01-03 | Cilag Gmbh International | Controlling activation of an ultrasonic surgical instrument according to the presence of tissue |
US11304699B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Method for adaptive control schemes for surgical network control and interaction |
US10755813B2 (en) | 2017-12-28 | 2020-08-25 | Ethicon Llc | Communication of smoke evacuation system parameters to hub or cloud in smoke evacuation module for interactive surgical platform |
US11633237B2 (en) | 2017-12-28 | 2023-04-25 | Cilag Gmbh International | Usage and technique analysis of surgeon / staff performance against a baseline to optimize device utilization and performance for both current and future procedures |
US10944728B2 (en) | 2017-12-28 | 2021-03-09 | Ethicon Llc | Interactive surgical systems with encrypted communication capabilities |
US11076921B2 (en) | 2017-12-28 | 2021-08-03 | Cilag Gmbh International | Adaptive control program updates for surgical hubs |
US11304763B2 (en) | 2017-12-28 | 2022-04-19 | Cilag Gmbh International | Image capturing of the areas outside the abdomen to improve placement and control of a surgical device in use |
US11364075B2 (en) | 2017-12-28 | 2022-06-21 | Cilag Gmbh International | Radio frequency energy device for delivering combined electrical signals |
US11051876B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Surgical evacuation flow paths |
US11045591B2 (en) | 2017-12-28 | 2021-06-29 | Cilag Gmbh International | Dual in-series large and small droplet filters |
US20190201139A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Communication arrangements for robot-assisted surgical platforms |
US11559307B2 (en) | 2017-12-28 | 2023-01-24 | Cilag Gmbh International | Method of robotic hub communication, detection, and control |
US11896443B2 (en) | 2017-12-28 | 2024-02-13 | Cilag Gmbh International | Control of a surgical system through a surgical barrier |
US11864728B2 (en) | 2017-12-28 | 2024-01-09 | Cilag Gmbh International | Characterization of tissue irregularities through the use of mono-chromatic light refractivity |
US11432885B2 (en) | 2017-12-28 | 2022-09-06 | Cilag Gmbh International | Sensing arrangements for robot-assisted surgical platforms |
US11832840B2 (en) | 2017-12-28 | 2023-12-05 | Cilag Gmbh International | Surgical instrument having a flexible circuit |
US10758310B2 (en) | 2017-12-28 | 2020-09-01 | Ethicon Llc | Wireless pairing of a surgical device with another device within a sterile surgical field based on the usage and situational awareness of devices |
US11324557B2 (en) | 2017-12-28 | 2022-05-10 | Cilag Gmbh International | Surgical instrument with a sensing array |
US10892995B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Surgical network determination of prioritization of communication, interaction, or processing based on system or device needs |
US11419630B2 (en) | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Surgical system distributed processing |
US11179208B2 (en) | 2017-12-28 | 2021-11-23 | Cilag Gmbh International | Cloud-based medical analytics for security and authentication trends and reactive measures |
US11160605B2 (en) | 2017-12-28 | 2021-11-02 | Cilag Gmbh International | Surgical evacuation sensing and motor control |
US11317937B2 (en) | 2018-03-08 | 2022-05-03 | Cilag Gmbh International | Determining the state of an ultrasonic end effector |
US11903601B2 (en) | 2017-12-28 | 2024-02-20 | Cilag Gmbh International | Surgical instrument comprising a plurality of drive systems |
US11026751B2 (en) | 2017-12-28 | 2021-06-08 | Cilag Gmbh International | Display of alignment of staple cartridge to prior linear staple line |
US11423007B2 (en) * | 2017-12-28 | 2022-08-23 | Cilag Gmbh International | Adjustment of device control programs based on stratified contextual data in addition to the data |
US11666331B2 (en) | 2017-12-28 | 2023-06-06 | Cilag Gmbh International | Systems for detecting proximity of surgical end effector to cancerous tissue |
US11056244B2 (en) | 2017-12-28 | 2021-07-06 | Cilag Gmbh International | Automated data scaling, alignment, and organizing based on predefined parameters within surgical networks |
US11234756B2 (en) | 2017-12-28 | 2022-02-01 | Cilag Gmbh International | Powered surgical tool with predefined adjustable control algorithm for controlling end effector parameter |
US11446052B2 (en) | 2017-12-28 | 2022-09-20 | Cilag Gmbh International | Variation of radio frequency and ultrasonic power level in cooperation with varying clamp arm pressure to achieve predefined heat flux or power applied to tissue |
US10966791B2 (en) | 2017-12-28 | 2021-04-06 | Ethicon Llc | Cloud-based medical analytics for medical facility segmented individualization of instrument function |
US11100631B2 (en) | 2017-12-28 | 2021-08-24 | Cilag Gmbh International | Use of laser light and red-green-blue coloration to determine properties of back scattered light |
US11786245B2 (en) | 2017-12-28 | 2023-10-17 | Cilag Gmbh International | Surgical systems with prioritized data transmission capabilities |
US11659023B2 (en) | 2017-12-28 | 2023-05-23 | Cilag Gmbh International | Method of hub communication |
US11529187B2 (en) | 2017-12-28 | 2022-12-20 | Cilag Gmbh International | Surgical evacuation sensor arrangements |
US11602393B2 (en) | 2017-12-28 | 2023-03-14 | Cilag Gmbh International | Surgical evacuation sensing and generator control |
BR112020013024A2 (en) * | 2017-12-28 | 2020-11-24 | Ethicon Llc | adjustment of device control programs based on stratified contextual data in addition to the data |
US10892899B2 (en) | 2017-12-28 | 2021-01-12 | Ethicon Llc | Self describing data packets generated at an issuing instrument |
US20190201118A1 (en) | 2017-12-28 | 2019-07-04 | Ethicon Llc | Display arrangements for robot-assisted surgical platforms |
US11278281B2 (en) | 2017-12-28 | 2022-03-22 | Cilag Gmbh International | Interactive surgical system |
US10849697B2 (en) | 2017-12-28 | 2020-12-01 | Ethicon Llc | Cloud interface for coupled surgical devices |
US11376002B2 (en) | 2017-12-28 | 2022-07-05 | Cilag Gmbh International | Surgical instrument cartridge sensor assemblies |
US11284936B2 (en) | 2017-12-28 | 2022-03-29 | Cilag Gmbh International | Surgical instrument having a flexible electrode |
US11179175B2 (en) | 2017-12-28 | 2021-11-23 | Cilag Gmbh International | Controlling an ultrasonic surgical instrument according to tissue location |
US11678881B2 (en) | 2017-12-28 | 2023-06-20 | Cilag Gmbh International | Spatial awareness of surgical hubs in operating rooms |
US20190206536A1 (en) * | 2018-01-01 | 2019-07-04 | Brian Hausman | System and method for prescription monitoring and drug dispensation utilizing a distributed ledger |
EP3749944A4 (en) * | 2018-02-06 | 2021-04-21 | Siemens Healthcare Diagnostics, Inc. | Predictive inventory control apparatus and methods |
US11389188B2 (en) | 2018-03-08 | 2022-07-19 | Cilag Gmbh International | Start temperature of blade |
US11589915B2 (en) | 2018-03-08 | 2023-02-28 | Cilag Gmbh International | In-the-jaw classifier based on a model |
US11259830B2 (en) | 2018-03-08 | 2022-03-01 | Cilag Gmbh International | Methods for controlling temperature in ultrasonic device |
US11471156B2 (en) | 2018-03-28 | 2022-10-18 | Cilag Gmbh International | Surgical stapling devices with improved rotary driven closure systems |
US11090047B2 (en) | 2018-03-28 | 2021-08-17 | Cilag Gmbh International | Surgical instrument comprising an adaptive control system |
US11096688B2 (en) | 2018-03-28 | 2021-08-24 | Cilag Gmbh International | Rotary driven firing members with different anvil and channel engagement features |
US11278280B2 (en) | 2018-03-28 | 2022-03-22 | Cilag Gmbh International | Surgical instrument comprising a jaw closure lockout |
US11259806B2 (en) | 2018-03-28 | 2022-03-01 | Cilag Gmbh International | Surgical stapling devices with features for blocking advancement of a camming assembly of an incompatible cartridge installed therein |
US11207067B2 (en) | 2018-03-28 | 2021-12-28 | Cilag Gmbh International | Surgical stapling device with separate rotary driven closure and firing systems and firing member that engages both jaws while firing |
US11213294B2 (en) | 2018-03-28 | 2022-01-04 | Cilag Gmbh International | Surgical instrument comprising co-operating lockout features |
US10973520B2 (en) | 2018-03-28 | 2021-04-13 | Ethicon Llc | Surgical staple cartridge with firing member driven camming assembly that has an onboard tissue cutting feature |
US11219453B2 (en) | 2018-03-28 | 2022-01-11 | Cilag Gmbh International | Surgical stapling devices with cartridge compatible closure and firing lockout arrangements |
US11464511B2 (en) | 2019-02-19 | 2022-10-11 | Cilag Gmbh International | Surgical staple cartridges with movable authentication key arrangements |
US11357503B2 (en) | 2019-02-19 | 2022-06-14 | Cilag Gmbh International | Staple cartridge retainers with frangible retention features and methods of using same |
US11291444B2 (en) | 2019-02-19 | 2022-04-05 | Cilag Gmbh International | Surgical stapling assembly with cartridge based retainer configured to unlock a closure lockout |
US11369377B2 (en) | 2019-02-19 | 2022-06-28 | Cilag Gmbh International | Surgical stapling assembly with cartridge based retainer configured to unlock a firing lockout |
US11317915B2 (en) | 2019-02-19 | 2022-05-03 | Cilag Gmbh International | Universal cartridge based key feature that unlocks multiple lockout arrangements in different surgical staplers |
EP3956742A4 (en) * | 2019-04-17 | 2023-04-12 | Companion Medical, Inc. | Prime differentiation in medication delivery system |
USD950728S1 (en) | 2019-06-25 | 2022-05-03 | Cilag Gmbh International | Surgical staple cartridge |
USD952144S1 (en) | 2019-06-25 | 2022-05-17 | Cilag Gmbh International | Surgical staple cartridge retainer with firing system authentication key |
USD964564S1 (en) | 2019-06-25 | 2022-09-20 | Cilag Gmbh International | Surgical staple cartridge retainer with a closure system authentication key |
WO2021026004A1 (en) * | 2019-08-02 | 2021-02-11 | Abbott Diabetes Care Inc. | Systems, devices, and methods relating to medication dose guidance |
US11836141B2 (en) * | 2021-10-04 | 2023-12-05 | Red Hat, Inc. | Ranking database queries |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656114B1 (en) * | 1998-11-30 | 2003-12-02 | Novo Noadisk A/S | Method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions |
US20040259956A1 (en) * | 2003-03-11 | 2004-12-23 | Curtis Wright | Titration dosing regimen for controlled release tramadol |
US20050277911A1 (en) * | 2004-05-27 | 2005-12-15 | Janice Stewart | Apparatus and method for therapeutic delivery of medication |
US20070255321A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Efficacy visualization |
Family Cites Families (1348)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2755036A (en) | 1953-07-03 | 1956-07-17 | Terho Mikko Jooseppi | Cable drum |
US3260656A (en) | 1962-09-27 | 1966-07-12 | Corning Glass Works | Method and apparatus for electrolytically determining a species in a fluid |
US3304413A (en) | 1963-03-26 | 1967-02-14 | Hewlett Packard Co | Cardiac output computer |
GB1191363A (en) | 1968-02-19 | 1970-05-13 | Pavelle Ltd | Improvements in or relating to Electronic Thermostats. |
US3653841A (en) | 1969-12-19 | 1972-04-04 | Hoffmann La Roche | Methods and compositions for determining glucose in blood |
US3651318A (en) | 1970-01-26 | 1972-03-21 | Jan A Czekajewski | Cardiac output computer |
US3776832A (en) | 1970-11-10 | 1973-12-04 | Energetics Science | Electrochemical detection cell |
US3719564A (en) | 1971-05-10 | 1973-03-06 | Philip Morris Inc | Method of determining a reducible gas concentration and sensor therefor |
US3698386A (en) | 1971-07-16 | 1972-10-17 | Robert Fried | Cardiac rhythm computer device |
US3768014A (en) | 1972-01-28 | 1973-10-23 | Gen Electric | Cardiac pacemaker rate/interval computer system |
US3837339A (en) | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US3949388A (en) | 1972-11-13 | 1976-04-06 | Monitron Industries, Inc. | Physiological sensor and transmitter |
US3908657A (en) | 1973-01-15 | 1975-09-30 | Univ Johns Hopkins | System for continuous withdrawal of blood |
GB1394171A (en) | 1973-05-16 | 1975-05-14 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4100048A (en) | 1973-09-20 | 1978-07-11 | U.S. Philips Corporation | Polarographic cell |
US3926760A (en) | 1973-09-28 | 1975-12-16 | Du Pont | Process for electrophoretic deposition of polymer |
US3923060A (en) | 1974-04-23 | 1975-12-02 | Jr Everett H Ellinwood | Apparatus and method for implanted self-powered medication dispensing having timing and evaluator means |
US4003379A (en) | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US3919051A (en) | 1974-07-11 | 1975-11-11 | Honeywell Inc | Biological analyzer and method |
US3972320A (en) | 1974-08-12 | 1976-08-03 | Gabor Ujhelyi Kalman | Patient monitoring system |
US4245634A (en) | 1975-01-22 | 1981-01-20 | Hospital For Sick Children | Artificial beta cell |
US4036749A (en) | 1975-04-30 | 1977-07-19 | Anderson Donald R | Purification of saline water |
US3979274A (en) | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4016866A (en) | 1975-12-18 | 1977-04-12 | General Electric Company | Implantable electrochemical sensor |
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DE2625834B2 (en) | 1976-06-09 | 1978-10-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Method for the determination of substrates or enzyme activities |
US4059406A (en) | 1976-07-12 | 1977-11-22 | E D T Supplies Limited | Electrochemical detector system |
GB1579690A (en) | 1976-08-16 | 1980-11-19 | Medtronic Inc | Electromedical apparatus |
US4076596A (en) | 1976-10-07 | 1978-02-28 | Leeds & Northrup Company | Apparatus for electrolytically determining a species in a fluid and method of use |
US4129128A (en) | 1977-02-23 | 1978-12-12 | Mcfarlane Richard H | Securing device for catheter placement assembly |
FR2387659A1 (en) | 1977-04-21 | 1978-11-17 | Armines | GLYCEMIA CONTROL AND REGULATION DEVICE |
US4098574A (en) | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
US4178916A (en) | 1977-09-26 | 1979-12-18 | Mcnamara Elger W | Diabetic insulin alarm system |
JPS5912135B2 (en) | 1977-09-28 | 1984-03-21 | 松下電器産業株式会社 | enzyme electrode |
US4154231A (en) | 1977-11-23 | 1979-05-15 | Russell Robert B | System for non-invasive cardiac diagnosis |
US4151845A (en) | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
JPS5921500B2 (en) | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
DK151000C (en) | 1978-02-17 | 1988-06-13 | Radiometer As | PROCEDURE AND APPARATUS FOR DETERMINING A PATIENT'S IN VIVO PLASMA-PH VALUE |
US4172770A (en) | 1978-03-27 | 1979-10-30 | Technicon Instruments Corporation | Flow-through electrochemical system analytical method |
DE2817363C2 (en) | 1978-04-20 | 1984-01-26 | Siemens AG, 1000 Berlin und 8000 München | Method for determining the concentration of sugar and a suitable electrocatalytic sugar sensor |
US4958632A (en) | 1978-07-20 | 1990-09-25 | Medtronic, Inc. | Adaptable, digital computer controlled cardiac pacemaker |
US4344438A (en) | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
JPS55500431A (en) | 1978-08-15 | 1980-07-17 | ||
HU177369B (en) | 1978-09-08 | 1981-09-28 | Radelkis Electrokemiai | Industrial molecule-selective sensing device and method for producing same |
EP0010375B1 (en) | 1978-10-02 | 1983-07-20 | Xerox Corporation | Electrostatographic processing system |
US4240438A (en) | 1978-10-02 | 1980-12-23 | Wisconsin Alumni Research Foundation | Method for monitoring blood glucose levels and elements |
JPS584982B2 (en) | 1978-10-31 | 1983-01-28 | 松下電器産業株式会社 | enzyme electrode |
AU530979B2 (en) | 1978-12-07 | 1983-08-04 | Aus. Training Aids Pty. Ltd., | Detecting position of bullet fired at target |
US4247297A (en) | 1979-02-23 | 1981-01-27 | Miles Laboratories, Inc. | Test means and method for interference resistant determination of oxidizing substances |
US4271449A (en) | 1979-04-04 | 1981-06-02 | Rockwell International Corporation | Method and apparatus for protecting alternating current circuits |
US4573994A (en) | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4365637A (en) | 1979-07-05 | 1982-12-28 | Dia-Med, Inc. | Perspiration indicating alarm for diabetics |
CS210174B1 (en) * | 1979-07-12 | 1982-01-29 | Ivan Emmer | Method of making the electric hygrometric sensor |
US4467811A (en) | 1979-08-02 | 1984-08-28 | Children's Hospital Medical Center | Method of polarographic analysis of lactic acid and lactate |
US4401122A (en) | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4458686A (en) | 1979-08-02 | 1984-07-10 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4293396A (en) | 1979-09-27 | 1981-10-06 | Prototech Company | Thin carbon-cloth-based electrocatalytic gas diffusion electrodes, and electrochemical cells comprising the same |
DE3114441A1 (en) | 1980-04-11 | 1982-03-04 | Radiometer A/S, 2400 Koebenhavn | ELECTROCHEMICAL MEASURING ELECTRODE DEVICE |
US4450842A (en) | 1980-04-25 | 1984-05-29 | Cordis Corporation | Solid state reference electrode |
US4340458A (en) | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
CA1169323A (en) | 1980-06-03 | 1984-06-19 | Anthony M. Albisser | Insulin infusion device |
US4331869A (en) | 1980-06-23 | 1982-05-25 | Capintec, Inc. | Dynamic cardiac quality assurance phantom system and method |
US4356074A (en) | 1980-08-25 | 1982-10-26 | The Yellow Springs Instrument Company, Inc. | Substrate specific galactose oxidase enzyme electrodes |
US4404066A (en) | 1980-08-25 | 1983-09-13 | The Yellow Springs Instrument Company | Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme |
US4352960A (en) | 1980-09-30 | 1982-10-05 | Baptist Medical Center Of Oklahoma, Inc. | Magnetic transcutaneous mount for external device of an associated implant |
USRE32947E (en) | 1980-09-30 | 1989-06-13 | Baptist Medical Center Of Oklahoma, Inc. | Magnetic transcutaneous mount for external device of an associated implant |
US4444892A (en) | 1980-10-20 | 1984-04-24 | Malmros Mark K | Analytical device having semiconductive organic polymeric element associated with analyte-binding substance |
US4425920A (en) | 1980-10-24 | 1984-01-17 | Purdue Research Foundation | Apparatus and method for measurement and control of blood pressure |
US4407959A (en) | 1980-10-29 | 1983-10-04 | Fuji Electric Co., Ltd. | Blood sugar analyzing apparatus |
US4420564A (en) | 1980-11-21 | 1983-12-13 | Fuji Electric Company, Ltd. | Blood sugar analyzer having fixed enzyme membrane sensor |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4483924A (en) | 1980-12-09 | 1984-11-20 | Fuji Electric Company, Ltd. | System for controlling a printer in a blood sugar analyzer |
US4390621A (en) | 1980-12-15 | 1983-06-28 | Miles Laboratories, Inc. | Method and device for detecting glucose concentration |
US4436094A (en) | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
US4427004A (en) | 1981-03-16 | 1984-01-24 | Viridan Inc. | Annular flow entrainment nebulizer |
EP0064369B1 (en) | 1981-04-24 | 1986-10-08 | Kabushiki Kaisha Kyoto Daiichi Kagaku | A device for automatically and continuously measuring the constituent parts of blood |
AT369254B (en) | 1981-05-07 | 1982-12-27 | Otto Dipl Ing Dr Tech Prohaska | MEDICAL PROBE |
FR2508305B1 (en) | 1981-06-25 | 1986-04-11 | Slama Gerard | DEVICE FOR CAUSING A LITTLE BITE TO COLLECT A BLOOD DROP |
US4440175A (en) | 1981-08-10 | 1984-04-03 | University Patents, Inc. | Membrane electrode for non-ionic species |
DE3138194A1 (en) | 1981-09-25 | 1983-04-14 | Basf Ag, 6700 Ludwigshafen | WATER-INSOLUBLE POROESES PROTEIN MATERIAL, THEIR PRODUCTION AND USE |
DE3278334D1 (en) | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US4431004A (en) | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4418148A (en) | 1981-11-05 | 1983-11-29 | Miles Laboratories, Inc. | Multilayer enzyme electrode membrane |
JPS5886083A (en) | 1981-11-12 | 1983-05-23 | Wako Pure Chem Ind Ltd | Stabilizing agent for glycerol-3-phosphoric acid oxidase |
US4494950A (en) | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
US4462048A (en) | 1982-02-11 | 1984-07-24 | Rca Corporation | Noise reduction circuitry for audio signals |
JPS58153154A (en) | 1982-03-09 | 1983-09-12 | Ajinomoto Co Inc | Qualified electrode |
US4417588A (en) | 1982-03-22 | 1983-11-29 | Critikon, Inc. | Apparatus and method for initiating cardiac output computations |
US4581336A (en) | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
FI831399L (en) | 1982-04-29 | 1983-10-30 | Agripat Sa | KONTAKTLINS AV HAERDAD POLYVINYL ALCOHOL |
EP0096228B1 (en) | 1982-06-01 | 1986-09-10 | Ferag AG | Device for addressing newspapers, periodicals and like printed products |
DE3221339A1 (en) | 1982-06-05 | 1983-12-08 | Basf Ag, 6700 Ludwigshafen | METHOD FOR THE ELECTROCHEMICAL HYDRATION OF NICOTINAMIDADENINE-DINUCLEOTIDE |
US4427770A (en) | 1982-06-14 | 1984-01-24 | Miles Laboratories, Inc. | High glucose-determining analytical element |
US4633881A (en) | 1982-07-01 | 1987-01-06 | The General Hospital Corporation | Ambulatory ventricular function monitor |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
US4509531A (en) | 1982-07-28 | 1985-04-09 | Teledyne Industries, Inc. | Personal physiological monitor |
US4534356A (en) | 1982-07-30 | 1985-08-13 | Diamond Shamrock Chemicals Company | Solid state transcutaneous blood gas sensors |
DE3228551A1 (en) | 1982-07-30 | 1984-02-02 | Siemens AG, 1000 Berlin und 8000 München | METHOD FOR DETERMINING SUGAR CONCENTRATION |
US4571292A (en) | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4595479A (en) | 1982-11-09 | 1986-06-17 | Ajinomoto Co., Inc. | Modified electrode |
US4552840A (en) | 1982-12-02 | 1985-11-12 | California And Hawaiian Sugar Company | Enzyme electrode and method for dextran analysis |
US4527240A (en) | 1982-12-29 | 1985-07-02 | Kvitash Vadim I | Balascopy method for detecting and rapidly evaluating multiple imbalances within multi-parametric systems |
CA1231016A (en) | 1983-01-23 | 1988-01-05 | Amir Porat | Syringe |
US4461691A (en) | 1983-02-10 | 1984-07-24 | The United States Of America As Represented By The United States Department Of Energy | Organic conductive films for semiconductor electrodes |
US4679562A (en) | 1983-02-16 | 1987-07-14 | Cardiac Pacemakers, Inc. | Glucose sensor |
WO1984003562A1 (en) | 1983-03-11 | 1984-09-13 | Matsushita Electric Ind Co Ltd | Biosensor |
FR2544525A1 (en) | 1983-04-12 | 1984-10-19 | Simatec Sarl | PORTABLE APPARATUS FOR SEIZING AND PROCESSING INFORMATION RELATING TO THE HEALTH OF A PERSON |
IT1170375B (en) | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Implantable device for measuring body fluid parameters |
GB2154003B (en) | 1983-12-16 | 1988-02-17 | Genetics Int Inc | Diagnostic aid |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
CA1218704A (en) | 1983-05-05 | 1987-03-03 | Graham Davis | Assay systems using more than one enzyme |
CA1220818A (en) | 1983-05-05 | 1987-04-21 | Hugh A.O. Hill | Assay techniques utilising specific binding agents |
US5682884A (en) | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
US5509410A (en) | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
US4484987A (en) | 1983-05-19 | 1984-11-27 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4650547A (en) | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4569589A (en) | 1983-05-25 | 1986-02-11 | University Of Pennsylvania | Lung water computer system |
US4524114A (en) | 1983-07-05 | 1985-06-18 | Allied Corporation | Bifunctional air electrode |
US4538616A (en) | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US4543955A (en) | 1983-08-01 | 1985-10-01 | Cordis Corporation | System for controlling body implantable action device |
US4655880A (en) | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
SE8305704D0 (en) | 1983-10-18 | 1983-10-18 | Leo Ab | Cuvette |
US4560534A (en) | 1983-11-02 | 1985-12-24 | Miles Laboratories, Inc. | Polymer catalyst transducers |
GB8417949D0 (en) | 1984-07-13 | 1984-08-15 | Palmer G C | Sampling fluid |
US4522690A (en) | 1983-12-01 | 1985-06-11 | Honeywell Inc. | Electrochemical sensing of carbon monoxide |
DE3479522D1 (en) | 1983-12-16 | 1989-09-28 | Medisense Inc | Assay for nucleic acids |
US4685903A (en) | 1984-01-06 | 1987-08-11 | Pacesetter Infusion, Ltd. | External infusion pump apparatus |
US4684537A (en) | 1984-04-30 | 1987-08-04 | R. E. Stiftung | Process for the sensitization of an oxidation/reduction photocatalyst, and photocatalyst thus obtained |
NL8401536A (en) | 1984-05-11 | 1985-12-02 | Medscan B V I O | BLOOD SAMPLING UNIT. |
CA1261256A (en) | 1984-06-13 | 1989-09-26 | Ian A. Shanks | Devices for use in chemical test procedures |
US5141868A (en) | 1984-06-13 | 1992-08-25 | Internationale Octrooi Maatschappij "Octropa" Bv | Device for use in chemical test procedures |
GB8417301D0 (en) | 1984-07-06 | 1984-08-08 | Serono Diagnostics Ltd | Assay |
DK8601218A (en) | 1984-07-18 | 1986-03-17 | ||
DE3429596A1 (en) | 1984-08-10 | 1986-02-20 | Siemens AG, 1000 Berlin und 8000 München | DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE |
US4820399A (en) | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
CA1254091A (en) | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
JPH0134911Y2 (en) | 1984-10-11 | 1989-10-24 | ||
GB2168815A (en) | 1984-11-13 | 1986-06-25 | Genetics Int Inc | Bioelectrochemical assay electrode |
US4936956A (en) | 1984-11-23 | 1990-06-26 | Massachusetts Institute Of Technology | Microelectrochemical devices based on inorganic redox active material and method for sensing |
US4721601A (en) | 1984-11-23 | 1988-01-26 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
US4717673A (en) | 1984-11-23 | 1988-01-05 | Massachusetts Institute Of Technology | Microelectrochemical devices |
US5034192A (en) | 1984-11-23 | 1991-07-23 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
JPH0617889B2 (en) | 1984-11-27 | 1994-03-09 | 株式会社日立製作所 | Biochemical sensor |
EP0186210B1 (en) | 1984-12-28 | 1992-04-22 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Ion sensor |
GB8500729D0 (en) | 1985-01-11 | 1985-02-13 | Hill H A O | Surface-modified electrode |
US4847785A (en) | 1985-01-22 | 1989-07-11 | International Business Machines Corp. | Interactive display for trend or bar graph |
EP0200321A3 (en) | 1985-03-20 | 1987-03-11 | Ingeborg J. Hochmair | Transcutaneous signal transmission system |
US5279294A (en) | 1985-04-08 | 1994-01-18 | Cascade Medical, Inc. | Medical diagnostic system |
US4627445A (en) | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
US4674652A (en) | 1985-04-11 | 1987-06-23 | Aten Edward M | Controlled dispensing device |
US4781798A (en) | 1985-04-19 | 1988-11-01 | The Regents Of The University Of California | Transparent multi-oxygen sensor array and method of using same |
US4671288A (en) | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US5185256A (en) | 1985-06-21 | 1993-02-09 | Matsushita Electric Industrial Co., Ltd. | Method for making a biosensor |
EP0230472B2 (en) | 1985-06-21 | 2000-12-13 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of manufacturing same |
US4938860A (en) | 1985-06-28 | 1990-07-03 | Miles Inc. | Electrode for electrochemical sensors |
US4835372A (en) | 1985-07-19 | 1989-05-30 | Clincom Incorporated | Patient care system |
EP0231217B1 (en) | 1985-07-23 | 1989-09-06 | Winfried Jean Werding | Thrust regulator comprising a mounting housing |
US4653513A (en) | 1985-08-09 | 1987-03-31 | Dombrowski Mitchell P | Blood sampler |
US4796634A (en) | 1985-08-09 | 1989-01-10 | Lawrence Medical Systems, Inc. | Methods and apparatus for monitoring cardiac output |
US4805624A (en) | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
GB8522834D0 (en) | 1985-09-16 | 1985-10-23 | Ici Plc | Sensor |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4890620A (en) | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US5140393A (en) | 1985-10-08 | 1992-08-18 | Sharp Kabushiki Kaisha | Sensor device |
US4920969A (en) | 1985-10-08 | 1990-05-01 | Capintec, Inc. | Ambulatory physiological evaluation system including cardiac monitoring |
US5007427A (en) | 1987-05-07 | 1991-04-16 | Capintec, Inc. | Ambulatory physiological evaluation system including cardiac monitoring |
US5111818A (en) | 1985-10-08 | 1992-05-12 | Capintec, Inc. | Ambulatory physiological evaluation system including cardiac monitoring |
US4627908A (en) | 1985-10-24 | 1986-12-09 | Chevron Research Company | Process for stabilizing lube base stocks derived from bright stock |
US4830959A (en) | 1985-11-11 | 1989-05-16 | Medisense, Inc. | Electrochemical enzymic assay procedures |
GB8529300D0 (en) | 1985-11-28 | 1986-01-02 | Ici Plc | Membrane |
US4857713A (en) | 1986-02-14 | 1989-08-15 | Brown Jack D | Hospital error avoidance system |
US4776944A (en) | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
WO1987006040A1 (en) | 1986-03-31 | 1987-10-08 | Puritan-Bennett Corporation | Computer gated positive expiratory pressure system |
US4685463A (en) | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
GB8608700D0 (en) | 1986-04-10 | 1986-05-14 | Genetics Int Inc | Measurement of electroactive species in solution |
US4726378A (en) | 1986-04-11 | 1988-02-23 | Minnesota Mining And Manufacturing Company | Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus |
US4994167A (en) | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4909908A (en) | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
DE3614821A1 (en) | 1986-05-02 | 1987-11-05 | Siemens Ag | IMPLANTABLE, CALIBRABLE MEASURING DEVICE FOR A BODY SUBSTANCE AND CALIBRATION METHOD |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
GB8612861D0 (en) | 1986-05-27 | 1986-07-02 | Cambridge Life Sciences | Immobilised enzyme biosensors |
US4750496A (en) | 1987-01-28 | 1988-06-14 | Xienta, Inc. | Method and apparatus for measuring blood glucose concentration |
US4837049A (en) | 1986-06-17 | 1989-06-06 | Alfred E. Mann Foundation For Scientific Research | Method of making an electrode array |
US4969468A (en) | 1986-06-17 | 1990-11-13 | Alfred E. Mann Foundation For Scientific Research | Electrode array for use in connection with a living body and method of manufacture |
US4911794A (en) | 1986-06-20 | 1990-03-27 | Molecular Devices Corporation | Measuring with zero volume cell |
US5001054A (en) | 1986-06-26 | 1991-03-19 | Becton, Dickinson And Company | Method for monitoring glucose |
JPS636451A (en) | 1986-06-27 | 1988-01-12 | Terumo Corp | Enzyme sensor |
US4803625A (en) | 1986-06-30 | 1989-02-07 | Buddy Systems, Inc. | Personal health monitor |
US4764416A (en) | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
US4784736A (en) | 1986-07-07 | 1988-11-15 | Bend Research, Inc. | Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers |
US4917800A (en) | 1986-07-07 | 1990-04-17 | Bend Research, Inc. | Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers |
US4726716A (en) | 1986-07-21 | 1988-02-23 | Mcguire Thomas V | Fastener for catheter |
GB8618022D0 (en) | 1986-07-23 | 1986-08-28 | Unilever Plc | Electrochemical measurements |
US4935346A (en) | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
US5049487A (en) | 1986-08-13 | 1991-09-17 | Lifescan, Inc. | Automated initiation of timing of reflectance readings |
GB8621061D0 (en) | 1986-09-01 | 1986-10-08 | Hewlett Packard Ltd | User interface simulation |
US4894137A (en) | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
US5055171A (en) | 1986-10-06 | 1991-10-08 | T And G Corporation | Ionic semiconductor materials and applications thereof |
US4897162A (en) | 1986-11-14 | 1990-01-30 | The Cleveland Clinic Foundation | Pulse voltammetry |
JPS63131057A (en) | 1986-11-20 | 1988-06-03 | Terumo Corp | Enzyme sensor |
EP0333779A4 (en) | 1986-12-12 | 1990-02-06 | Metrologic Instr Inc | Bar code reader with digitizer and sequencer. |
DE3700119A1 (en) | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
US4934369A (en) | 1987-01-30 | 1990-06-19 | Minnesota Mining And Manufacturing Company | Intravascular blood parameter measurement system |
AT391998B (en) | 1987-02-02 | 1990-12-27 | Falko Dr Skrabal | Device for determining the concentration of at least one medicinal substance in living organisms |
EP0278647A3 (en) | 1987-02-09 | 1989-09-20 | AT&T Corp. | Electronchemical processes involving enzymes |
GB2201248B (en) | 1987-02-24 | 1991-04-17 | Ici Plc | Enzyme electrode sensors |
US5002054A (en) | 1987-02-25 | 1991-03-26 | Ash Medical Systems, Inc. | Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body |
US4777953A (en) | 1987-02-25 | 1988-10-18 | Ash Medical Systems, Inc. | Capillary filtration and collection method for long-term monitoring of blood constituents |
US4854322A (en) | 1987-02-25 | 1989-08-08 | Ash Medical Systems, Inc. | Capillary filtration and collection device for long-term monitoring of blood constituents |
GB2204408A (en) | 1987-03-04 | 1988-11-09 | Plessey Co Plc | Biosensor device |
US4848351A (en) | 1987-03-04 | 1989-07-18 | Sentry Medical Products, Inc. | Medical electrode assembly |
US4923586A (en) | 1987-03-31 | 1990-05-08 | Daikin Industries, Ltd. | Enzyme electrode unit |
US4935345A (en) | 1987-04-07 | 1990-06-19 | Arizona Board Of Regents | Implantable microelectronic biochemical sensor incorporating thin film thermopile |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US5352348A (en) | 1987-04-09 | 1994-10-04 | Nova Biomedical Corporation | Method of using enzyme electrode |
US4749985A (en) | 1987-04-13 | 1988-06-07 | United States Of America As Represented By The United States Department Of Energy | Functional relationship-based alarm processing |
EP0290683A3 (en) | 1987-05-01 | 1988-12-14 | Diva Medical Systems B.V. | Diabetes management system and apparatus |
US5216597A (en) | 1987-05-01 | 1993-06-01 | Diva Medical Systems Bv | Diabetes therapy management system, apparatus and method |
US5286364A (en) | 1987-06-08 | 1994-02-15 | Rutgers University | Surface-modified electochemical biosensor |
US4822337A (en) | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
DE3721237A1 (en) | 1987-06-27 | 1989-01-05 | Boehringer Mannheim Gmbh | DIAGNOSTIC TEST CARRIER AND METHOD FOR THE PRODUCTION THEREOF |
JPH07122624B2 (en) | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | Biosensor |
GB8718430D0 (en) | 1987-08-04 | 1987-09-09 | Ici Plc | Sensor |
US4874500A (en) | 1987-07-15 | 1989-10-17 | Sri International | Microelectrochemical sensor and sensor array |
JPS6423155A (en) | 1987-07-17 | 1989-01-25 | Daikin Ind Ltd | Electrode refreshing device for biosensor |
US5135003A (en) | 1987-08-11 | 1992-08-04 | Terumo Kabushiki Kaisha | Automatic sphygmomanometer |
US5037527A (en) | 1987-08-28 | 1991-08-06 | Kanzaki Paper Mfg. Co., Ltd. | Reference electrode and a measuring apparatus using the same |
US4858617A (en) | 1987-09-10 | 1989-08-22 | Ith, Inc. | Cardiac probe enabling use of personal computer for monitoring heart activity or the like |
US4974929A (en) | 1987-09-22 | 1990-12-04 | Baxter International, Inc. | Fiber optical probe connector for physiologic measurement devices |
NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
US4845035A (en) | 1987-10-06 | 1989-07-04 | The United States Of America As Represented By The Secretary Of Agriculture | Enzyme immobilization with a hydrolyzed polysaccharide graft copolymer |
US4815469A (en) | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
JPH01140054A (en) | 1987-11-26 | 1989-06-01 | Nec Corp | Glucose sensor |
DK158130C (en) | 1987-11-30 | 1990-09-03 | Uno Plast As | APPARATUS FOR COLLECTION AND MEASUREMENT OF BODY LIQUID |
US4856340A (en) | 1987-12-01 | 1989-08-15 | Minimed Technologies | Pressure diaphragm for a medication infusion system |
US4813424A (en) | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
US5073500A (en) | 1988-01-08 | 1991-12-17 | Inax Corporation | Method and apparatus for detecting urinary constituents |
US4890621A (en) | 1988-01-19 | 1990-01-02 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
US5126247A (en) | 1988-02-26 | 1992-06-30 | Enzymatics, Inc. | Method, system and devices for the assay and detection of biochemical molecules |
US5128015A (en) | 1988-03-15 | 1992-07-07 | Tall Oak Ventures | Method and apparatus for amperometric diagnostic analysis |
US5108564A (en) | 1988-03-15 | 1992-04-28 | Tall Oak Ventures | Method and apparatus for amperometric diagnostic analysis |
US4957115A (en) | 1988-03-25 | 1990-09-18 | New England Medical Center Hosp. | Device for determining the probability of death of cardiac patients |
EP0359831B2 (en) | 1988-03-31 | 2007-06-20 | Matsushita Electric Industrial Co., Ltd. | Biosensor and process for its production |
US4942127A (en) | 1988-05-06 | 1990-07-17 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
US5206145A (en) | 1988-05-19 | 1993-04-27 | Thorn Emi Plc | Method of measuring the concentration of a substance in a sample solution |
US4874499A (en) | 1988-05-23 | 1989-10-17 | Massachusetts Institute Of Technology | Electrochemical microsensors and method of making such sensors |
US5094951A (en) | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
WO1990000367A1 (en) | 1988-07-14 | 1990-01-25 | Bomed Medical Manufacturing, Ltd. | Management of hemodynamic state of a patient |
GB8817421D0 (en) | 1988-07-21 | 1988-08-24 | Medisense Inc | Bioelectrochemical electrodes |
US4925268A (en) | 1988-07-25 | 1990-05-15 | Abbott Laboratories | Fiber-optic physiological probes |
US4954129A (en) | 1988-07-25 | 1990-09-04 | Abbott Laboratories | Hydrodynamic clot flushing |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US5340722A (en) | 1988-08-24 | 1994-08-23 | Avl Medical Instruments Ag | Method for the determination of the concentration of an enzyme substrate and a sensor for carrying out the method |
US4844076A (en) | 1988-08-26 | 1989-07-04 | The Johns Hopkins University | Ingestible size continuously transmitting temperature monitoring pill |
US5264106A (en) | 1988-10-07 | 1993-11-23 | Medisense, Inc. | Enhanced amperometric sensor |
US4995402A (en) | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
US4920977A (en) | 1988-10-25 | 1990-05-01 | Becton, Dickinson And Company | Blood collection assembly with lancet and microcollection tube |
GB2225637A (en) | 1988-11-03 | 1990-06-06 | Royal Free Hosp School Med | Portable apparatus for foetal monitors |
GB8825800D0 (en) | 1988-11-04 | 1988-12-07 | Baker J | Cardiac device |
JPH02128152A (en) | 1988-11-08 | 1990-05-16 | Nec Corp | Immobilization of enzyme and biosensor |
US5054300A (en) | 1988-11-09 | 1991-10-08 | Ohi Seisakusho Co., Ltd. | Vehicle door lock system |
CA2002660A1 (en) | 1988-11-10 | 1990-05-10 | Susan J. Mroczkowski | Method for electrical detection of a binding reaction |
US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
US5360404A (en) | 1988-12-14 | 1994-11-01 | Inviro Medical Devices Ltd. | Needle guard and needle assembly for syringe |
DE3842700A1 (en) | 1988-12-19 | 1990-06-21 | Boehringer Mannheim Gmbh | METHOD FOR PROTEIN IMMOBILIZATION ON A SOLID PHASE, PROTEIN-CARRYING SOLID PHASE PRODUCED THEREOF AND THE USE THEREOF |
FI99250C (en) | 1989-01-10 | 1997-12-29 | Nintendo Co Ltd | System for preventing unauthorized use of external memory |
US5068536A (en) | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
US5077476A (en) | 1990-06-27 | 1991-12-31 | Futrex, Inc. | Instrument for non-invasive measurement of blood glucose |
AT392847B (en) | 1989-01-27 | 1991-06-25 | Avl Verbrennungskraft Messtech | SENSOR ELECTRODE ARRANGEMENT |
US5153827A (en) | 1989-01-30 | 1992-10-06 | Omni-Flow, Inc. | An infusion management and pumping system having an alarm handling system |
US5016201A (en) | 1989-02-06 | 1991-05-14 | Bryan Avron I | System for calibrating, monitoring and reporting the status of a pH sensor |
EP0384504A1 (en) | 1989-02-24 | 1990-08-29 | Duphar International Research B.V | Detection strip for detecting and identifying chemical air contaminants, and portable detection kit comprising said strips |
US5205920A (en) | 1989-03-03 | 1993-04-27 | Noboru Oyama | Enzyme sensor and method of manufacturing the same |
DE69027233T2 (en) | 1989-03-03 | 1996-10-10 | Edward W Stark | Signal processing method and apparatus |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US5089112A (en) | 1989-03-20 | 1992-02-18 | Associated Universities, Inc. | Electrochemical biosensor based on immobilized enzymes and redox polymers |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
EP0396788A1 (en) | 1989-05-08 | 1990-11-14 | Dräger Nederland B.V. | Process and sensor for measuring the glucose content of glucosecontaining fluids |
US5096560A (en) | 1989-05-30 | 1992-03-17 | Mitsubishi Petrochemical Co., Ltd. | Electrode for electrochemical detectors |
US5236567A (en) | 1989-05-31 | 1993-08-17 | Nakano Vinegar Co., Ltd. | Enzyme sensor |
US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
US5198367A (en) | 1989-06-09 | 1993-03-30 | Masuo Aizawa | Homogeneous amperometric immunoassay |
US4899839A (en) | 1989-06-14 | 1990-02-13 | Dessertine Albert L | Compliance and patient status monitoring system and method |
US5016172A (en) | 1989-06-14 | 1991-05-14 | Ramp Comsystems, Inc. | Patient compliance and status monitoring system |
FR2648353B1 (en) | 1989-06-16 | 1992-03-27 | Europhor Sa | MICRODIALYSIS PROBE |
CH677149A5 (en) | 1989-07-07 | 1991-04-15 | Disetronic Ag | |
JPH0737991B2 (en) | 1989-07-13 | 1995-04-26 | 株式会社京都第一科学 | Method for measuring glucose concentration |
US5272060A (en) | 1989-07-13 | 1993-12-21 | Kyoto Daiichi Kagaku Co., Ltd. | Method for determination of glucose concentration in whole blood |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US4986271A (en) | 1989-07-19 | 1991-01-22 | The University Of New Mexico | Vivo refillable glucose sensor |
US4979509A (en) | 1989-07-19 | 1990-12-25 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5320725A (en) | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5264105A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US4944299A (en) | 1989-08-08 | 1990-07-31 | Siemens-Pacesetter, Inc. | High speed digital telemetry system for implantable device |
US4931795A (en) | 1989-08-09 | 1990-06-05 | Alfred E. Mann Foundation | Digital to analog signal converter |
US5190041A (en) | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5101814A (en) | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
DK0415288T3 (en) | 1989-08-25 | 1996-07-22 | Toto Ltd | Toilet apparatus with system for inspection of health conditions |
US5568400A (en) | 1989-09-01 | 1996-10-22 | Stark; Edward W. | Multiplicative signal correction method and apparatus |
US5095904A (en) | 1989-09-08 | 1992-03-17 | Cochlear Pty. Ltd. | Multi-peak speech procession |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
US5522865A (en) | 1989-09-22 | 1996-06-04 | Alfred E. Mann Foundation For Scientific Research | Voltage/current control system for a human tissue stimulator |
US4991582A (en) | 1989-09-22 | 1991-02-12 | Alfred E. Mann Foundation For Scientific Research | Hermetically sealed ceramic and metal package for electronic devices implantable in living bodies |
US5084828A (en) | 1989-09-29 | 1992-01-28 | Healthtech Services Corp. | Interactive medication delivery system |
FR2652736A1 (en) | 1989-10-06 | 1991-04-12 | Neftel Frederic | IMPLANTABLE DEVICE FOR EVALUATING THE RATE OF GLUCOSE. |
EP0429076B1 (en) | 1989-11-24 | 1996-01-31 | Matsushita Electric Industrial Co., Ltd. | Preparation of biosensor |
US4994068A (en) | 1989-11-24 | 1991-02-19 | Unidex, Inc. | Combination sterile pad support and lancet containing lancet disposal element |
US5036860A (en) | 1989-11-24 | 1991-08-06 | Medical Device Technologies, Inc. | Disposable soft tissue biopsy apparatus |
US5082550A (en) | 1989-12-11 | 1992-01-21 | The United States Of America As Represented By The Department Of Energy | Enzyme electrochemical sensor electrode and method of making it |
US6040194A (en) | 1989-12-14 | 2000-03-21 | Sensor Technologies, Inc. | Methods and device for detecting and quantifying substances in body fluids |
US5342789A (en) | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
EP0505494B1 (en) | 1989-12-15 | 1995-07-12 | Boehringer Mannheim Corporation | Redox mediator reagent and biosensor |
US5508171A (en) | 1989-12-15 | 1996-04-16 | Boehringer Mannheim Corporation | Assay method with enzyme electrode system |
US4990845A (en) | 1989-12-18 | 1991-02-05 | Alfred E. Mann Foundation For Scientific Research | Floating current source |
US5036861A (en) | 1990-01-11 | 1991-08-06 | Sembrowich Walter L | Method and apparatus for non-invasively monitoring plasma glucose levels |
US5078854A (en) | 1990-01-22 | 1992-01-07 | Mallinckrodt Sensor Systems, Inc. | Polarographic chemical sensor with external reference electrode |
US5286362A (en) | 1990-02-03 | 1994-02-15 | Boehringer Mannheim Gmbh | Method and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor |
US5109850A (en) | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
US5114678A (en) | 1990-03-21 | 1992-05-19 | Miles Inc. | Device for wiping a reagent strip |
US5501956A (en) | 1990-03-23 | 1996-03-26 | Molecular Devices Corporation | Polyredox couples in analyte determinations |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
US5161532A (en) | 1990-04-19 | 1992-11-10 | Teknekron Sensor Development Corporation | Integral interstitial fluid sensor |
GB2243211A (en) | 1990-04-20 | 1991-10-23 | Philips Electronic Associated | Analytical instrument and method of calibrating an analytical instrument |
DE4014109A1 (en) | 1990-05-02 | 1991-11-07 | Siemens Ag | ELECROCHEMICAL DETERMINATION OF THE OXYGEN CONCENTRATION |
US5059158A (en) | 1990-05-08 | 1991-10-22 | E.B.T., Inc. | Electronic transmission control system for a bicycle |
US5265888A (en) | 1990-06-22 | 1993-11-30 | Nintendo Co., Ltd. | Game apparatus and memory cartridge used therefor |
US5250439A (en) | 1990-07-19 | 1993-10-05 | Miles Inc. | Use of conductive sensors in diagnostic assays |
US5202261A (en) | 1990-07-19 | 1993-04-13 | Miles Inc. | Conductive sensors and their use in diagnostic assays |
JPH0820412B2 (en) | 1990-07-20 | 1996-03-04 | 松下電器産業株式会社 | Quantitative analysis method and device using disposable sensor |
US5182707A (en) | 1990-07-23 | 1993-01-26 | Healthdyne, Inc. | Apparatus for recording reagent test strip data by comparison to color lights on a reference panel |
US5176662A (en) | 1990-08-23 | 1993-01-05 | Minimed Technologies, Ltd. | Subcutaneous injection set with improved cannula mounting arrangement |
CA2049589A1 (en) | 1990-08-24 | 1992-02-25 | Naoki Tsukamura | Stool-type apparatus for sampling and assay of urine with swingable carriage |
US5120421A (en) | 1990-08-31 | 1992-06-09 | The United States Of America As Represented By The United States Department Of Energy | Electrochemical sensor/detector system and method |
GB9019126D0 (en) | 1990-09-01 | 1990-10-17 | Cranfield Biotech Ltd | Electrochemical biosensor stability |
US5217442A (en) | 1990-09-28 | 1993-06-08 | Minimed Technologies | Aspiration and refill kit for a medication infusion pump |
WO1992005775A1 (en) | 1990-09-28 | 1992-04-16 | Pfizer Inc. | Dispensing device containing a hydrophobic medium |
US5251126A (en) | 1990-10-29 | 1993-10-05 | Miles Inc. | Diabetes data analysis and interpretation method |
US5058592A (en) | 1990-11-02 | 1991-10-22 | Whisler G Douglas | Adjustable mountable doppler ultrasound transducer device |
US5176644A (en) | 1990-11-29 | 1993-01-05 | Minimed Technologies, Ltd. | Medication infusion pump with improved liquid-vapor pressure reservoir |
US5197322A (en) | 1990-11-29 | 1993-03-30 | Minimed Technologies, Ltd. | Pressure reservoir filling process for an implantable medication infusion pump |
JP2646848B2 (en) | 1990-11-30 | 1997-08-27 | 日本電気株式会社 | Glucose sensor measurement method |
ATE155575T1 (en) | 1990-12-12 | 1997-08-15 | Sherwood Medical Co | CALIBRATION OF AN INFRARED THERMOMETER USING AREA CALIBRATION CURVE REPRESENTATION |
NL9002764A (en) | 1990-12-14 | 1992-07-01 | Tno | ELECTRODE, FITTED WITH A POLYMER COATING WITH A REDOX ENZYM BOND TO IT. |
AU1356792A (en) | 1991-01-25 | 1992-08-27 | Markwell Medical Institute, Inc. | Implantable biological fluid measuring device |
FR2673289B1 (en) | 1991-02-21 | 1994-06-17 | Asulab Sa | SENSOR FOR MEASURING THE QUANTITY OF A COMPONENT IN SOLUTION. |
FR2673183B1 (en) | 1991-02-21 | 1996-09-27 | Asulab Sa | MONO, BIS OR TRIS (2,2'-BIPYRIDINE SUBSTITUTED) COMPLEXES OF A SELECTED METAL AMONG IRON, RUTHENIUM, OSMIUM OR VANADIUM AND THEIR PREPARATION PROCESSES. |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5192415A (en) | 1991-03-04 | 1993-03-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor utilizing enzyme and a method for producing the same |
US5469855A (en) | 1991-03-08 | 1995-11-28 | Exergen Corporation | Continuous temperature monitor |
DE4108804A1 (en) | 1991-03-18 | 1992-09-24 | Lauerer Friedrich | ELECTROMEDICAL PROTECTIVE CIRCUIT |
DE4138702A1 (en) | 1991-03-22 | 1992-09-24 | Madaus Medizin Elektronik | METHOD AND DEVICE FOR THE DIAGNOSIS AND QUANTITATIVE ANALYSIS OF APNOE AND FOR THE SIMULTANEOUS DETERMINATION OF OTHER DISEASES |
GB9107193D0 (en) | 1991-04-05 | 1991-05-22 | Wilson Robert | Analytical devices |
US5208154A (en) | 1991-04-08 | 1993-05-04 | The United States Of America As Represented By The Department Of Energy | Reversibly immobilized biological materials in monolayer films on electrodes |
US5192416A (en) | 1991-04-09 | 1993-03-09 | New Mexico State University Technology Transfer Corporation | Method and apparatus for batch injection analysis |
US5293546A (en) | 1991-04-17 | 1994-03-08 | Martin Marietta Corporation | Oxide coated metal grid electrode structure in display devices |
US5122925A (en) | 1991-04-22 | 1992-06-16 | Control Products, Inc. | Package for electronic components |
JP3118015B2 (en) | 1991-05-17 | 2000-12-18 | アークレイ株式会社 | Biosensor and separation and quantification method using the same |
US5209229A (en) | 1991-05-20 | 1993-05-11 | Telectronics Pacing Systems, Inc. | Apparatus and method employing plural electrode configurations for cardioversion of atrial fibrillation in an arrhythmia control system |
FI88223C (en) | 1991-05-22 | 1993-04-13 | Polar Electro Oy | Telemetric transmitter unit |
JP2816262B2 (en) | 1991-07-09 | 1998-10-27 | 工業技術院長 | Carbon microsensor electrode and method of manufacturing the same |
DE4123348A1 (en) | 1991-07-15 | 1993-01-21 | Boehringer Mannheim Gmbh | ELECTROCHEMICAL ANALYSIS SYSTEM |
JP2740587B2 (en) | 1991-07-18 | 1998-04-15 | 工業技術院長 | Micro composite electrode and method of manufacturing the same |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5284156A (en) | 1991-08-30 | 1994-02-08 | M3 Systems, Inc. | Automatic tissue sampling apparatus |
GB9120144D0 (en) | 1991-09-20 | 1991-11-06 | Imperial College | A dialysis electrode device |
US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5264103A (en) | 1991-10-18 | 1993-11-23 | Matsushita Electric Industrial Co., Ltd. | Biosensor and a method for measuring a concentration of a substrate in a sample |
DE9113046U1 (en) | 1991-10-19 | 1991-12-19 | Frese, Volker, 7100 Heilbronn, De | |
US5236143A (en) | 1991-10-23 | 1993-08-17 | Dragon Bradley P | Intravenous tubing retractor apparatus |
US5217595A (en) | 1991-10-25 | 1993-06-08 | The Yellow Springs Instrument Company, Inc. | Electrochemical gas sensor |
US5415164A (en) | 1991-11-04 | 1995-05-16 | Biofield Corp. | Apparatus and method for screening and diagnosing trauma or disease in body tissues |
US5193540A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5358514A (en) | 1991-12-18 | 1994-10-25 | Alfred E. Mann Foundation For Scientific Research | Implantable microdevice with self-attaching electrodes |
US5193539A (en) | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Implantable microstimulator |
US5372427A (en) | 1991-12-19 | 1994-12-13 | Texas Instruments Incorporated | Temperature sensor |
US5271815A (en) | 1991-12-26 | 1993-12-21 | Via Medical Corporation | Method for measuring glucose |
AU3274693A (en) | 1991-12-31 | 1993-07-28 | Abbott Laboratories | Composite membrane |
US5285792A (en) | 1992-01-10 | 1994-02-15 | Physio-Control Corporation | System for producing prioritized alarm messages in a medical instrument |
US5246867A (en) | 1992-01-17 | 1993-09-21 | University Of Maryland At Baltimore | Determination and quantification of saccharides by luminescence lifetimes and energy transfer |
NL9200207A (en) | 1992-02-05 | 1993-09-01 | Nedap Nv | IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION. |
JP3144030B2 (en) | 1992-02-24 | 2001-03-07 | 東陶機器株式会社 | Health management network system |
US5431691A (en) | 1992-03-02 | 1995-07-11 | Siemens Pacesetter, Inc. | Method and system for recording and displaying a sequential series of pacing events |
US5309919A (en) | 1992-03-02 | 1994-05-10 | Siemens Pacesetter, Inc. | Method and system for recording, reporting, and displaying the distribution of pacing events over time and for using same to optimize programming |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
FR2690622B1 (en) | 1992-04-29 | 1995-01-20 | Chronotec | Programmable ambulatory infusion pump system. |
US5711001A (en) | 1992-05-08 | 1998-01-20 | Motorola, Inc. | Method and circuit for acquisition by a radio receiver |
US5227042A (en) | 1992-05-15 | 1993-07-13 | The United States Of America As Represented By The United States Department Of Energy | Catalyzed enzyme electrodes |
US5580527A (en) | 1992-05-18 | 1996-12-03 | Moltech Corporation | Polymeric luminophores for sensing of oxygen |
US5269212A (en) | 1992-05-26 | 1993-12-14 | The Fletcher-Terry Company | Mat cutter |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5337258A (en) | 1992-07-10 | 1994-08-09 | Microsoft Corporation | Cost metrics |
US5278079A (en) | 1992-09-02 | 1994-01-11 | Enzymatics, Inc. | Sealing device and method for inhibition of flow in capillary measuring devices |
US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
CA2079192C (en) | 1992-09-25 | 1995-12-26 | Bernard Strong | Combined lancet and multi-function cap and lancet injector for use therewith |
US5898025A (en) | 1992-09-25 | 1999-04-27 | Henkel Kommanditgesellschaft Auf Aktien | Mildly alkaline dishwashing detergents |
US5376070A (en) | 1992-09-29 | 1994-12-27 | Minimed Inc. | Data transfer system for an infusion pump |
US5400782A (en) | 1992-10-07 | 1995-03-28 | Graphic Controls Corporation | Integral medical electrode including a fusible conductive substrate |
US5421816A (en) | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
US5387327A (en) | 1992-10-19 | 1995-02-07 | Duquesne University Of The Holy Ghost | Implantable non-enzymatic electrochemical glucose sensor |
US5320098A (en) | 1992-10-20 | 1994-06-14 | Sun Microsystems, Inc. | Optical transdermal link |
WO1994010553A1 (en) | 1992-10-23 | 1994-05-11 | Optex Biomedical, Inc. | Fibre-optic probe for the measurement of fluid parameters |
DE69331664T2 (en) | 1992-11-09 | 2002-10-17 | Ilife Systems Inc | DEVICE AND METHOD FOR REMOTELY MEASURING PHYSIOLOGICAL SIZES |
US6210272B1 (en) | 1997-12-22 | 2001-04-03 | Health Hero Network, Inc. | Multi-player interactive electronic game for health education |
US5913310A (en) | 1994-05-23 | 1999-06-22 | Health Hero Network, Inc. | Method for diagnosis and treatment of psychological and emotional disorders using a microprocessor-based video game |
US20010011224A1 (en) | 1995-06-07 | 2001-08-02 | Stephen James Brown | Modular microprocessor-based health monitoring system |
US5678571A (en) | 1994-05-23 | 1997-10-21 | Raya Systems, Inc. | Method for treating medical conditions using a microprocessor-based video game |
US6968375B1 (en) | 1997-03-28 | 2005-11-22 | Health Hero Network, Inc. | Networked system for interactive communication and remote monitoring of individuals |
US5960403A (en) | 1992-11-17 | 1999-09-28 | Health Hero Network | Health management process control system |
US5940801A (en) | 1994-04-26 | 1999-08-17 | Health Hero Network, Inc. | Modular microprocessor-based diagnostic measurement apparatus and method for psychological conditions |
US5601435A (en) | 1994-11-04 | 1997-02-11 | Intercare | Method and apparatus for interactively monitoring a physiological condition and for interactively providing health related information |
US5887133A (en) | 1997-01-15 | 1999-03-23 | Health Hero Network | System and method for modifying documents sent over a communications network |
US5951300A (en) | 1997-03-10 | 1999-09-14 | Health Hero Network | Online system and method for providing composite entertainment and health information |
US5307263A (en) | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
US5997476A (en) | 1997-03-28 | 1999-12-07 | Health Hero Network, Inc. | Networked system for interactive communication and remote monitoring of individuals |
US5897493A (en) | 1997-03-28 | 1999-04-27 | Health Hero Network, Inc. | Monitoring system for remotely querying individuals |
US5933136A (en) | 1996-12-23 | 1999-08-03 | Health Hero Network, Inc. | Network media access control system for encouraging patient compliance with a treatment plan |
US6068615A (en) | 1994-07-22 | 2000-05-30 | Health Hero Network, Inc. | Inductance-based dose measurement in syringes |
US5832448A (en) | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
US5879163A (en) | 1996-06-24 | 1999-03-09 | Health Hero Network, Inc. | On-line health education and feedback system using motivational driver profile coding and automated content fulfillment |
US6330426B2 (en) | 1994-05-23 | 2001-12-11 | Stephen J. Brown | System and method for remote education using a memory card |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US6186145B1 (en) | 1994-05-23 | 2001-02-13 | Health Hero Network, Inc. | Method for diagnosis and treatment of psychological and emotional conditions using a microprocessor-based virtual reality simulator |
US5918603A (en) | 1994-05-23 | 1999-07-06 | Health Hero Network, Inc. | Method for treating medical conditions using a microprocessor-based video game |
US6334778B1 (en) | 1994-04-26 | 2002-01-01 | Health Hero Network, Inc. | Remote psychological diagnosis and monitoring system |
US7970620B2 (en) | 1992-11-17 | 2011-06-28 | Health Hero Network, Inc. | Multi-user remote health monitoring system with biometrics support |
US5899855A (en) | 1992-11-17 | 1999-05-04 | Health Hero Network, Inc. | Modular microprocessor-based health monitoring system |
US6196970B1 (en) | 1999-03-22 | 2001-03-06 | Stephen J. Brown | Research data collection and analysis |
US6101478A (en) | 1997-04-30 | 2000-08-08 | Health Hero Network | Multi-user remote health monitoring system |
US6168563B1 (en) | 1992-11-17 | 2001-01-02 | Health Hero Network, Inc. | Remote health monitoring and maintenance system |
US5782814A (en) | 1994-07-22 | 1998-07-21 | Raya Systems, Inc. | Apparatus for determining and recording injection doses in syringes using electrical inductance |
US5569212A (en) | 1994-07-22 | 1996-10-29 | Raya Systems, Inc. | Apparatus for electrically determining injection doses in syringes |
US5371687A (en) | 1992-11-20 | 1994-12-06 | Boehringer Mannheim Corporation | Glucose test data acquisition and management system |
ZA938555B (en) | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
DK148592D0 (en) | 1992-12-10 | 1992-12-10 | Novo Nordisk As | APPARATUS |
US5299571A (en) | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
FR2701117B1 (en) | 1993-02-04 | 1995-03-10 | Asulab Sa | Electrochemical measurement system with multizone sensor, and its application to glucose measurement. |
JPH0816669B2 (en) | 1993-02-18 | 1996-02-21 | 日本電気株式会社 | Method for manufacturing glucose sensor |
GB9304306D0 (en) | 1993-03-03 | 1993-04-21 | Univ Alberta | Glucose sensor |
US5257971A (en) | 1993-03-16 | 1993-11-02 | Minimed Technologies, Ltd. | Recondition process for a medication infusion pump |
US5433710A (en) | 1993-03-16 | 1995-07-18 | Minimed, Inc. | Medication infusion pump with fluoropolymer valve seat |
US5257980A (en) | 1993-04-05 | 1993-11-02 | Minimed Technologies, Ltd. | Subcutaneous injection set with crimp-free soft cannula |
DK0622119T3 (en) * | 1993-04-23 | 2000-04-10 | Roche Diagnostics Gmbh | Test element storage system |
GB9309797D0 (en) | 1993-05-12 | 1993-06-23 | Medisense Inc | Electrochemical sensors |
US5364797A (en) | 1993-05-20 | 1994-11-15 | Mobil Oil Corp. | Sensor device containing mesoporous crystalline material |
JP3713516B2 (en) | 1993-05-29 | 2005-11-09 | ケンブリッジ ライフ サイエンシズ パブリック リミテッド カンパニー | Sensors based on polymer transformations |
DE4318519C2 (en) | 1993-06-03 | 1996-11-28 | Fraunhofer Ges Forschung | Electrochemical sensor |
US5366609A (en) | 1993-06-08 | 1994-11-22 | Boehringer Mannheim Corporation | Biosensing meter with pluggable memory key |
DE4320463A1 (en) | 1993-06-21 | 1994-12-22 | Boehringer Mannheim Gmbh | Blood lancet device for drawing blood for diagnostic purposes |
US5477855A (en) | 1993-07-16 | 1995-12-26 | Alfred E. Mann Foundation For Scientific Research | Shield for conductors of an implantable device |
US5413690A (en) | 1993-07-23 | 1995-05-09 | Boehringer Mannheim Corporation | Potentiometric biosensor and the method of its use |
US5410474A (en) | 1993-07-27 | 1995-04-25 | Miles Inc. | Buttonless memory system for an electronic measurement device |
US5384547A (en) * | 1993-08-02 | 1995-01-24 | Motorola, Inc. | Apparatus and method for attenuating a multicarrier input signal of a linear device |
US5837546A (en) | 1993-08-24 | 1998-11-17 | Metrika, Inc. | Electronic assay device and method |
CA2170402C (en) | 1993-08-24 | 2000-07-18 | Michael P. Allen | Novel disposable electronic assay device |
US5377258A (en) | 1993-08-30 | 1994-12-27 | National Medical Research Council | Method and apparatus for an automated and interactive behavioral guidance system |
US5456692A (en) | 1993-09-03 | 1995-10-10 | Pacesetter, Inc. | System and method for noninvasively altering the function of an implanted pacemaker |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
EP0644266A1 (en) | 1993-09-22 | 1995-03-22 | Siemens Aktiengesellschaft | Working electrode for electrochemical-enzymatical sensor systems |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
DE69322968T2 (en) | 1993-10-22 | 1999-07-08 | Siemens Elema Ab | Method and device for continuously monitoring an anolyte level |
US5399823A (en) | 1993-11-10 | 1995-03-21 | Minimed Inc. | Membrane dome switch with tactile feel regulator shim |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5445611A (en) | 1993-12-08 | 1995-08-29 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal delivery with ultrasound and chemical enhancers |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
DE4339188A1 (en) | 1993-11-16 | 1995-05-18 | Mueller & Sebastiani Elek Gmbh | Portable device for recording body-specific measurement data |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5497772A (en) | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
CA2155932A1 (en) | 1993-12-14 | 1995-06-22 | Tadakazu Yamauchi | Medical measuring apparatus |
US5724968A (en) | 1993-12-29 | 1998-03-10 | First Opinion Corporation | Computerized medical diagnostic system including meta function |
US6206829B1 (en) | 1996-07-12 | 2001-03-27 | First Opinion Corporation | Computerized medical diagnostic and treatment advice system including network access |
US5589326A (en) | 1993-12-30 | 1996-12-31 | Boehringer Mannheim Corporation | Osmium-containing redox mediator |
DE4401400A1 (en) | 1994-01-19 | 1995-07-20 | Ernst Prof Dr Pfeiffer | Method and arrangement for continuously monitoring the concentration of a metabolite |
FR2715566B1 (en) | 1994-02-03 | 1996-03-08 | Synthelabo | Concentrated aqueous solutions of argatroban. |
EP0752099A1 (en) | 1994-02-09 | 1997-01-08 | Abbott Laboratories | Diagnostic flow cell device |
FI95574C (en) | 1994-02-16 | 1996-02-26 | Valtion Teknillinen | Electron-conducting molecular preparations |
US5437999A (en) | 1994-02-22 | 1995-08-01 | Boehringer Mannheim Corporation | Electrochemical sensor |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
DE4408718A1 (en) | 1994-03-15 | 1995-09-21 | Henkel Kgaa | Breakage and storage stable, polyfunctional cleaning tablets, process for their preparation and their use |
US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5456940A (en) | 1994-03-28 | 1995-10-10 | Minimed Inc. | System for lubricating a syringe barrel |
US5527307A (en) | 1994-04-01 | 1996-06-18 | Minimed Inc. | Implantable medication infusion pump with discharge side port |
US5505713A (en) | 1994-04-01 | 1996-04-09 | Minimed Inc. | Indwelling catheter with stable enzyme coating |
AU2200895A (en) * | 1994-04-04 | 1995-10-23 | Motorola, Inc. | Method and apparatus for activating and accessing remote meter interface devices |
US5609575A (en) | 1994-04-11 | 1997-03-11 | Graseby Medical Limited | Infusion pump and method with dose-rate calculation |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
JP3061351B2 (en) | 1994-04-25 | 2000-07-10 | 松下電器産業株式会社 | Method and apparatus for quantifying specific compounds |
EP0760138A4 (en) | 1994-04-26 | 1998-04-01 | Raya Systems Inc | Modular microprocessor-based diagnostic measurement system for psychological conditions |
US5370622A (en) | 1994-04-28 | 1994-12-06 | Minimed Inc. | Proctective case for a medication infusion pump |
US5476460A (en) | 1994-04-29 | 1995-12-19 | Minimed Inc. | Implantable infusion port with reduced internal volume |
EP0758377A1 (en) | 1994-05-03 | 1997-02-19 | Novo Nordisk A/S | Alkaline glucose oxidase |
DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
TW275570B (en) | 1994-05-05 | 1996-05-11 | Boehringer Mannheim Gmbh | |
US5545191A (en) | 1994-05-06 | 1996-08-13 | Alfred E. Mann Foundation For Scientific Research | Method for optimally positioning and securing the external unit of a transcutaneous transducer of the skin of a living body |
US5484404A (en) | 1994-05-06 | 1996-01-16 | Alfred E. Mann Foundation For Scientific Research | Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems |
US5651767A (en) | 1994-05-06 | 1997-07-29 | Alfred F. Mann Foundation For Scientific Research | Replaceable catheter system for physiological sensors, stimulating electrodes and/or implantable fluid delivery systems |
US5482473A (en) | 1994-05-09 | 1996-01-09 | Minimed Inc. | Flex circuit connector |
JP3027306B2 (en) | 1994-06-02 | 2000-04-04 | 松下電器産業株式会社 | Biosensor and manufacturing method thereof |
US5472317A (en) | 1994-06-03 | 1995-12-05 | Minimed Inc. | Mounting clip for a medication infusion pump |
US5514103A (en) | 1994-06-14 | 1996-05-07 | Minimed Inc. | Medication infusion pump with improved pressure reservoir |
US5462525A (en) | 1994-06-14 | 1995-10-31 | Minimed, Inc., A Delaware Corporation | Flow sensor for an infusion pump |
US5460618A (en) | 1994-06-20 | 1995-10-24 | Minimed Inc. | Side slit catheter |
US5771890A (en) | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
US5494562A (en) | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
US5514253A (en) | 1994-07-13 | 1996-05-07 | I-Stat Corporation | Method of measuring gas concentrations and microfabricated sensing device for practicing same |
US5605152A (en) | 1994-07-18 | 1997-02-25 | Minimed Inc. | Optical glucose sensor |
US5792117A (en) | 1994-07-22 | 1998-08-11 | Raya Systems, Inc. | Apparatus for optically determining and electronically recording injection doses in syringes |
US6110148A (en) | 1994-07-22 | 2000-08-29 | Health Hero Network, Inc. | Capacitance-based dose measurements in syringes |
US5720733A (en) | 1994-07-22 | 1998-02-24 | Raya Systems, Inc. | Apparatus for determining and recording injection doses in syringes using electrical capacitance measurements |
US5629981A (en) | 1994-07-29 | 1997-05-13 | Texas Instruments Incorporated | Information management and security system |
US5518006A (en) | 1994-08-09 | 1996-05-21 | International Technidyne Corp. | Blood sampling device |
DE4430023A1 (en) | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Electrochemical sensor |
WO1996007908A1 (en) | 1994-09-08 | 1996-03-14 | Lifescan, Inc. | Optically readable strip for analyte detection having on-strip standard |
US5526120A (en) | 1994-09-08 | 1996-06-11 | Lifescan, Inc. | Test strip with an asymmetrical end insuring correct insertion for measuring |
US5505709A (en) | 1994-09-15 | 1996-04-09 | Minimed, Inc., A Delaware Corporation | Mated infusion pump and syringe |
US5549115A (en) | 1994-09-28 | 1996-08-27 | Heartstream, Inc. | Method and apparatus for gathering event data using a removable data storage medium and clock |
US5667983A (en) | 1994-10-24 | 1997-09-16 | Chiron Diagnostics Corporation | Reagents with enhanced performance in clinical diagnostic systems |
US5545152A (en) | 1994-10-28 | 1996-08-13 | Minimed Inc. | Quick-connect coupling for a medication infusion system |
IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
US5487751A (en) | 1994-11-04 | 1996-01-30 | Physio-Control Corporation | Mechanical connector for securing compatible medical instruments together |
US6256643B1 (en) | 1998-03-10 | 2001-07-03 | Baxter International Inc. | Systems and methods for storing, retrieving, and manipulating data in medical processing devices |
JPH08154903A (en) | 1994-12-09 | 1996-06-18 | Hitachi Ltd | Living body information monitoring sheet |
US5637095A (en) | 1995-01-13 | 1997-06-10 | Minimed Inc. | Medication infusion pump with flexible drive plunger |
US5562713A (en) | 1995-01-18 | 1996-10-08 | Pacesetter, Inc. | Bidirectional telemetry apparatus and method for implantable device |
US6153069A (en) | 1995-02-09 | 2000-11-28 | Tall Oak Ventures | Apparatus for amperometric Diagnostic analysis |
US6515593B1 (en) | 1995-02-15 | 2003-02-04 | Izex Technologies, Inc. | Communication system for an instrumented orthopedic restraining device and method therefor |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5651869A (en) | 1995-02-28 | 1997-07-29 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US5647853A (en) | 1995-03-03 | 1997-07-15 | Minimed Inc. | Rapid response occlusion detector for a medication infusion pump |
US5596150A (en) | 1995-03-08 | 1997-01-21 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Capacitance probe for fluid flow and volume measurements |
JPH08247987A (en) | 1995-03-15 | 1996-09-27 | Omron Corp | Portable measuring instrument |
US5582697A (en) | 1995-03-17 | 1996-12-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5650062A (en) | 1995-03-17 | 1997-07-22 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US6170318B1 (en) | 1995-03-27 | 2001-01-09 | California Institute Of Technology | Methods of use for sensor based fluid detection devices |
US5786439A (en) | 1996-10-24 | 1998-07-28 | Minimed Inc. | Hydrophilic, swellable coatings for biosensors |
US5882494A (en) | 1995-03-27 | 1999-03-16 | Minimed, Inc. | Polyurethane/polyurea compositions containing silicone for biosensor membranes |
JP3498105B2 (en) | 1995-04-07 | 2004-02-16 | アークレイ株式会社 | Sensor, method for manufacturing the same, and measuring method using the sensor |
US5695949A (en) | 1995-04-07 | 1997-12-09 | Lxn Corp. | Combined assay for current glucose level and intermediate or long-term glycemic control |
DE19515524C2 (en) | 1995-04-27 | 1999-09-09 | Private Uni Witten Herdecke Gm | Method and device for the continuous detection of at least one substance in a gaseous or liquid mixture by means of a sensor electrode |
US5752512A (en) | 1995-05-10 | 1998-05-19 | Massachusetts Institute Of Technology | Apparatus and method for non-invasive blood analyte measurement |
US5876484A (en) | 1995-05-17 | 1999-03-02 | Phytotech, Inc. | Method for removing soluble metals from an aqueous phase |
US5628310A (en) | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
US5640764A (en) | 1995-05-22 | 1997-06-24 | Alfred E. Mann Foundation For Scientific Research | Method of forming a tubular feed-through hermetic seal for an implantable medical device |
US6035237A (en) | 1995-05-23 | 2000-03-07 | Alfred E. Mann Foundation | Implantable stimulator that prevents DC current flow without the use of discrete output coupling capacitors |
US5665065A (en) | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
US5623925A (en) | 1995-06-05 | 1997-04-29 | Cmed, Inc. | Virtual medical instrument for performing medical diagnostic testing on patients |
US5584813A (en) | 1995-06-07 | 1996-12-17 | Minimed Inc. | Subcutaneous injection set |
US5567302A (en) | 1995-06-07 | 1996-10-22 | Molecular Devices Corporation | Electrochemical system for rapid detection of biochemical agents that catalyze a redox potential change |
US5721783A (en) | 1995-06-07 | 1998-02-24 | Anderson; James C. | Hearing aid with wireless remote processor |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
JP2819260B2 (en) | 1995-07-11 | 1998-10-30 | 株式会社朋友メディカル | Catheter extension tube |
US5611900A (en) | 1995-07-20 | 1997-03-18 | Michigan State University | Microbiosensor used in-situ |
US6041253A (en) | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
US6002961A (en) | 1995-07-25 | 1999-12-14 | Massachusetts Institute Of Technology | Transdermal protein delivery using low-frequency sonophoresis |
US5947921A (en) | 1995-12-18 | 1999-09-07 | Massachusetts Institute Of Technology | Chemical and physical enhancers and ultrasound for transdermal drug delivery |
US7016713B2 (en) * | 1995-08-09 | 2006-03-21 | Inlight Solutions, Inc. | Non-invasive determination of direction and rate of change of an analyte |
US5750926A (en) | 1995-08-16 | 1998-05-12 | Alfred E. Mann Foundation For Scientific Research | Hermetically sealed electrical feedthrough for use with implantable electronic devices |
DE19530376C2 (en) | 1995-08-18 | 1999-09-02 | Fresenius Ag | Biosensor |
US5786584A (en) | 1995-09-06 | 1998-07-28 | Eli Lilly And Company | Vial and cartridge reading device providing audio feedback for a blood glucose monitoring system |
US5682233A (en) | 1995-09-08 | 1997-10-28 | Integ, Inc. | Interstitial fluid sampler |
US5768591A (en) | 1995-09-08 | 1998-06-16 | Iq Systems | Method of de-bugging host-processor software in a distributed processing system having a host processor and at least one object oriented processor |
US5989409A (en) | 1995-09-11 | 1999-11-23 | Cygnus, Inc. | Method for glucose sensing |
US5735273A (en) | 1995-09-12 | 1998-04-07 | Cygnus, Inc. | Chemical signal-impermeable mask |
US5628890A (en) | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5665222A (en) | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
US5701894A (en) | 1995-11-09 | 1997-12-30 | Del Mar Avionics | Modular physiological computer-recorder |
US5748103A (en) | 1995-11-13 | 1998-05-05 | Vitalcom, Inc. | Two-way TDMA telemetry system with power conservation features |
US5807315A (en) | 1995-11-13 | 1998-09-15 | Minimed, Inc. | Methods and devices for the delivery of monomeric proteins |
DE19543020A1 (en) | 1995-11-18 | 1997-05-22 | Boehringer Mannheim Gmbh | Method and device for determining analytical data on the interior of a scattering matrix |
US6002954A (en) | 1995-11-22 | 1999-12-14 | The Regents Of The University Of California | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
WO1997019188A1 (en) | 1995-11-22 | 1997-05-29 | Minimed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
US6766183B2 (en) | 1995-11-22 | 2004-07-20 | Medtronic Minimed, Inc. | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
US5981294A (en) | 1995-11-29 | 1999-11-09 | Metrika, Inc. | Device for blood separation in a diagnostic device |
US5730654A (en) | 1995-12-18 | 1998-03-24 | Raya Systems, Inc. | Multi-player video game for health education |
EP0868144B1 (en) | 1995-12-19 | 2005-01-26 | Abbott Laboratories | Device for the detection of analyte and administration of a therapeutic substance |
JP3316820B2 (en) | 1995-12-28 | 2002-08-19 | シィグナス インコーポレィティド | Apparatus and method for continuous monitoring of a physiological analyte of a subject |
US5827184A (en) | 1995-12-29 | 1998-10-27 | Minnesota Mining And Manufacturing Company | Self-packaging bioelectrodes |
JP3365184B2 (en) | 1996-01-10 | 2003-01-08 | 松下電器産業株式会社 | Biosensor |
US5830341A (en) | 1996-01-23 | 1998-11-03 | Gilmartin; Markas A. T. | Electrodes and metallo isoindole ringed compounds |
US5740431A (en) * | 1996-01-24 | 1998-04-14 | Electronic Data Systems Corporation | Configuration file management |
US5704922A (en) | 1996-01-25 | 1998-01-06 | Raya Systems, Inc. | Syringe having electrical contact points for metering doses |
US5628309A (en) | 1996-01-25 | 1997-05-13 | Raya Systems, Inc. | Meter for electrically measuring and recording injection syringe doses |
EP0889703B1 (en) | 1996-02-05 | 2001-11-21 | Diasense, Inc. | Apparatus for non-invasive glucose sensing |
FI960636A (en) | 1996-02-12 | 1997-08-13 | Nokia Mobile Phones Ltd | A procedure for monitoring the health of a patient |
FI118509B (en) | 1996-02-12 | 2007-12-14 | Nokia Oyj | A method and apparatus for predicting blood glucose levels in a patient |
US5708247A (en) | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US6241862B1 (en) | 1996-02-14 | 2001-06-05 | Inverness Medical Technology, Inc. | Disposable test strips with integrated reagent/blood separation layer |
US20010044588A1 (en) | 1996-02-22 | 2001-11-22 | Mault James R. | Monitoring system |
US5948512A (en) | 1996-02-22 | 1999-09-07 | Seiko Epson Corporation | Ink jet recording ink and recording method |
US5753452A (en) | 1996-04-04 | 1998-05-19 | Lifescan, Inc. | Reagent test strip for blood glucose determination |
CA2250400A1 (en) | 1996-04-30 | 1997-11-06 | Metrika, Inc. | Method and device for measuring reflected optical radiation |
DE19618597B4 (en) | 1996-05-09 | 2005-07-21 | Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm | Method for determining the concentration of tissue glucose |
US5968839A (en) | 1996-05-13 | 1999-10-19 | Metrika, Inc. | Method and device producing a predetermined distribution of detectable change in assays |
US20040249420A1 (en) | 1996-05-14 | 2004-12-09 | Medtronic, Inc. | Prioritized rule based method and apparatus for diagnosis and treatment of arrhythmias |
US5951492A (en) | 1996-05-17 | 1999-09-14 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling and analyzing body fluid |
US5879311A (en) | 1996-05-17 | 1999-03-09 | Mercury Diagnostics, Inc. | Body fluid sampling device and methods of use |
JP3494660B2 (en) | 1996-05-17 | 2004-02-09 | アミラ メディカル | A device that squeezes body fluid from the incision |
US5857983A (en) | 1996-05-17 | 1999-01-12 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling body fluid |
AU3070397A (en) | 1996-05-17 | 1997-12-05 | Mercury Diagnostics Inc. | Methods and apparatus for sampling body fluid |
EP0906062B1 (en) | 1996-05-17 | 2007-12-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US5954685A (en) | 1996-05-24 | 1999-09-21 | Cygnus, Inc. | Electrochemical sensor with dual purpose electrode |
US5735285A (en) | 1996-06-04 | 1998-04-07 | Data Critical Corp. | Method and hand-held apparatus for demodulating and viewing frequency modulated biomedical signals |
EP0914178B1 (en) | 1996-06-18 | 2003-03-12 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
US6032199A (en) | 1996-06-26 | 2000-02-29 | Sun Microsystems, Inc. | Transport independent invocation and servant interfaces that permit both typecode interpreted and compiled marshaling |
CA2259254C (en) | 1996-07-08 | 2008-02-19 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US5707502A (en) | 1996-07-12 | 1998-01-13 | Chiron Diagnostics Corporation | Sensors for measuring analyte concentrations and methods of making same |
US6741163B1 (en) | 1996-08-13 | 2004-05-25 | Corinna A. Roberts | Decorative motion detector |
US5804048A (en) | 1996-08-15 | 1998-09-08 | Via Medical Corporation | Electrode assembly for assaying glucose |
US5945345A (en) | 1996-08-27 | 1999-08-31 | Metrika, Inc. | Device for preventing assay interference using silver or lead to remove the interferant |
FI112029B (en) | 1996-09-02 | 2003-10-31 | Nokia Corp | Device for taking and analyzing samples in liquid form, such as blood samples |
US5869963A (en) | 1996-09-12 | 1999-02-09 | Alps Electric Co., Ltd. | Magnetoresistive sensor and head |
DK0929644T3 (en) | 1996-09-24 | 2002-05-21 | Henkel Ecolab Gmbh & Co Ohg | Manufacture of surfactant-containing, compact detergent |
US5718234A (en) | 1996-09-30 | 1998-02-17 | Northrop Grumman Corporation | Physiological data communication system |
US6148094A (en) | 1996-09-30 | 2000-11-14 | David J. Kinsella | Pointing device with biometric sensor |
US5977476A (en) | 1996-10-16 | 1999-11-02 | United Solar Systems Corporation | High efficiency photovoltaic device |
EP2290362B1 (en) | 1996-10-30 | 2013-01-23 | F. Hoffmann-La Roche AG | Synchronized analyte testing system |
US6443942B2 (en) | 1996-11-01 | 2002-09-03 | Minimed, Inc. | Medication device with protein stabilizing surface coating |
US5854078A (en) | 1996-11-06 | 1998-12-29 | University Of Pittsburgh | Polymerized crystalline colloidal array sensor methods |
US5771001A (en) | 1996-11-18 | 1998-06-23 | Cobb; Marlon J. | Personal alarm system |
WO1998022820A1 (en) | 1996-11-21 | 1998-05-28 | Lawrence Livermore National Laboratory | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
US6027459A (en) | 1996-12-06 | 2000-02-22 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US6043437A (en) | 1996-12-20 | 2000-03-28 | Alfred E. Mann Foundation | Alumina insulation for coating implantable components and other microminiature devices |
US6151586A (en) | 1996-12-23 | 2000-11-21 | Health Hero Network, Inc. | Computerized reward system for encouraging participation in a health management program |
US5914026A (en) | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
US5957958A (en) | 1997-01-15 | 1999-09-28 | Advanced Bionics Corporation | Implantable electrode arrays |
US5860917A (en) | 1997-01-15 | 1999-01-19 | Chiron Corporation | Method and apparatus for predicting therapeutic outcomes |
ES2124186B1 (en) | 1997-01-20 | 1999-08-01 | Carpe Diem Salud S L | SECTION AND TELEMATIC CONTROL SYSTEM OF PHYSIOLOGICAL PARAMETERS OF PATIENTS. |
US5974124A (en) | 1997-01-21 | 1999-10-26 | Med Graph | Method and system aiding medical diagnosis and treatment |
US6122351A (en) | 1997-01-21 | 2000-09-19 | Med Graph, Inc. | Method and system aiding medical diagnosis and treatment |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
US5851197A (en) | 1997-02-05 | 1998-12-22 | Minimed Inc. | Injector for a subcutaneous infusion set |
US6607509B2 (en) * | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
DE69809391T2 (en) * | 1997-02-06 | 2003-07-10 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
US5785681A (en) | 1997-02-25 | 1998-07-28 | Minimed Inc. | Flow rate controller for a medication infusion pump |
EP1011426A1 (en) | 1997-02-26 | 2000-06-28 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6208894B1 (en) | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US5827179A (en) | 1997-02-28 | 1998-10-27 | Qrs Diagnostic, Llc | Personal computer card for collection for real-time biological data |
US6159147A (en) | 1997-02-28 | 2000-12-12 | Qrs Diagnostics, Llc | Personal computer card for collection of real-time biological data |
US5950632A (en) | 1997-03-03 | 1999-09-14 | Motorola, Inc. | Medical communication apparatus, system, and method |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6139718A (en) | 1997-03-25 | 2000-10-31 | Cygnus, Inc. | Electrode with improved signal to noise ratio |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US5942979A (en) | 1997-04-07 | 1999-08-24 | Luppino; Richard | On guard vehicle safety warning system |
US6248065B1 (en) | 1997-04-30 | 2001-06-19 | Health Hero Network, Inc. | Monitoring system for remotely querying individuals |
US5779665A (en) | 1997-05-08 | 1998-07-14 | Minimed Inc. | Transdermal introducer assembly |
AU3128497A (en) | 1997-05-14 | 1998-12-08 | Metrika Laboratories, Inc. | Method and device for producing a predetermined distribution of detectable change in assays |
AU7296298A (en) | 1997-05-14 | 1998-12-08 | Sony Electronics Inc. | Antenna arrangement for portable two-way radio apparatus |
TW357517B (en) | 1997-05-29 | 1999-05-01 | Koji Akai | Monitoring system |
EP0986757B1 (en) | 1997-06-04 | 2008-02-20 | Sensor Technologies, Inc. | Method and device for detecting or quantifying carbohydrate containing compounds |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5957890A (en) | 1997-06-09 | 1999-09-28 | Minimed Inc. | Constant flow medication infusion pump |
ATE489633T1 (en) | 1997-06-10 | 2010-12-15 | Lpath Inc | METHOD FOR EARLY DETECTION OF HEART DISEASES |
EP0990151A2 (en) | 1997-06-16 | 2000-04-05 | ELAN CORPORATION, Plc | Methods of calibrating and testing a sensor for (in vivo) measurement of an analyte and devices for use in such methods |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
SE9702658D0 (en) | 1997-07-09 | 1997-07-09 | Thomas Carlsson | Regeneration of biosensors |
US5857967A (en) | 1997-07-09 | 1999-01-12 | Hewlett-Packard Company | Universally accessible healthcare devices with on the fly generation of HTML files |
US6063459A (en) | 1997-07-21 | 2000-05-16 | Velte; Stephen K. | Antenna ornament |
US6066243A (en) | 1997-07-22 | 2000-05-23 | Diametrics Medical, Inc. | Portable immediate response medical analyzer having multiple testing modules |
GB9716254D0 (en) | 1997-08-01 | 1997-10-08 | Hypoguard Uk Ltd | Test device |
AU753694B2 (en) | 1997-08-01 | 2002-10-24 | Advanced Bionics Corporation | Implantable device with improved battery recharging and powering configuration |
WO1999007277A1 (en) | 1997-08-09 | 1999-02-18 | Roche Diagnostics Gmbh | Analytical device for in vivo analysis in the body of a patient |
KR100241052B1 (en) | 1997-08-27 | 2000-02-01 | 박찬구 | Process for preparation of block copolymer |
US6731976B2 (en) | 1997-09-03 | 2004-05-04 | Medtronic, Inc. | Device and method to measure and communicate body parameters |
US5999848A (en) | 1997-09-12 | 1999-12-07 | Alfred E. Mann Foundation | Daisy chainable sensors and stimulators for implantation in living tissue |
US6071391A (en) | 1997-09-12 | 2000-06-06 | Nok Corporation | Enzyme electrode structure |
US5999849A (en) | 1997-09-12 | 1999-12-07 | Alfred E. Mann Foundation | Low power rectifier circuit for implantable medical device |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
US5917346A (en) | 1997-09-12 | 1999-06-29 | Alfred E. Mann Foundation | Low power current to frequency converter circuit for use in implantable sensors |
US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
AU9599498A (en) | 1997-09-30 | 1999-04-23 | M-Biotech, Inc. | Biosensor |
US5904671A (en) * | 1997-10-03 | 1999-05-18 | Navot; Nir | Tampon wetness detection system |
US20010032278A1 (en) | 1997-10-07 | 2001-10-18 | Brown Stephen J. | Remote generation and distribution of command programs for programmable devices |
US6097831A (en) | 1997-10-14 | 2000-08-01 | Chiron Corporation | Non-contract method for assay reagent volume dispense verification |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
US6081736A (en) | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
FI107080B (en) | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | measuring device |
US6144922A (en) | 1997-10-31 | 2000-11-07 | Mercury Diagnostics, Incorporated | Analyte concentration information collection and communication system |
EP1025530A2 (en) | 1997-10-31 | 2000-08-09 | Amira Medical | Analyte concentration information collection and communication s ystem |
JPH11141577A (en) | 1997-11-05 | 1999-05-25 | Nsk Warner Kk | One-way clutch |
US5931791A (en) | 1997-11-05 | 1999-08-03 | Instromedix, Inc. | Medical patient vital signs-monitoring apparatus |
US6044285A (en) | 1997-11-12 | 2000-03-28 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
US5971941A (en) | 1997-12-04 | 1999-10-26 | Hewlett-Packard Company | Integrated system and method for sampling blood and analysis |
US6071294A (en) | 1997-12-04 | 2000-06-06 | Agilent Technologies, Inc. | Lancet cartridge for sampling blood |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6033866A (en) | 1997-12-08 | 2000-03-07 | Biomedix, Inc. | Highly sensitive amperometric bi-mediator-based glucose biosensor |
EP1038176B1 (en) | 1997-12-19 | 2003-11-12 | Amira Medical | Embossed test strip system |
US6198957B1 (en) | 1997-12-19 | 2001-03-06 | Varian, Inc. | Radiotherapy machine including magnetic resonance imaging system |
US6073031A (en) | 1997-12-24 | 2000-06-06 | Nortel Networks Corporation | Desktop docking station for use with a wireless telephone handset |
CA2484271C (en) | 1997-12-31 | 2007-04-24 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US5954700A (en) | 1998-01-13 | 1999-09-21 | Minimed Inc. | Medication cartridge for an electronic pen-type injector, or the like, and method of making the same |
US6110152A (en) | 1998-01-13 | 2000-08-29 | Minimed Inc. | Medication cartridge for an electronic pen-type injector, infusion pump, electronic delivery device, or the like, and method of making the same |
KR100324159B1 (en) | 1998-01-21 | 2002-02-16 | 니시무로 타이죠 | Video data recording medium, video data recording apparatus and video data playback apparatus |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6056718A (en) | 1998-03-04 | 2000-05-02 | Minimed Inc. | Medication infusion set |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6530915B1 (en) | 1998-03-06 | 2003-03-11 | Spectrx, Inc. | Photothermal structure for biomedical applications, and method therefor |
WO1999044507A1 (en) | 1998-03-06 | 1999-09-10 | Spectrx, Inc. | Integrated tissue poration, fluid harvesting and analysis device, and method therefor |
US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
US6587705B1 (en) | 1998-03-13 | 2003-07-01 | Lynn Kim | Biosensor, iontophoretic sampling system, and methods of use thereof |
GB9805896D0 (en) | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
US6505059B1 (en) | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
JPH11296598A (en) | 1998-04-07 | 1999-10-29 | Seizaburo Arita | System and method for predicting blood-sugar level and record medium where same method is recorded |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
ATE246356T1 (en) | 1998-05-13 | 2003-08-15 | Cygnus Therapeutic Systems | DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENTS |
WO1999058190A1 (en) | 1998-05-13 | 1999-11-18 | Cygnus, Inc. | Collection assemblies for transdermal sampling system |
EP1077634B1 (en) | 1998-05-13 | 2003-07-30 | Cygnus, Inc. | Monitoring of physiological analytes |
WO1999058050A1 (en) | 1998-05-13 | 1999-11-18 | Cygnus, Inc. | Signal processing for measurement of physiological analytes |
US7043287B1 (en) | 1998-05-18 | 2006-05-09 | Abbott Laboratories | Method for modulating light penetration depth in tissue and diagnostic applications using same |
WO1999060391A1 (en) | 1998-05-20 | 1999-11-25 | Arkray, Inc. | Method and apparatus for electrochemical measurement using statistical technique |
US6121611A (en) | 1998-05-20 | 2000-09-19 | Molecular Imaging Corporation | Force sensing probe for scanning probe microscopy |
US6246330B1 (en) | 1998-05-29 | 2001-06-12 | Wyn Y. Nielsen | Elimination-absorber monitoring system |
US6026320A (en) | 1998-06-08 | 2000-02-15 | Cardiac Pacemakers, Inc. | Heart rate variability as an indicator of exercise capacity |
US6301499B1 (en) | 1998-06-08 | 2001-10-09 | Cardiac Pacemakers, Inc. | Heart rate variability as an indicator of exercise capacity |
US6294281B1 (en) | 1998-06-17 | 2001-09-25 | Therasense, Inc. | Biological fuel cell and method |
US6736797B1 (en) | 1998-06-19 | 2004-05-18 | Unomedical A/S | Subcutaneous infusion set |
US6280587B1 (en) | 1998-07-02 | 2001-08-28 | Nec Corporation | Enzyme electrode and a biosensor and a measuring apparatus therewith |
US7384396B2 (en) | 1998-07-21 | 2008-06-10 | Spectrx Inc. | System and method for continuous analyte monitoring |
US6267724B1 (en) | 1998-07-30 | 2001-07-31 | Microfab Technologies, Inc. | Implantable diagnostic sensor |
EP1102560A4 (en) | 1998-08-07 | 2003-03-12 | Infinite Biomedical Technologi | Implantable myocardial ischemia detection, indication and action technology |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6558320B1 (en) | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US6535753B1 (en) | 1998-08-20 | 2003-03-18 | Microsense International, Llc | Micro-invasive method for painless detection of analytes in extra-cellular space |
US6281006B1 (en) | 1998-08-24 | 2001-08-28 | Therasense, Inc. | Electrochemical affinity assay |
US6251260B1 (en) | 1998-08-24 | 2001-06-26 | Therasense, Inc. | Potentiometric sensors for analytic determination |
US6304766B1 (en) | 1998-08-26 | 2001-10-16 | Sensors For Medicine And Science | Optical-based sensing devices, especially for in-situ sensing in humans |
ES2306525T3 (en) | 1998-08-26 | 2008-11-01 | Sensors For Medicine And Science, Inc. | OPTICAL-BASED DETECTION DEVICES. |
US6266645B1 (en) | 1998-09-01 | 2001-07-24 | Imetrikus, Inc. | Risk adjustment tools for analyzing patient electronic discharge records |
US6464848B1 (en) | 1998-09-03 | 2002-10-15 | Nec Corporation | Reference electrode, a biosensor and a measuring apparatus therewith |
US6602678B2 (en) | 1998-09-04 | 2003-08-05 | Powderject Research Limited | Non- or minimally invasive monitoring methods |
CA2342801A1 (en) | 1998-09-04 | 2000-03-16 | Powderject Research Limited | Monitoring methods using particle delivery methods |
US6918874B1 (en) | 1998-09-10 | 2005-07-19 | Spectrx, Inc. | Attribute compensation for analyte detection and/or continuous monitoring |
WO2000013580A1 (en) | 1998-09-11 | 2000-03-16 | Amira Medical | Device for determination of an analyte in a body fluid intergrated with an insulin pump |
KR20000019716A (en) | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising bioflavonoid compounds for descending blood sugar |
ATE254877T1 (en) | 1998-09-17 | 2003-12-15 | Cygnus Therapeutic Systems | DEVICE FOR PRESSING A GEL/SENSOR UNIT |
US6853854B1 (en) | 1998-09-18 | 2005-02-08 | Q Step Technologies, Llc | Noninvasive measurement system |
US6254586B1 (en) | 1998-09-25 | 2001-07-03 | Minimed Inc. | Method and kit for supplying a fluid to a subcutaneous placement site |
US5951521A (en) | 1998-09-25 | 1999-09-14 | Minimed Inc. | Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site |
WO2000018294A1 (en) | 1998-09-30 | 2000-04-06 | Sicel Medical Group | Methods, systems, and associated implantable devices for dynamic monitoring of tumors |
US6180416B1 (en) | 1998-09-30 | 2001-01-30 | Cygnus, Inc. | Method and device for predicting physiological values |
DE69908602T2 (en) | 1998-09-30 | 2004-06-03 | Cygnus, Inc., Redwood City | METHOD AND DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENTS |
US6201980B1 (en) | 1998-10-05 | 2001-03-13 | The Regents Of The University Of California | Implantable medical sensor system |
WO2000019887A1 (en) | 1998-10-08 | 2000-04-13 | Minimed Inc. | Telemetered characteristic monitor system |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6391643B1 (en) | 1998-10-28 | 2002-05-21 | Cygnus, Inc. | Kit and method for quality control testing of an iontophoretic sampling system |
US6248093B1 (en) | 1998-10-29 | 2001-06-19 | Minimed Inc. | Compact pump drive system |
US6602469B1 (en) | 1998-11-09 | 2003-08-05 | Lifestream Technologies, Inc. | Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system |
US6497729B1 (en) | 1998-11-20 | 2002-12-24 | The University Of Connecticut | Implant coating for control of tissue/implant interactions |
US6377894B1 (en) | 1998-11-30 | 2002-04-23 | Abbott Laboratories | Analyte test instrument having improved calibration and communication processes |
JP4243435B2 (en) | 1998-11-30 | 2009-03-25 | ノボ ノルディスク アクティーゼルスカブ | Medical system for use by a patient for medical self-treatment and method for controlling the system |
US6161095A (en) | 1998-12-16 | 2000-12-12 | Health Hero Network, Inc. | Treatment regimen compliance and efficacy with feedback |
JP2002531194A (en) | 1998-12-02 | 2002-09-24 | ユーティー−バトル,エルエルシー | In vivo biosensor device and method of use |
US6329929B1 (en) | 1998-12-21 | 2001-12-11 | Medtronic Inc. | Telemetry system with phase-locking noise suppressing receiver |
US7436511B2 (en) * | 1999-01-22 | 2008-10-14 | Sensys Medical, Inc. | Analyte filter method and apparatus |
WO2000045897A1 (en) | 1999-02-03 | 2000-08-10 | Synergy Innovations, Inc. | In-bed exercise machine and method of use |
EP1135052A1 (en) | 1999-02-12 | 2001-09-26 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
JP2002537031A (en) | 1999-02-18 | 2002-11-05 | バイオバルブ テクノロジーズ インコーポレイテッド | Electroactive pores |
US6283943B1 (en) | 1999-02-19 | 2001-09-04 | Minimed Inc. | Negative pressure pump |
US6280416B1 (en) | 1999-02-19 | 2001-08-28 | Minimed Inc. | Constant flow medication infusion pump |
JP4801839B2 (en) | 1999-02-25 | 2011-10-26 | メドトロニック ミニメド インコーポレイテッド | Test plug and cable for glucose monitor |
US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
TW537880B (en) | 1999-03-11 | 2003-06-21 | Remote Medical Corp | Method for improving patient compliance with a medical program |
US20010049096A1 (en) | 1999-03-23 | 2001-12-06 | Stephen J. Brown | Sample identification with analyte determination |
US6704587B1 (en) | 1999-04-01 | 2004-03-09 | Spectrx, Inc. | Dual function assay device |
GB9907815D0 (en) | 1999-04-06 | 1999-06-02 | Univ Cambridge Tech | Implantable sensor |
US6285897B1 (en) | 1999-04-07 | 2001-09-04 | Endonetics, Inc. | Remote physiological monitoring system |
US6336900B1 (en) | 1999-04-12 | 2002-01-08 | Agilent Technologies, Inc. | Home hub for reporting patient health parameters |
US6494829B1 (en) | 1999-04-15 | 2002-12-17 | Nexan Limited | Physiological sensor array |
US6416471B1 (en) | 1999-04-15 | 2002-07-09 | Nexan Limited | Portable remote patient telemonitoring system |
US6200265B1 (en) | 1999-04-16 | 2001-03-13 | Medtronic, Inc. | Peripheral memory patch and access method for use with an implantable medical device |
CA2369336A1 (en) | 1999-04-22 | 2000-11-02 | Cygnus, Inc. | Hydrogel in an iontophoretic device to measure glucose |
US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6475750B1 (en) | 1999-05-11 | 2002-11-05 | M-Biotech, Inc. | Glucose biosensor |
US6835553B2 (en) | 1999-05-11 | 2004-12-28 | M-Biotech, Inc. | Photometric glucose measurement system using glucose-sensitive hydrogel |
US6858403B2 (en) | 1999-05-11 | 2005-02-22 | M-Biotech, Inc. | Polymer matrix containing catalase co-immobilized with analytic enzyme that generates hydrogen peroxide |
US6359444B1 (en) * | 1999-05-28 | 2002-03-19 | University Of Kentucky Research Foundation | Remote resonant-circuit analyte sensing apparatus with sensing structure and associated method of sensing |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
US6193873B1 (en) | 1999-06-15 | 2001-02-27 | Lifescan, Inc. | Sample detection to initiate timing of an electrochemical assay |
WO2000078210A1 (en) | 1999-06-17 | 2000-12-28 | Minimed Inc. | Characteristic monitor system for use with analyte sensor |
US6259587B1 (en) | 1999-06-17 | 2001-07-10 | Minimed Inc. | Direct current motor safety circuits for fluid delivery systems |
US6423035B1 (en) | 1999-06-18 | 2002-07-23 | Animas Corporation | Infusion pump with a sealed drive mechanism and improved method of occlusion detection |
JP4801301B2 (en) | 1999-06-18 | 2011-10-26 | アボット ダイアベティス ケア インコーポレイテッド | In vivo analyte sensor with limited mass transfer |
US6907127B1 (en) | 1999-06-18 | 2005-06-14 | Digital Video Express, L.P. | Hierarchical key management encoding and decoding |
US6368274B1 (en) | 1999-07-01 | 2002-04-09 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
US6252032B1 (en) | 1999-07-07 | 2001-06-26 | Minimed Inc. | UV absorbing polymer |
US6413393B1 (en) | 1999-07-07 | 2002-07-02 | Minimed, Inc. | Sensor including UV-absorbing polymer and method of manufacture |
DE19935165A1 (en) | 1999-07-28 | 2001-02-01 | Roche Diagnostics Gmbh | Method and arrangement for determining the concentration of glucose in a body fluid |
US6899684B2 (en) | 1999-08-02 | 2005-05-31 | Healthetech, Inc. | Method of respiratory gas analysis using a metabolic calorimeter |
US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
US6442637B1 (en) | 1999-08-12 | 2002-08-27 | Handspring, Inc. | Expandable mobile computer system |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6923763B1 (en) | 1999-08-23 | 2005-08-02 | University Of Virginia Patent Foundation | Method and apparatus for predicting the risk of hypoglycemia |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US7133717B2 (en) | 1999-08-25 | 2006-11-07 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery and diagnostic sampling |
US6239925B1 (en) | 1999-09-03 | 2001-05-29 | Key Plastics, Inc. | Instrument cluster lens assembly and method of making |
US6366793B1 (en) | 1999-09-10 | 2002-04-02 | Beckman Coulter, Inc. | Minimally invasive methods for measuring analtes in vivo |
US6343225B1 (en) | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
US6682938B1 (en) | 1999-09-15 | 2004-01-27 | The Regents Of The University Of California | Glucose sensing molecules having selected fluorescent properties |
US6673625B2 (en) | 1999-09-15 | 2004-01-06 | The Regents Of The University Of California | Saccharide sensing molecules having enhanced fluorescent properties |
AT408182B (en) | 1999-09-17 | 2001-09-25 | Schaupp Lukas Dipl Ing Dr Tech | DEVICE FOR VIVO MEASURING SIZES IN LIVING ORGANISMS |
WO2001028416A1 (en) | 1999-09-24 | 2001-04-26 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
AU7718500A (en) | 1999-09-28 | 2001-04-30 | Imetrikus, Inc. | Internet brokering service based upon individual health profiles |
US6478736B1 (en) | 1999-10-08 | 2002-11-12 | Healthetech, Inc. | Integrated calorie management system |
US7317938B2 (en) | 1999-10-08 | 2008-01-08 | Sensys Medical, Inc. | Method of adapting in-vitro models to aid in noninvasive glucose determination |
US20020062069A1 (en) | 1999-10-08 | 2002-05-23 | Mault James R. | System and method of integrated calorie management using interactive television |
US20020107433A1 (en) | 1999-10-08 | 2002-08-08 | Mault James R. | System and method of personal fitness training using interactive television |
CA2386811A1 (en) | 1999-10-08 | 2001-04-19 | Healthetech, Inc. | Monitoring caloric expenditure rate and caloric diet |
US6612306B1 (en) | 1999-10-13 | 2003-09-02 | Healthetech, Inc. | Respiratory nitric oxide meter |
US7039810B1 (en) | 1999-11-02 | 2006-05-02 | Medtronic, Inc. | Method and apparatus to secure data transfer from medical device systems |
US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
US6253804B1 (en) | 1999-11-05 | 2001-07-03 | Minimed Inc. | Needle safe transfer guard |
AU1607801A (en) | 1999-11-15 | 2001-05-30 | Therasense, Inc. | Transition metal complexes with bidentate ligand having an imidazole ring |
US6658396B1 (en) | 1999-11-29 | 2003-12-02 | Tang Sharon S | Neural network drug dosage estimation |
US6602191B2 (en) | 1999-12-17 | 2003-08-05 | Q-Tec Systems Llp | Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity |
DE19962342A1 (en) | 1999-12-23 | 2001-07-12 | Henkel Ecolab Gmbh & Co Ohg | Peracids with good adhesion to surfaces |
DE19962343A1 (en) | 1999-12-23 | 2001-07-05 | Henkel Ecolab Gmbh & Co Ohg | Disinfectant washing of delicate textiles with peracids |
US6295463B1 (en) | 2000-01-04 | 2001-09-25 | Sensormedics Corporation | Skin protection mount for transcutaneous sensor application |
US6513532B2 (en) | 2000-01-19 | 2003-02-04 | Healthetech, Inc. | Diet and activity-monitoring device |
US6974437B2 (en) | 2000-01-21 | 2005-12-13 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
US6383767B1 (en) | 2000-01-21 | 2002-05-07 | Motorola, Inc. | Luminescent in vivo glucose measurement |
ATE552869T1 (en) | 2000-01-21 | 2012-04-15 | Medtronic Minimed Inc | MICROPROCESSOR-CONTROLLED, AMBULATORY MEDICAL DEVICE WITH HAND-HOLD COMMUNICATION DEVICE |
US7369635B2 (en) | 2000-01-21 | 2008-05-06 | Medtronic Minimed, Inc. | Rapid discrimination preambles and methods for using the same |
WO2001052935A1 (en) | 2000-01-21 | 2001-07-26 | Medical Research Group, Inc. | Ambulatory medical apparatus and method having telemetry modifiable control software |
US6734162B2 (en) | 2000-01-24 | 2004-05-11 | Minimed Inc. | Mixed buffer system for stabilizing polypeptide formulations |
US6485923B1 (en) | 2000-02-02 | 2002-11-26 | Lifescan, Inc. | Reagent test strip for analyte determination having hemolyzing agent |
US6716577B1 (en) | 2000-02-02 | 2004-04-06 | Lifescan, Inc. | Electrochemical test strip for use in analyte determination |
US6629934B2 (en) | 2000-02-02 | 2003-10-07 | Healthetech, Inc. | Indirect calorimeter for medical applications |
US20010037060A1 (en) | 2000-02-08 | 2001-11-01 | Thompson Richard P. | Web site for glucose monitoring |
US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US6484045B1 (en) | 2000-02-10 | 2002-11-19 | Medtronic Minimed, Inc. | Analyte sensor and method of making the same |
US20030060765A1 (en) | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
WO2001060448A1 (en) | 2000-02-18 | 2001-08-23 | University Of Utah Research Foundation | Methods for extracting substances using alternating current |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7890295B2 (en) * | 2000-02-23 | 2011-02-15 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6706159B2 (en) | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
FR2806156B1 (en) | 2000-03-07 | 2002-05-31 | Ciat Sa | PLATE HEAT EXCHANGER |
US20010039504A1 (en) | 2000-03-15 | 2001-11-08 | Linberg Kurt R. | Individualized, integrated and informative internet portal for holistic management of patients with implantable devices |
US6405066B1 (en) | 2000-03-17 | 2002-06-11 | The Regents Of The University Of California | Implantable analyte sensor |
DZ3338A1 (en) | 2000-03-29 | 2001-10-04 | Univ Virginia | METHOD, SYSTEM AND COMPUTER PROGRAM FOR EVALUATING GLYCEMIC REGULATION OF DIABETES FROM AUTOMATICALLY CONTROLLED DATA |
US6610012B2 (en) | 2000-04-10 | 2003-08-26 | Healthetech, Inc. | System and method for remote pregnancy monitoring |
US6587995B1 (en) | 2000-04-19 | 2003-07-01 | Koninklijke Philips Electronics N.V. | Enhanced programmable core model with integrated graphical debugging functionality |
US6440068B1 (en) | 2000-04-28 | 2002-08-27 | International Business Machines Corporation | Measuring user health as measured by multiple diverse health measurement devices utilizing a personal storage device |
IT1314759B1 (en) | 2000-05-08 | 2003-01-03 | Menarini Farma Ind | INSTRUMENTATION FOR MEASUREMENT AND CONTROL OF THE CONTENT OF GLUCOSIOLACTATE OR OTHER METABOLITES IN BIOLOGICAL FLUIDS |
AU2001263022A1 (en) | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
US7769420B2 (en) * | 2000-05-15 | 2010-08-03 | Silver James H | Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US6340421B1 (en) | 2000-05-16 | 2002-01-22 | Minimed Inc. | Microelectrogravimetric method for plating a biosensor |
US6885883B2 (en) | 2000-05-16 | 2005-04-26 | Cygnus, Inc. | Methods for improving performance and reliability of biosensors |
US6482158B2 (en) | 2000-05-19 | 2002-11-19 | Healthetech, Inc. | System and method of ultrasonic mammography |
EP1283689A4 (en) | 2000-05-25 | 2005-03-09 | Healthetech Inc | Weight control method using physical activity based parameters |
EP1284642A4 (en) | 2000-05-25 | 2005-03-09 | Healthetech Inc | Physiological monitoring using wrist-mounted device |
AU2001260710A1 (en) | 2000-06-02 | 2001-12-11 | Arkray, Inc. | Measurement device, and measured data transmitting method |
WO2001093743A2 (en) | 2000-06-07 | 2001-12-13 | Healthetech, Inc. | Breath ketone analyzer |
WO2001096024A2 (en) | 2000-06-14 | 2001-12-20 | Board Of Regents, The University Of Texas System | Apparatus and method for fluid injection |
US7261690B2 (en) | 2000-06-16 | 2007-08-28 | Bodymedia, Inc. | Apparatus for monitoring health, wellness and fitness |
US20020016719A1 (en) | 2000-06-19 | 2002-02-07 | Nemeth Louis G. | Methods and systems for providing medical data to a third party in accordance with configurable distribution parameters |
US6699188B2 (en) | 2000-06-22 | 2004-03-02 | Guidance Interactive Technologies | Interactive reward devices and methods |
US6494830B1 (en) | 2000-06-22 | 2002-12-17 | Guidance Interactive Technologies, Inc. | Handheld controller for monitoring/using medical parameters |
US6540675B2 (en) | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
WO2002012251A1 (en) | 2000-08-04 | 2002-02-14 | Sensors For Medicine And Science, Inc. | Detection of analytes in aqueous environments |
DE10038835B4 (en) | 2000-08-04 | 2005-07-07 | Roche Diagnostics Gmbh | Microdialysis system |
JP2002055076A (en) | 2000-09-08 | 2002-02-20 | Nec Corp | Electrochemical sensor |
WO2002017210A2 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
WO2002015777A1 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Methods and devices for prediction of hypoglycemic events |
US6553244B2 (en) | 2000-08-18 | 2003-04-22 | Cygnus, Inc. | Analyte monitoring device alarm augmentation system |
US6675030B2 (en) * | 2000-08-21 | 2004-01-06 | Euro-Celtique, S.A. | Near infrared blood glucose monitoring system |
US20020026937A1 (en) | 2000-08-28 | 2002-03-07 | Mault James R. | Respiratory gas sensors in folw path |
US20020026111A1 (en) | 2000-08-28 | 2002-02-28 | Neil Ackerman | Methods of monitoring glucose levels in a subject and uses thereof |
US6741876B1 (en) | 2000-08-31 | 2004-05-25 | Cme Telemetrix Inc. | Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths |
US20020047867A1 (en) | 2000-09-07 | 2002-04-25 | Mault James R | Image based diet logging |
US20020124017A1 (en) | 2000-09-22 | 2002-09-05 | Mault James R. | Personal digital assistant with food scale accessory |
AU2001291189A1 (en) | 2000-09-22 | 2002-04-02 | Knobbe, Lim And Buckingham | Method and apparatus for real-time estimation and control of pysiological parameters |
US20020103425A1 (en) | 2000-09-27 | 2002-08-01 | Mault James R. | self-contained monitoring device particularly useful for monitoring physiological conditions |
IL138788A0 (en) | 2000-09-29 | 2001-10-31 | Falk Fish | Method and kit for the transdermal determination of analyte concentration in blood |
AU2001296456A1 (en) | 2000-09-29 | 2002-04-08 | Healthetech, Inc. | Indirect calorimetry system |
AU9658801A (en) | 2000-10-04 | 2002-04-15 | Insulet Corp | Data collection assembly for patient infusion system |
US6537243B1 (en) | 2000-10-12 | 2003-03-25 | Abbott Laboratories | Device and method for obtaining interstitial fluid from a patient for diagnostic tests |
US20020133378A1 (en) | 2000-10-13 | 2002-09-19 | Mault James R. | System and method of integrated calorie management |
WO2002047465A2 (en) | 2000-10-26 | 2002-06-20 | Healthetech, Inc. | Body supported activity and condition monitor |
TW537878B (en) | 2000-10-31 | 2003-06-21 | Trustmed Com Corp | Method for recording, tracking and analyzing blood sugar level, and device thereof |
US6695860B1 (en) | 2000-11-13 | 2004-02-24 | Isense Corp. | Transcutaneous sensor insertion device |
US20020083461A1 (en) | 2000-11-22 | 2002-06-27 | Hutcheson Stewart Douglas | Method and system for providing interactive services over a wireless communications network |
WO2002043590A1 (en) | 2000-11-30 | 2002-06-06 | Arkray, Inc. | Measuring device equipped with comment input function |
US6574510B2 (en) | 2000-11-30 | 2003-06-03 | Cardiac Pacemakers, Inc. | Telemetry apparatus and method for an implantable medical device |
US6645142B2 (en) | 2000-12-01 | 2003-11-11 | Optiscan Biomedical Corporation | Glucose monitoring instrument having network connectivity |
JP2002174610A (en) | 2000-12-08 | 2002-06-21 | Nec Corp | Biosensor and liquid sample measurement method using biosensor |
US20020077766A1 (en) | 2000-12-11 | 2002-06-20 | Mault James R. | Remote temperature monitoring system |
US7052483B2 (en) | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
GB0030929D0 (en) | 2000-12-19 | 2001-01-31 | Inverness Medical Ltd | Analyte measurement |
US20020147135A1 (en) | 2000-12-21 | 2002-10-10 | Oliver Schnell | Method and device for producing an adapted travel treatment plan for administering a medicine in the event of a long-haul journey |
DE60115707T2 (en) | 2000-12-21 | 2006-08-10 | Insulet Corp., Beverly | REMOTE CONTROL MEDICAL DEVICE |
US6642015B2 (en) | 2000-12-29 | 2003-11-04 | Minimed Inc. | Hydrophilic polymeric material for coating biosensors |
US6512986B1 (en) | 2000-12-30 | 2003-01-28 | Lifescan, Inc. | Method for automated exception-based quality control compliance for point-of-care devices |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6800451B2 (en) | 2001-01-05 | 2004-10-05 | Sensors For Medicine And Science, Inc. | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
US6627058B1 (en) | 2001-01-17 | 2003-09-30 | E. I. Du Pont De Nemours And Company | Thick film conductor composition for use in biosensors |
US6529752B2 (en) | 2001-01-17 | 2003-03-04 | David T. Krausman | Sleep disorder breathing event counter |
BR0206604A (en) | 2001-01-22 | 2004-02-17 | Hoffmann La Roche | Lancet device that has capillary action |
US6723046B2 (en) | 2001-01-29 | 2004-04-20 | Cybernet Systems Corporation | At-home health data management method and apparatus |
US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
US6927246B2 (en) | 2001-02-15 | 2005-08-09 | Medtronic Minimed, Inc. | Polymers functionalized with fluorescent boronate motifs and methods for making them |
AU2002248464A1 (en) | 2001-02-21 | 2002-09-12 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
CA2434731C (en) | 2001-02-22 | 2010-01-26 | Insulet Corporation | Modular infusion device and method |
WO2002073503A2 (en) * | 2001-03-14 | 2002-09-19 | Baxter International Inc. | Internet based therapy management system |
AU2002247321A1 (en) | 2001-03-14 | 2002-09-24 | Vitaltrak Technology, Inc. | Tracking device |
US6968294B2 (en) | 2001-03-15 | 2005-11-22 | Koninklijke Philips Electronics N.V. | Automatic system for monitoring person requiring care and his/her caretaker |
US6952603B2 (en) | 2001-03-16 | 2005-10-04 | Roche Diagnostics Operations, Inc. | Subcutaneous analyte sensor |
US6622045B2 (en) | 2001-03-29 | 2003-09-16 | Pacesetter, Inc. | System and method for remote programming of implantable cardiac stimulation devices |
US6595929B2 (en) | 2001-03-30 | 2003-07-22 | Bodymedia, Inc. | System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6454710B1 (en) | 2001-04-11 | 2002-09-24 | Motorola, Inc. | Devices and methods for monitoring an analyte |
US6983176B2 (en) * | 2001-04-11 | 2006-01-03 | Rio Grande Medical Technologies, Inc. | Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy |
US6694158B2 (en) | 2001-04-11 | 2004-02-17 | Motorola, Inc. | System using a portable detection device for detection of an analyte through body tissue |
US6574490B2 (en) | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
GR1003802B (en) * | 2001-04-17 | 2002-02-08 | Micrel �.�.�. ������� ��������� ��������������� ��������� | Tele-medicine system |
US20030208409A1 (en) | 2001-04-30 | 2003-11-06 | Mault James R. | Method and apparatus for diet control |
US6676816B2 (en) * | 2001-05-11 | 2004-01-13 | Therasense, Inc. | Transition metal complexes with (pyridyl)imidazole ligands and sensors using said complexes |
US7395214B2 (en) | 2001-05-11 | 2008-07-01 | Craig P Shillingburg | Apparatus, device and method for prescribing, administering and monitoring a treatment regimen for a patient |
US6932894B2 (en) * | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
DE60214375T2 (en) | 2001-05-18 | 2007-08-30 | Polymer Technology Systems, Inc., Indianapolis | DEVICE FOR EXAMINING BODY FLUIDS WITH SOLVENTLY FIXED, PORTABLE TEST DEVICE |
US6549796B2 (en) | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
JP4836354B2 (en) | 2001-06-05 | 2011-12-14 | アークレイ株式会社 | Data communication adapter |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US7179226B2 (en) | 2001-06-21 | 2007-02-20 | Animas Corporation | System and method for managing diabetes |
EP1403795A4 (en) | 2001-06-22 | 2007-08-01 | Arkray Inc | Information communication system |
WO2003000127A2 (en) | 2001-06-22 | 2003-01-03 | Cygnus, Inc. | Method for improving the performance of an analyte monitoring system |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US20030040683A1 (en) | 2001-07-06 | 2003-02-27 | Peter Rule | Site selection for determining analyte concentration in living tissue |
US20030032868A1 (en) | 2001-07-09 | 2003-02-13 | Henning Graskov | Method and system for controlling data information between two portable apparatuses |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US6754516B2 (en) | 2001-07-19 | 2004-06-22 | Nellcor Puritan Bennett Incorporated | Nuisance alarm reductions in a physiological monitor |
US20030023182A1 (en) | 2001-07-26 | 2003-01-30 | Mault James R. | Respiratory connector for respiratory gas analysis |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
WO2003014735A1 (en) | 2001-08-03 | 2003-02-20 | General Hospital Corporation | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
JP3775263B2 (en) | 2001-08-10 | 2006-05-17 | ニプロ株式会社 | Recording medium and blood glucose measurement system using the recording medium |
US20030036927A1 (en) * | 2001-08-20 | 2003-02-20 | Bowen Susan W. | Healthcare information search system and user interface |
EP1320322A1 (en) | 2001-08-20 | 2003-06-25 | Inverness Medical Limited | Wireless diabetes management devices and methods for using the same |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US6740072B2 (en) * | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6915147B2 (en) | 2001-09-07 | 2005-07-05 | Medtronic Minimed, Inc. | Sensing apparatus and process |
US6671554B2 (en) | 2001-09-07 | 2003-12-30 | Medtronic Minimed, Inc. | Electronic lead for a medical implant device, method of making same, and method and apparatus for inserting same |
US7052591B2 (en) | 2001-09-21 | 2006-05-30 | Therasense, Inc. | Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking |
US6830562B2 (en) | 2001-09-27 | 2004-12-14 | Unomedical A/S | Injector device for placing a subcutaneous infusion set |
WO2003030731A2 (en) | 2001-10-09 | 2003-04-17 | Optiscan Biomedical Corporation | Method and apparatus for improving clinical accuracy of analyte measurements |
US7854230B2 (en) | 2001-10-22 | 2010-12-21 | O.R. Solutions, Inc. | Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray |
US6809507B2 (en) | 2001-10-23 | 2004-10-26 | Medtronic Minimed, Inc. | Implantable sensor electrodes and electronic circuitry |
CN1267867C (en) | 2001-10-23 | 2006-08-02 | 西铁城时计株式会社 | Data collection system |
US6923936B2 (en) | 2001-10-23 | 2005-08-02 | Medtronic Minimed, Inc. | Sterile device and method for producing same |
US20030175806A1 (en) | 2001-11-21 | 2003-09-18 | Peter Rule | Method and apparatus for improving the accuracy of alternative site analyte concentration measurements |
US20030105407A1 (en) | 2001-11-30 | 2003-06-05 | Pearce, Edwin M. | Disposable flow tube for respiratory gas analysis |
WO2003049609A1 (en) | 2001-12-07 | 2003-06-19 | Micronix, Inc. | Consolidated body fluid testing device and method |
US6957102B2 (en) | 2001-12-10 | 2005-10-18 | Medtronic Emergency Response Systems, Inc. | Enhanced interface for a medical device and a terminal |
TWI293363B (en) | 2001-12-11 | 2008-02-11 | Sensors For Med & Science Inc | High performance fluorescent optical sensor |
US7018568B2 (en) | 2001-12-20 | 2006-03-28 | Animas Technologies Llc | Highly catalytic screen-printing ink |
US7022072B2 (en) | 2001-12-27 | 2006-04-04 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
US7524309B2 (en) | 2001-12-28 | 2009-04-28 | Medtronic Minimed, Inc. | Variable length flexible conduit feeder |
US6602909B1 (en) | 2002-01-23 | 2003-08-05 | Charles Ignatius Jarowski | Selected essential amino acid supplementation of dietary proteins to lower urinary urea and peak glucose levels |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20030212379A1 (en) | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
EP1487519B1 (en) | 2002-02-26 | 2013-06-12 | TecPharma Licensing AG | Insertion device for an insertion set and method of using the same |
US6744350B2 (en) | 2002-02-28 | 2004-06-01 | Smiths Medical Md, Inc. | Insulin pump having missed meal bolus alarm |
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
US7468032B2 (en) | 2002-12-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Advanced patient management for identifying, displaying and assisting with correlating health-related data |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
EP1499231A4 (en) | 2002-03-08 | 2007-09-26 | Sensys Medical Inc | Compact apparatus for noninvasive measurement of glucose through near-infrared spectroscopy |
US6957107B2 (en) | 2002-03-13 | 2005-10-18 | Cardionet, Inc. | Method and apparatus for monitoring and communicating with an implanted medical device |
DE60334365D1 (en) | 2002-03-22 | 2010-11-11 | Animas Technologies Llc | INCREASED PERFORMANCE OF AN ANALYSIS MONITORING DEVICE |
US6936006B2 (en) | 2002-03-22 | 2005-08-30 | Novo Nordisk, A/S | Atraumatic insertion of a subcutaneous device |
GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
US7027848B2 (en) | 2002-04-04 | 2006-04-11 | Inlight Solutions, Inc. | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte |
US7563232B2 (en) | 2002-04-19 | 2009-07-21 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7052251B2 (en) | 2002-04-22 | 2006-05-30 | Medtronic Minimed, Inc. | Shape memory alloy wire driven positive displacement micropump with pulsatile output |
US20030232370A1 (en) | 2002-04-22 | 2003-12-18 | Trifiro Mark A. | Glucose sensor and uses thereof |
JP2004000555A (en) | 2002-04-25 | 2004-01-08 | Matsushita Electric Ind Co Ltd | Dosage determination support device, syringe, and health care support system |
US6902207B2 (en) | 2002-05-01 | 2005-06-07 | Medtronic Minimed, Inc. | Self sealing disconnect device |
US7015817B2 (en) * | 2002-05-14 | 2006-03-21 | Shuan Michael Copley | Personal tracking device |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US6865407B2 (en) | 2002-07-11 | 2005-03-08 | Optical Sensors, Inc. | Calibration technique for non-invasive medical devices |
US20040010207A1 (en) | 2002-07-15 | 2004-01-15 | Flaherty J. Christopher | Self-contained, automatic transcutaneous physiologic sensing system |
AU2003302720B9 (en) | 2002-07-19 | 2008-08-21 | Smiths Detection-Pasadena, Inc. | Non-specific sensor array detectors |
US8512276B2 (en) | 2002-07-24 | 2013-08-20 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
JPWO2004014228A1 (en) | 2002-08-09 | 2005-11-24 | 松下電器産業株式会社 | Data measuring apparatus, healthcare data acquisition system, and healthcare data acquisition method |
WO2004015539A2 (en) | 2002-08-13 | 2004-02-19 | University Of Virginia Patent Foundation | Managing and processing self-monitoring blood glucose |
US7150975B2 (en) | 2002-08-19 | 2006-12-19 | Animas Technologies, Llc | Hydrogel composition for measuring glucose flux |
US20050118726A1 (en) | 2002-08-26 | 2005-06-02 | Schultz Jerome S. | System and method for detecting bioanalytes and method for producing a bioanalyte sensor |
US20080052317A1 (en) | 2002-08-27 | 2008-02-28 | Francis Katharine R | Medication dose calculator and associated methods |
ES2384558T3 (en) | 2002-09-11 | 2012-07-06 | Becton Dickinson And Company | Blood glucose monitoring including convenient visual presentation of averages and measurement values |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US6991096B2 (en) | 2002-09-27 | 2006-01-31 | Medtronic Minimed, Inc. | Packaging system |
US20040122530A1 (en) | 2002-09-30 | 2004-06-24 | Steffen Hansen | Indicating device with estimating feature |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
US7192405B2 (en) | 2002-09-30 | 2007-03-20 | Becton, Dickinson And Company | Integrated lancet and bodily fluid sensor |
JP4263568B2 (en) | 2002-10-07 | 2009-05-13 | 理想科学工業株式会社 | Stencil printing machine |
JP4599296B2 (en) | 2002-10-11 | 2010-12-15 | ベクトン・ディキンソン・アンド・カンパニー | System and method for initiating and maintaining continuous long-term control of the concentration of a substance in a patient's body using a feedback or model-based controller coupled to a single needle or multi-needle intradermal (ID) delivery device |
US7079977B2 (en) | 2002-10-15 | 2006-07-18 | Medtronic, Inc. | Synchronization and calibration of clocks for a medical device and calibrated clock |
US20040108226A1 (en) | 2002-10-28 | 2004-06-10 | Constantin Polychronakos | Continuous glucose quantification device and method |
US7233817B2 (en) | 2002-11-01 | 2007-06-19 | Brian Yen | Apparatus and method for pattern delivery of radiation and biological characteristic analysis |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7572237B2 (en) | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
GB0226648D0 (en) | 2002-11-15 | 2002-12-24 | Koninkl Philips Electronics Nv | Usage data harvesting |
US7052472B1 (en) | 2002-12-18 | 2006-05-30 | Dsp Diabetes Sentry Products, Inc. | Systems and methods for detecting symptoms of hypoglycemia |
US20040122353A1 (en) | 2002-12-19 | 2004-06-24 | Medtronic Minimed, Inc. | Relay device for transferring information between a sensor system and a fluid delivery system |
US20050038680A1 (en) | 2002-12-19 | 2005-02-17 | Mcmahon Kevin Lee | System and method for glucose monitoring |
US7395117B2 (en) | 2002-12-23 | 2008-07-01 | Cardiac Pacemakers, Inc. | Implantable medical device having long-term wireless capabilities |
US6978182B2 (en) | 2002-12-27 | 2005-12-20 | Cardiac Pacemakers, Inc. | Advanced patient management system including interrogator/transceiver unit |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US7396330B2 (en) | 2003-01-07 | 2008-07-08 | Triage Data Networks | Wireless, internet-based medical-diagnostic system |
US7018366B2 (en) | 2003-01-17 | 2006-03-28 | William Craig Easter | Vacuum assisted relief system (VARS) |
US20040172284A1 (en) | 2003-02-13 | 2004-09-02 | Roche Diagnostics Corporation | Information management system |
US20040164961A1 (en) | 2003-02-21 | 2004-08-26 | Debasis Bal | Method, system and computer product for continuously monitoring data sources for an event of interest |
US9872890B2 (en) | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
WO2004088304A2 (en) | 2003-04-01 | 2004-10-14 | Piet Moerman | Method and device for utilizing analyte levels to assist in the treatment of diabetes, insulin resistance and metabolic syndrome |
US20040199056A1 (en) | 2003-04-03 | 2004-10-07 | International Business Machines Corporation | Body monitoring using local area wireless interfaces |
US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US20050038674A1 (en) | 2003-04-15 | 2005-02-17 | Braig James R. | System and method for managing a chronic medical condition |
JP2007525241A (en) | 2003-04-18 | 2007-09-06 | インシュレット コーポレイション | User interface for infusion pump remote control and method of use thereof |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
US20040249250A1 (en) | 2003-06-04 | 2004-12-09 | Mcgee Michael D. | System and apparatus for monitoring and prompting medical self-care events and communicating medical self-care status |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US20050016276A1 (en) | 2003-06-06 | 2005-01-27 | Palo Alto Sensor Technology Innovation | Frequency encoding of resonant mass sensors |
US20040253736A1 (en) | 2003-06-06 | 2004-12-16 | Phil Stout | Analytical device with prediction module and related methods |
US20040249254A1 (en) | 2003-06-06 | 2004-12-09 | Joel Racchini | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US20040254429A1 (en) | 2003-06-11 | 2004-12-16 | Health & Life Co., Ltd. | Data storage device for integrating data of several medical measuring instruments |
US20040254433A1 (en) | 2003-06-12 | 2004-12-16 | Bandis Steven D. | Sensor introducer system, apparatus and method |
US7155290B2 (en) | 2003-06-23 | 2006-12-26 | Cardiac Pacemakers, Inc. | Secure long-range telemetry for implantable medical device |
US7510564B2 (en) | 2003-06-27 | 2009-03-31 | Abbott Diabetes Care Inc. | Lancing device |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US7366556B2 (en) * | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
JP2007500336A (en) | 2003-07-25 | 2007-01-11 | デックスコム・インコーポレーテッド | Electrode system for electrochemical sensors |
US20070173709A1 (en) | 2005-04-08 | 2007-07-26 | Petisce James R | Membranes for an analyte sensor |
US20050176136A1 (en) | 2003-11-19 | 2005-08-11 | Dexcom, Inc. | Afinity domain for analyte sensor |
US7467003B2 (en) | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7424318B2 (en) | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7761130B2 (en) * | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7651596B2 (en) | 2005-04-08 | 2010-01-26 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
US7108778B2 (en) | 2003-07-25 | 2006-09-19 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US7460898B2 (en) * | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7925321B2 (en) * | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7189341B2 (en) | 2003-08-15 | 2007-03-13 | Animas Technologies, Llc | Electrochemical sensor ink compositions, electrodes, and uses thereof |
US8346482B2 (en) | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8233959B2 (en) * | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US20050055474A1 (en) * | 2003-09-08 | 2005-03-10 | Chien-Hsin Yang | Monitor apparatus for computer system |
DE10343863A1 (en) | 2003-09-23 | 2005-04-14 | Roche Diagnostics Gmbh | Method and device for continuously monitoring the concentration of an analyte |
US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
WO2005041103A2 (en) | 2003-10-29 | 2005-05-06 | Novo Nordisk A/S | Medical advisory system |
US6928380B2 (en) | 2003-10-30 | 2005-08-09 | International Business Machines Corporation | Thermal measurements of electronic devices during operation |
US20050096516A1 (en) | 2003-10-30 | 2005-05-05 | Orhan Soykan | Optical detector of organic analyte |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US7496392B2 (en) | 2003-11-26 | 2009-02-24 | Becton, Dickinson And Company | Fiber optic device for sensing analytes |
US20050148003A1 (en) | 2003-11-26 | 2005-07-07 | Steven Keith | Methods of correcting a luminescence value, and methods of determining a corrected analyte concentration |
US7787923B2 (en) | 2003-11-26 | 2010-08-31 | Becton, Dickinson And Company | Fiber optic device for sensing analytes and method of making same |
US8364231B2 (en) * | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
US20080200788A1 (en) | 2006-10-04 | 2008-08-21 | Dexcorn, Inc. | Analyte sensor |
US20080197024A1 (en) | 2003-12-05 | 2008-08-21 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
DE602004029092D1 (en) | 2003-12-05 | 2010-10-21 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTIC SENSOR |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
ES2646312T3 (en) | 2003-12-08 | 2017-12-13 | Dexcom, Inc. | Systems and methods to improve electromechanical analyte sensors |
US20050137471A1 (en) | 2003-12-18 | 2005-06-23 | Hans-Peter Haar | Continuous glucose monitoring device |
US7384397B2 (en) | 2003-12-30 | 2008-06-10 | Medtronic Minimed, Inc. | System and method for sensor recalibration |
US20050182451A1 (en) | 2004-01-12 | 2005-08-18 | Adam Griffin | Implantable device with improved radio frequency capabilities |
US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
US7580812B2 (en) | 2004-01-28 | 2009-08-25 | Honeywell International Inc. | Trending system and method using window filtering |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
US7699964B2 (en) | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US7364592B2 (en) | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
JP3590053B1 (en) | 2004-02-24 | 2004-11-17 | 株式会社日立製作所 | Blood glucose measurement device |
RU2345705C2 (en) | 2004-02-26 | 2009-02-10 | Диабетес Тулз Сведен Аб | Metabolic control, method and device for obtaining indications about health-determining state of examined person |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
DE102004011135A1 (en) | 2004-03-08 | 2005-09-29 | Disetronic Licensing Ag | Method and apparatus for calculating a bolus amount |
US20050221504A1 (en) | 2004-04-01 | 2005-10-06 | Petruno Patrick T | Optoelectronic rapid diagnostic test system |
US6971274B2 (en) | 2004-04-02 | 2005-12-06 | Sierra Instruments, Inc. | Immersible thermal mass flow meter |
US7815569B2 (en) | 2004-04-21 | 2010-10-19 | University Of Virginia Patent Foundation | Method, system and computer program product for evaluating the accuracy of blood glucose monitoring sensors/devices |
US7324850B2 (en) * | 2004-04-29 | 2008-01-29 | Cardiac Pacemakers, Inc. | Method and apparatus for communication between a handheld programmer and an implantable medical device |
US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US8277713B2 (en) * | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US7651845B2 (en) * | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
US20050261660A1 (en) | 2004-05-24 | 2005-11-24 | Choi Soo B | Method for controlling insulin pump using Bluetooth protocol |
WO2005119555A2 (en) | 2004-06-01 | 2005-12-15 | Lifescan, Inc. | Methods and systems of automating medical device data management |
US7118667B2 (en) | 2004-06-02 | 2006-10-10 | Jin Po Lee | Biosensors having improved sample application and uses thereof |
US20060010098A1 (en) * | 2004-06-04 | 2006-01-12 | Goodnow Timothy T | Diabetes care host-client architecture and data management system |
US20060001538A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Methods of monitoring the concentration of an analyte |
US20060036187A1 (en) | 2004-06-30 | 2006-02-16 | Hester Vos | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US20060001551A1 (en) | 2004-06-30 | 2006-01-05 | Ulrich Kraft | Analyte monitoring system with wireless alarm |
MXPA06014896A (en) | 2004-07-01 | 2007-08-20 | Vivomedical Inc | Non-invasive glucose measurement. |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
WO2006127694A2 (en) * | 2004-07-13 | 2006-11-30 | Dexcom, Inc. | Analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) * | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20080242961A1 (en) | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US7261691B1 (en) | 2004-08-02 | 2007-08-28 | Kwabena Asomani | Personalized emergency medical monitoring and transmission system |
US8313433B2 (en) | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
US20060058602A1 (en) | 2004-08-17 | 2006-03-16 | Kwiatkowski Krzysztof C | Interstitial fluid analyzer |
CN101091114A (en) | 2004-08-31 | 2007-12-19 | 生命扫描苏格兰有限公司 | Method of manufacturing an auto-calibrating sensor |
EP1799101A4 (en) * | 2004-09-02 | 2008-11-19 | Proteus Biomedical Inc | Methods and apparatus for tissue activation and monitoring |
US8500054B2 (en) | 2004-09-27 | 2013-08-06 | Deka Products Limited Partnership | Infusion set improvements |
US20090118589A1 (en) | 2004-12-28 | 2009-05-07 | Hiromu Ueshima | Health management support system and recording medium |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US20090082693A1 (en) * | 2004-12-29 | 2009-03-26 | Therasense, Inc. | Method and apparatus for providing temperature sensor module in a data communication system |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US20070027381A1 (en) | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
US7502644B2 (en) * | 2005-01-25 | 2009-03-10 | Pacesetter, Inc. | System and method for distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device |
US7547281B2 (en) | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
US7499002B2 (en) * | 2005-02-08 | 2009-03-03 | International Business Machines Corporation | Retractable string interface for stationary and portable devices |
US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
KR100638727B1 (en) | 2005-02-28 | 2006-10-30 | 삼성전기주식회사 | Concurrent transceiver for zigbee and bluetooth |
US20090076360A1 (en) * | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7889069B2 (en) * | 2005-04-01 | 2011-02-15 | Codman & Shurtleff, Inc. | Wireless patient monitoring system |
US7590443B2 (en) | 2005-04-27 | 2009-09-15 | Pacesetter, Inc | System and method for detecting hypoglycemia based on a paced depolarization integral using an implantable medical device |
US8700157B2 (en) | 2005-04-29 | 2014-04-15 | Medtronic, Inc. | Telemetry head programmer for implantable medical device and system and method |
US20060247985A1 (en) | 2005-04-29 | 2006-11-02 | Therasense, Inc. | Method and system for monitoring consumable item usage and providing replenishment thereof |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
EP1881786B1 (en) | 2005-05-13 | 2017-11-15 | Trustees of Boston University | Fully automated control system for type 1 diabetes |
US7541935B2 (en) | 2005-05-19 | 2009-06-02 | Proacticare Llc | System and methods for monitoring caregiver performance |
US20070033074A1 (en) * | 2005-06-03 | 2007-02-08 | Medtronic Minimed, Inc. | Therapy management system |
CN100412804C (en) | 2005-06-03 | 2008-08-20 | 鸿富锦精密工业(深圳)有限公司 | Method and system for recognizing error codes of failure diagnosis card for main board |
US20060272652A1 (en) | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
US20070016449A1 (en) | 2005-06-29 | 2007-01-18 | Gary Cohen | Flexible glucose analysis using varying time report deltas and configurable glucose target ranges |
US7413124B2 (en) * | 2005-07-19 | 2008-08-19 | 3M Innovative Properties Company | RFID reader supporting one-touch search functionality |
US20070060869A1 (en) * | 2005-08-16 | 2007-03-15 | Tolle Mike C V | Controller device for an infusion pump |
US20070093786A1 (en) | 2005-08-16 | 2007-04-26 | Medtronic Minimed, Inc. | Watch controller for a medical device |
US7264985B2 (en) | 2005-08-31 | 2007-09-04 | Freescale Semiconductor, Inc. | Passive elements in MRAM embedded integrated circuits |
US20080314395A1 (en) | 2005-08-31 | 2008-12-25 | Theuniversity Of Virginia Patent Foundation | Accuracy of Continuous Glucose Sensors |
EP1921978B1 (en) | 2005-09-09 | 2012-08-01 | F. Hoffmann-La Roche AG | Device and program for diabetes care |
US9072476B2 (en) | 2005-09-23 | 2015-07-07 | Medtronic Minimed, Inc. | Flexible sensor apparatus |
US20070078314A1 (en) * | 2005-09-30 | 2007-04-05 | Grounsell Richard L | System and method for measuring and predicting insulin dosing rates |
US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US20090054747A1 (en) * | 2005-10-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and system for providing analyte sensor tester isolation |
US7583190B2 (en) * | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US20070173706A1 (en) | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
US7941200B2 (en) | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
US8160670B2 (en) * | 2005-12-28 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring: stabilizer for subcutaneous glucose sensor with incorporated antiglycolytic agent |
EP1968432A4 (en) | 2005-12-28 | 2009-10-21 | Abbott Diabetes Care Inc | Medical device insertion |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
EP1993637A2 (en) | 2006-02-15 | 2008-11-26 | Medingo Ltd. | Systems and methods for sensing analyte and dispensing therapeutic fluid |
US7885698B2 (en) * | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US8140312B2 (en) * | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US9392969B2 (en) * | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US7496852B2 (en) | 2006-05-16 | 2009-02-24 | International Business Machines Corporation | Graphically manipulating a database |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20080177149A1 (en) | 2006-06-16 | 2008-07-24 | Stefan Weinert | System and method for collecting patient information from which diabetes therapy may be determined |
US20090105560A1 (en) | 2006-06-28 | 2009-04-23 | David Solomon | Lifestyle and eating advisor based on physiological and biological rhythm monitoring |
US20080004601A1 (en) | 2006-06-28 | 2008-01-03 | Abbott Diabetes Care, Inc. | Analyte Monitoring and Therapy Management System and Methods Therefor |
WO2008001366A2 (en) | 2006-06-28 | 2008-01-03 | Endo-Rhythm Ltd. | Lifestyle and eating advisor based on physiological and biological rhythm monitoring |
US20090105571A1 (en) | 2006-06-30 | 2009-04-23 | Abbott Diabetes Care, Inc. | Method and System for Providing Data Communication in Data Management Systems |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US8932216B2 (en) * | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US9056165B2 (en) | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
DE102006043484B4 (en) * | 2006-09-15 | 2019-11-28 | Infineon Technologies Ag | Fuse structure and method for producing the same |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US20080092638A1 (en) | 2006-10-19 | 2008-04-24 | Bayer Healthcare Llc | Wireless analyte monitoring system |
EP2106238A4 (en) | 2006-10-26 | 2011-03-09 | Abbott Diabetes Care Inc | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US20080139910A1 (en) | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
WO2008071218A1 (en) | 2006-12-14 | 2008-06-19 | Egomedical Swiss Ag | Monitoring device |
US20080154513A1 (en) | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
US7613952B2 (en) | 2006-12-29 | 2009-11-03 | Inventec Corporation | Method for facilitating BIOS testing |
US20080161666A1 (en) | 2006-12-29 | 2008-07-03 | Abbott Diabetes Care, Inc. | Analyte devices and methods |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
US9597019B2 (en) | 2007-02-09 | 2017-03-21 | Lifescan, Inc. | Method of ensuring date and time on a test meter is accurate |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US20090093687A1 (en) | 2007-03-08 | 2009-04-09 | Telfort Valery G | Systems and methods for determining a physiological condition using an acoustic monitor |
US20080234943A1 (en) | 2007-03-20 | 2008-09-25 | Pinaki Ray | Computer program for diabetes management |
US9029157B2 (en) | 2007-04-12 | 2015-05-12 | Nipro Diagnostics, Inc. | Error detection and rejection for a diagnostic testing system |
CA2683959C (en) | 2007-04-14 | 2017-08-29 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2008128210A1 (en) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
EP2146625B1 (en) | 2007-04-14 | 2019-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
ES2817503T3 (en) | 2007-04-14 | 2021-04-07 | Abbott Diabetes Care Inc | Procedure and apparatus for providing data processing and control in a medical communication system |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
CA2685374A1 (en) | 2007-04-27 | 2008-11-06 | Abbott Diabetes Care Inc. | Test strip identification using conductive patterns |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080312845A1 (en) | 2007-05-14 | 2008-12-18 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20080300572A1 (en) | 2007-06-01 | 2008-12-04 | Medtronic Minimed, Inc. | Wireless monitor for a personal medical device system |
WO2008154312A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20080312518A1 (en) | 2007-06-14 | 2008-12-18 | Arkal Medical, Inc | On-demand analyte monitor and method of use |
WO2008151452A1 (en) | 2007-06-15 | 2008-12-18 | F. Hoffmann-La Roche Ag | Visualization of a parameter which is measured on the human body |
JP5680960B2 (en) | 2007-06-21 | 2015-03-04 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Health care device and method |
US8617069B2 (en) | 2007-06-21 | 2013-12-31 | Abbott Diabetes Care Inc. | Health monitor |
US9754078B2 (en) | 2007-06-21 | 2017-09-05 | Immersion Corporation | Haptic health feedback monitoring |
DK2170158T3 (en) | 2007-06-27 | 2017-09-18 | Hoffmann La Roche | Interface for input of patient information to a therapy system |
US8818782B2 (en) | 2007-06-27 | 2014-08-26 | Roche Diagnostics Operations, Inc. | System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof |
EP2170430A2 (en) | 2007-06-29 | 2010-04-07 | Roche Diagnostics GmbH | Method and apparatus for determining and delivering a drug bolus |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US20090036760A1 (en) | 2007-07-31 | 2009-02-05 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7731658B2 (en) * | 2007-08-16 | 2010-06-08 | Cardiac Pacemakers, Inc. | Glycemic control monitoring using implantable medical device |
US9968742B2 (en) * | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
US20090063402A1 (en) * | 2007-08-31 | 2009-03-05 | Abbott Diabetes Care, Inc. | Method and System for Providing Medication Level Determination |
DE102007047351A1 (en) | 2007-10-02 | 2009-04-09 | B. Braun Melsungen Ag | System and method for monitoring and controlling blood glucose levels |
US20090085768A1 (en) | 2007-10-02 | 2009-04-02 | Medtronic Minimed, Inc. | Glucose sensor transceiver |
CA3105353A1 (en) | 2007-10-10 | 2009-04-16 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7783442B2 (en) | 2007-10-31 | 2010-08-24 | Medtronic Minimed, Inc. | System and methods for calibrating physiological characteristic sensors |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164190A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Physiological condition simulation device and method |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
WO2009097450A1 (en) | 2008-01-30 | 2009-08-06 | Dexcom. Inc. | Continuous cardiac marker sensor system |
US20090299156A1 (en) | 2008-02-20 | 2009-12-03 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
JP5091881B2 (en) | 2008-02-20 | 2012-12-05 | カルソニックカンセイ株式会社 | Collision detection device |
WO2009105709A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
CN102047101A (en) | 2008-03-28 | 2011-05-04 | 德克斯康公司 | Polymer membranes for continuous analyte sensors |
CN103400028B (en) | 2008-04-04 | 2017-04-12 | 海吉雅有限公司 | Device for optimizing patient's insulin dosage regimen |
WO2009125421A1 (en) * | 2008-04-11 | 2009-10-15 | Indian Institute Of Science | A sub-threshold capfet sensor for sensing analyte, a method and system thereof |
US7938797B2 (en) | 2008-05-05 | 2011-05-10 | Asante Solutions, Inc. | Infusion pump system |
US8006004B2 (en) * | 2008-07-08 | 2011-08-23 | Nuvoton Technology Corp. | Non-intrusive debug port interface |
WO2010009172A1 (en) * | 2008-07-14 | 2010-01-21 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US20100025238A1 (en) * | 2008-07-31 | 2010-02-04 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
US8432070B2 (en) | 2008-08-25 | 2013-04-30 | Qualcomm Incorporated | Passive receivers for wireless power transmission |
US9943644B2 (en) * | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US20100057040A1 (en) * | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8734422B2 (en) * | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US20100063372A1 (en) * | 2008-09-09 | 2010-03-11 | Potts Russell O | Sweat collection devices for glucose measurement |
WO2010031059A2 (en) | 2008-09-15 | 2010-03-18 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
US20100095229A1 (en) | 2008-09-18 | 2010-04-15 | Abbott Diabetes Care, Inc. | Graphical user interface for glucose monitoring system |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
JP2012504932A (en) | 2008-10-02 | 2012-02-23 | レイデン エナジー インコーポレイテッド | Electronic current interrupt device for batteries |
US9320470B2 (en) | 2008-12-31 | 2016-04-26 | Medtronic Minimed, Inc. | Method and/or system for sensor artifact filtering |
US8974439B2 (en) | 2009-01-02 | 2015-03-10 | Asante Solutions, Inc. | Infusion pump system and methods |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
EP2394217A4 (en) | 2009-02-04 | 2016-05-04 | Abbott Diabetes Care Inc | Multi-function analyte test device and methods therefor |
US8394246B2 (en) | 2009-02-23 | 2013-03-12 | Roche Diagnostics Operations, Inc. | System and method for the electrochemical measurement of an analyte employing a remote sensor |
EP2413781B1 (en) | 2009-03-31 | 2019-07-24 | Abbott Diabetes Care Inc. | Overnight closed-loop insulin delivery with model predictive control and glucose measurement error model |
WO2010121229A1 (en) | 2009-04-16 | 2010-10-21 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US20100274515A1 (en) | 2009-04-28 | 2010-10-28 | Abbott Diabetes Care Inc. | Dynamic Analyte Sensor Calibration Based On Sensor Stability Profile |
US8595607B2 (en) | 2009-06-04 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
US9792408B2 (en) * | 2009-07-02 | 2017-10-17 | Covidien Lp | Method and apparatus to detect transponder tagged objects and to communicate with medical telemetry devices, for example during medical procedures |
US20110024043A1 (en) * | 2009-07-02 | 2011-02-03 | Dexcom, Inc. | Continuous analyte sensors and methods of making same |
EP2482724A2 (en) * | 2009-09-30 | 2012-08-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9949672B2 (en) | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
US8579879B2 (en) | 2010-02-19 | 2013-11-12 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
US20110208027A1 (en) | 2010-02-23 | 2011-08-25 | Roche Diagnostics Operations, Inc. | Methods And Systems For Providing Therapeutic Guidelines To A Person Having Diabetes |
WO2011133768A1 (en) | 2010-04-22 | 2011-10-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods related to analyte monitoring and management |
US9336353B2 (en) | 2010-06-25 | 2016-05-10 | Dexcom, Inc. | Systems and methods for communicating sensor data between communication devices of a glucose monitoring system |
EP4333325A2 (en) * | 2010-09-29 | 2024-03-06 | Dexcom, Inc. | Advanced continuous analyte monitoring system |
US9241631B2 (en) | 2010-10-27 | 2016-01-26 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
US20130035865A1 (en) * | 2011-08-05 | 2013-02-07 | Dexcom, Inc. | Systems and methods for detecting glucose level data patterns |
US20130235166A1 (en) | 2012-03-07 | 2013-09-12 | Cambridge Silicon Radio Limited | Synchronisation method |
-
2010
- 2010-02-03 US US12/699,844 patent/US8930203B2/en active Active
-
2014
- 2014-05-30 US US14/292,557 patent/US20140275910A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6656114B1 (en) * | 1998-11-30 | 2003-12-02 | Novo Noadisk A/S | Method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions |
US20040259956A1 (en) * | 2003-03-11 | 2004-12-23 | Curtis Wright | Titration dosing regimen for controlled release tramadol |
US20050277911A1 (en) * | 2004-05-27 | 2005-12-15 | Janice Stewart | Apparatus and method for therapeutic delivery of medication |
US20070255321A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Efficacy visualization |
Also Published As
Publication number | Publication date |
---|---|
US20100204557A1 (en) | 2010-08-12 |
US8930203B2 (en) | 2015-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8930203B2 (en) | Multi-function analyte test device and methods therefor | |
EP2394217A1 (en) | Multi-function analyte test device and methods therefor | |
US20240000348A1 (en) | Multi-function analyte monitor device and methods of use | |
US20210050085A1 (en) | Systems, devices, and methods relating to medication dose guidance | |
US20240108221A1 (en) | Method and system for providing data management in integrated analyte monitoring and infusion system | |
US8732188B2 (en) | Method and system for providing contextual based medication dosage determination | |
CA2766944C (en) | Analyte testing methods and device for calculating basal insulin therapy | |
US8766803B2 (en) | Dynamic data collection | |
US20190138505A1 (en) | Management Method and System For Implementation, Execution, Data Collection, and Date Analysis Of A Structured Collection Procedure Which Runs On A Collection Device | |
US20090164190A1 (en) | Physiological condition simulation device and method | |
US8374925B2 (en) | Method and system for monitoring consumable item usage and providing replenishment thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT DIABETES CARE INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIAIE, NAMVAR;COLE, JEAN-PIERRE;SLOAN, MARK KENT;AND OTHERS;SIGNING DATES FROM 20100209 TO 20100211;REEL/FRAME:033882/0497 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |